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This thesis describes research carried out to develop a norbornadienone based organic 
carbon monoxide releasing molecule (CORM) as a safe, solid CO source for various 
carbonylation reactions. Reaction of 2,5-dimethyl-3,4-diphenylcyclopentadienone dimer 
and bromomaleic anhydride gave cycloadduct 30 as an 8:1 inseparable mixture of the endo 
and exo-isomers in 96% yield. Treatment with DBU or triethylamine triggered release of 
CO from 30 which was then used in palladium catalysed carbonylation reactions.  
Ex situ generation of CO from 30 was utilised in the palladium-catalysed 
aminocarbonylation of p-iodoanisole (26) and n-butylamine (27) which gave N-butyl-4-
methoxybenzamide (28) in 88% yield. This protocol allowed the synthesis of N-butyl-4-
nitrobenzamide (45), 4-bromo-N-butylbenzamide (46), N-butylbenzamide (47) and N-
butyl-1-naphthamide (48) in good to excellent yields (81 – 99%). Furthermore, tertiary 
amides were generated from morpholine and substituted iodobenzenes using this protocol. 
These were isolated in yields ranging from 72 – 99%. 
 
A room temperature double carbonylation of p-iodoanisole (26) and n-butylamine (27) 
with 30 as an external CO source was also carried out and the α-ketoamide product N-
butyl-2-(4-methoxyphenyl)-2-oxoacetamide (54) was obtained in 64% yield.  
vi 
 
Having shown 30 to be a suitable CO donor for palladium-catalysed aminocarbonylation 
reactions, the protocol was adapted and applied to Suzuki-Miyaura carbonylations. 
Following optimisation of this reaction, the synthesis of biologically active molecules, 
such as the cholesterol reducing drug fenofibrate (39) was investigated. This involved the 
carbonylative Suzuki-Miyaura reaction of iodo-aryl ester 37 and 4-chlorophenylboronic 
acid (38) which was achieved in 80% yield following column chromatography. This 
system was also applied to the synthesis of synthetic cannabinoid compounds, which 
contain an indol-3-yl aryl ketone backbone.  
 
Following the successful synthesis of fenofibrate and various synthetic cannabinoids using 
cycloadduct 30 as a CO source, attention then turned to synthesis of analogues of the 
current lead compound oCOm-21, in order to provide more information about the 
mechanism of the CO release "trigger" of these norbornadienone-based CORMs. 
Following literature procedures reported by Burkart et al.117, maleimide 77 was converted 
to carboxyethoxy-maleimide 78 which was then reacted with Boc-protected ethylene 
diamine 79 to afford Boc-protected maleimide 80. Successive bromination and base-
induced elimination gave the required mono-bromo dienophile 81 that was reacted with 
diene dimer 4 to give the Boc-protected cycloadduct 82 as a 2:1 mixture of the endo and 
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exo isomers. The major endo-isomer was purified by flash chromatography and treated 
with 6 M HCl in 1,4-dioxane to afford oCOm-21 in 90% yield. 
 
Analogues of oCOm-21 were synthesised using a halogen exchange reaction to substitute 
the bromine substituent of dienophile 81 for either iodine or chlorine. The dienophiles were 
then reacted in the same manner with diene dimer 4 to give the Boc-protected cycloadducts 
86 and 89 which could then be deprotected with 6 M HCl in 1,4-dioxane to afford oCOm-
60 and -61 respectively. 
 
The CO release profiles of oCOm-21, -60 and -61 were indirectly monitored via HPLC-
MS, in order to investigate the mechanism of CO release. The rate of CO release from 
halo-cycloadducts increased in the order of oCOm-60 < -61 < -21 in which the elimination 
of HCl from oCOm-61 was proposed to occur via (E1cB)rev process, indicating the 
influence of the leaving group ability on the rate of elimination. The mechanism for the 
elimination of HX from oCOm-21 and -61 was presumed to occur via (E1cB)irr process 
where the deprotonation is the rate determining step. 
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Chapter 1  
Introduction 
This thesis discusses the synthesis of an organic carbon monoxide releasing molecule 
(CORM), to be used as a stable, safe, and solid carbon monoxide (CO) source. It details the 
development of a system wherein such molecules can be applied to various palladium 
catalysed carbonylation reactions and subsequent use of this system to synthesise 
biologically active compounds.  
The introduction contains a brief analysis of the biological behaviour of CO and its 
potential use as a therapeutic agent followed by earlier work previously carried out in the 
Larsen group to synthesise organic CORMs as CO prodrugs. Synthetic uses for CO will be 
discussed in more detail, in particular, its use in the synthesis of carbonyl-containing 
compounds via palladium catalysed carbonylation chemistry. 
1.1 Biological and chemical behaviour of CO 
CO gas has always been viewed in a negative light, with many attempts to minimise its 
accidental production, as it is known for being both an environmental pollutant and 
extremely toxic molecule.1 This toxicity arises from the ability of CO to strongly bind to 
haemoglobin (Hb) to form carboxyhaemoglobin (COHb).2 CO outcompetes oxygen, which 
leads to tissue hypoxia and in severe cases, death. However, in 1949 Sjöstrand reported 
that small amounts of CO are produced endogenously in humans, with this amount being 
higher in patients with certain pathological conditions.3 About 80% of this CO present in 
the body in is complexed as COHb and the remainder is distributed in tissues.4 In 
pathological conditions, such as hemolytic disease, asthma, and cystic fibrosis, the rate of 
CO production can be increased up to 100 fold.5 This finding indicated that endogenously 





1.2 Therapeutic effects of CO 
CO is now considered to be a gaseous signalling molecule (or gasotransmitter) and studies 
have shown that it has downstream effects such as increasing the production of cyclic 
guanosine monophosphate (cGMP) by binding to soluble guanylate cyclase (Figure 1.1). 
cGMP regulates the conductivity of ion channels, glycogenolysis and cellular apoptosis.6 It 
also causes the relaxation of smooth muscle tissue, which in blood vessels leads to 
vasodilation and increased blood flow.7 CO has also been shown to have anti-inflammatory 
and anti-apoptotic effects, through binding to p38 mitogen-activated protein kinases 
(MAPK).8 
 
Figure 1.1 Selected cellular targets of CO and downstream effects thereof. 
These downstream effects of CO can be applied therapeutically. One example is for the 
preservation of tissue in organ transplantation systems. The administration of CO to the 
donor, organ and/or recipient has been shown to have positive effects.1 Preclinical proof of 
concept has been exemplified in a pig model of kidney grafts, in which CO inhalation 
decreased ischaemia reperfusion injury, thereby helping to restore kidney function more 
rapidly and promoting repair of the associated tissue.1 CO can also be applied to the 
transplanted organ during transport and storage. CO can also be applied to the transplanted 
organ during transport and storage. The administration of a CO source to the preservation 




Due to the difficulty of controlling gas administration in a clinical setting, and the risk of a 
gas leak from pressurised CO cylinders, CO-releasing molecules (CORMs) or CO 
'prodrugs' have been developed as an alternative CO delivery system. These allow more 
controlled administration and mitigate many of the risks associated with the use of gaseous 
CO. 
1.3 CO releasing molecules in biological contexts 
1.3.1 Metal based CORMs 
 
At low doses CO has been shown to have other beneficial therapeutic effects. These 
include protection against hypoxic lung injury,12 vasodilation, anti-inflammatory,13 anti-
apoptotic, and anti-proliferative effects.14  The seminal work in the development of 
CORMs was carried out by Motterlini et al.15 who investigated the CO releasing properties 
of transition metal carbonyl complexes. Initial investigations yielded CORMs such as 
Mn2(CO)10 (CORM-1) and Ru2(CO)6Cl4 (CORM-2) (Table 1.1).
15 CORM-1 releases CO 
by photodissociation when exposed to light, whereas CORM-2 undergoes ligand 
substitution in DMSO to liberate CO. Both release mechanisms yield a maximum of one 
molecule of CO per CORM complex despite each compound containing multiple carbonyl 
ligands.15 Unfortunately, both CORM-1 and -2 were insoluble in water and toxic effects 
associated with the transition metal core were observed, making them incompatible with 
biological systems.  
Table 1.1 First generation transition metal CORMs developed by Motterlini et al.15 
Compound Chemical Structure Water Soluble 
CO Release 
(pH = 7.4, 37 ˚C) 
CORM-1 
 
No Light dependent 




Induced by ligand 
substitution 




Further research into water solubilisation gave tricarbonylchloro(glycinato)ruthenium(II) 
(CORM-3) (Table 1.2), which was water soluble. It was found that the release of CO from 
CORM-3 was triggered by ligand substitution in physiological buffers.16 The glycinate 
ligand is naturally present in the body and was therefore selected as a solubilising ligand 
for CORM-3 as it should not present toxicity problems. This research group also 
developed the non-transition metal containing CORM sodium boranocarbonate (CORM-
A1) which is water soluble, and releases CO upon acidification.17  
Table 1.2 Second generation CORMs developed by Motterlini.16-17 
Compound Chemical Structure Water Soluble 
CO Release 




Induced by ligand 
substitution 





(t1/2 ≈ 21 min, 
moderate) 
A further example, which was synthesised by Seixas et al. ten years after the first report on 
CORMs by Motterlini et al. is fac-[Mo(CO)3(histidinate)]Na also known as ALF186 
(Figure 1.2).18 This compound is soluble and stable in water under an inert atmosphere, but 
decomposes in solution in the presence of oxygen to release up to three equivalents of CO.  
 





1.3.2 Design and development of organic CORMs for biological purposes 
 
Our research group has synthesised non-toxic, water soluble, organic CO donor molecules, 
which release CO in a controlled manner, for use in biological systems.19 These organic 
CORMs utilize pH as the trigger for CO release and do not require CO gas for their 
synthesis. These compounds are based on norbornadienone (1) (Scheme 1.1) a well-known 
bridged carbonyl complex that can be synthesised using Diels-Alder chemistry.20 
Compounds of this type spontaneously undergo loss of CO to form the corresponding 
stable aromatic ring-by product.  
 
Scheme 1.1 Norbornadienone (1) undergoes spontaneous rearrangement to form benzene and CO.20 
However, norbornadienones are not stable nor easily obtained, and consequently there is a 
lack of control over the release of CO. Therefore, the Larsen group decided to base their 
molecules on the dihydro-congener norbornenone (3) (bicyclo[2.2.1]hept-2-en-7-one) 
(Figure 1.3). 
 
Figure 1.3 Structure of norbornenone 3 (bicyclo[2.2.1]hept-2-en-7-one). 
These compounds can be easily accessed via Diels-Alder chemistry, where the reaction of 
substituted cyclopentadienones (such as 4) with activated dienophiles (such as maleic 
anhydride (5) and its derivatives) forms stable cycloadducts such as 6 (Scheme 1.2). 
Decomposition of these CORMs is initiated by heat or photolysis, releasing CO gas.21-22 





Scheme 1.2 Formation and aromatisation of cycloadduct 6 to release CO. 
The concept was further investigated by Larsen and Woods, who further developed the 
organic CORM system.23 Diels-Alder chemistry was once again used to synthesise bridged 
carbonyl cycloadducts, but the system was modified to include leaving groups. This 
allowed a base-mediated elimination reaction to be used as the trigger to release CO from 
the cycloadduct.  Halogens are good leaving groups, and therefore halogen substituted 
maleic anhydride derivatives were examined as dienophiles. The most successful system is 
shown in Scheme 1.3, where the Diels-Alder cycloaddition of 2,5-dimethyl-3,4-
diphenylcyclopentadienone (4) (which exists predominantly as a dimer at room 
temperature) as the 4πs component, with N-phenyl-3-bromomaleimide (8), formed CORM 
9 in mainly the endo stereochemistry. 
 
Scheme 1.3 Diels-Alder reaction of diene 4 and dienophile 8 to generate 9.23 From this point forward the 
diene dimer 4 will be illustrated by the structure in brackets.  
Evidence for the endo stereochemistry of the cycloadduct 9 was provided by X-ray 
crystallography.23 The X-ray data were solved to give the structure shown in Figure 1.4.  
The five membered imide ring system lies across the newly formed six membered ring, 






Figure 1.4 X-ray crystal structure of endo 9.23 
Adduct 9 was found to eliminate HBr with concomitant evolution of CO gas upon 
treatment with an organic base (such as triethylamine (Et3N)). It was proposed that the 
reaction proceeded via an E1cB mechanism followed by cheletropic loss of CO from the 
norbornadienone intermediate B to produce aromatic by-product 10. 
 




Work is ongoing within the Larsen group to synthesise organic CORMs based on this 
norbornadienone system with different properties. Water soluble, fluorescent and polymer-
supported CORMs are all being investigated.19 
Recently, Ji and co-workers designed a similar base activated system (11) (Scheme 1.5) 
that also utilised diene dimer 4.25 An E1cB elimination of the substituted phenol (11) 
forming the transient norbornadienone (not shown) with concomitant loss of CO was 
proposed. 
 
Scheme 1.5 Base-activated organic CORM system (11) developed by Ji et al.25  
 
1.4 Synthetic and industrial applications of CO 
CO gas is also an important reagent in organic synthesis. It provides a key one-carbon 
building block for the preparation of carbonyl-containing compounds such as aldehydes, 
esters, ketones, carboxylic acids, and their derivatives. The carbonyl group is also a 
common functional group in bioactive compounds.26-27 CO is a cost-efficient building 
block for converting various bulk chemicals into a diverse set of useful products for our 
daily life.28 There are numerous examples of carbonylation reactions using CO gas, a few 





Scheme 1.6 Examples of transition metal catalysed carbonylation reactions. 
Reaction A is an example of a carbonylation reaction known as the Pauson-Khand reaction 
where a cyclic enone is formed.29 It involves a [2+2+1] cycloaddition of an alkyne, an 
alkene and CO, utilizing either a cobalt or ruthenium catalyst. In reaction B, CO is inserted 
into the C−O bond of an oxirane ring, giving rise to a β-hydroxy ester.30 The third reaction 
(C) is a similar carbonylation reaction, wherein CO is inserted into the C-N bond of an 
aziradine ring, again using a metal catalyst.31 In this example a β-lactam ring is formed, a 
key feature of β-lactam antibiotics, such as penicillin and its derivatives. Reaction D shows 
the widely used oxidative carbonylation reaction which involves the insertion of CO into 
an aryl–halide (Ar–X) bond. Incorporation of nucleophiles, such as amines, alcohols or 
water, gives products such as aromatic amides, esters and carboxylic acids respectively. 
Normally these reactions are carried out under an atmosphere of CO gas and require a 




Reactions involving CO are also of industrial importance. For example, the 
hydroformylation of alkenes (Scheme 1.7), also known as the ‘Oxo process’, provides a 
commercial source of aldehydes, using high pressures of CO gas.33 This process is 
transition metal catalysed, commonly by cobalt, iron or ruthenium and involves the 
addition of a mixture of CO and H2 to olefins.  In 2008 nearly 10.4 million tons of "oxo 
chemicals" were made industrially,34 involving huge amounts of pressurised CO. 
 
Scheme 1.7 Principle of hydroformylation. 
CO gas is also used in the Fischer–Tropsch process to convert hydrogen to crude liquid 
hydrocarbons,35 and the Monsanto Process which is used industrially to synthesise acetic 
acid via catalytic carbonylation of methanol.36 Both of these processes are transition metal 
catalysed and carried out at temperatures greater than 200 °C and pressures of 30-60 atm.35 
Carbonylation reactions are also used in the production of pharmaceuticals such as 
triptolide, an immunosuppressant drug used in the treatment of cancer (Scheme 1.8). CO is 
inserted into a C‒O bond of alkenyl triflate 12 with subsequent intramolecular attack of the 
alcohol to generate γ-lactone 13. Subsequent transformations give the target compound 
triptolide (14).37  
 




Industrially, such reactions are carried out under an atmosphere of CO with the gas stored 
in pressurised cylinders.  However, in research laboratories where CO gas is used 
intermittently CO gas cylinders are not ideal due to the inherent risk of leaks leading to 
poisoning. Carbon monoxide is known as the “silent killer”,38 as it is a chemical asphyxiant 
responsible for more than 50% of deaths by poisoning each year throughout the developed 
world.39 CO gas is colourless, odourless and tasteless, and side effects of poisoning often 
do not show until late stage exposure.  When CO is inhaled, it reaches the blood stream 
where it binds to Hb forming COHb.40 It has a far higher binding affinity (approximately 
200 times) for Hb than oxygen, resulting in the displacement of O2 by CO, and a decrease 
in the release of O2 to the tissues ultimately leading to tissue hypoxia and death.   
To avoid these inherent risks associated with the use of CO gas much work has been 
conducted into the use of CORMs as alternative CO sources for small scale synthetic 
carbonylation reactions. Previous work in the literature has utilized in situ generation of 
CO from many sources including aldehydes,41 formates,42 and formamides,43 and their 
derivatives. In early work the most commonly used CO sources were metal carbonyl 
compounds such as Mo(CO)6.
44 These metal containing reagents have limited applications 
in carbonylation reactions as they are often used in conjunction with complicated 
protocols.45 
1.5 Application of CORMs in synthetic chemistry 
Recently, non-metal containing CORMs such as silacarboxylic acids 15a-c, fluorescein 
analogue 1646 and cyclic α-diketones 17a-c47 (Figure 1.5) have been developed and many 
of these have been used as a CO source for carbonylation reactions.48 The 
silacarboxylic acid CORMs developed by Skrydstrup et al. produce CO on treatment with 
a fluoride-based desilylating reagent,48-49 whereas the fluorescein analogue (6-hydroxy-3-
oxo-3H-xanthene-9-carboxylic acid (16)) is activated to release CO by visible light (500 
nm).46 The release of CO from the cyclic α-diketone CORMs is also light mediated (400-
550 nm) giving two molecules of  CO and an anthracene derivative.47 Both 16 and 17a-c 





Figure 1.5 Examples of non-metal containing CORMs. 
Skrydstrup et al. designed a two chamber system, known as COware (Figure 1.6), for such 
carbonylation reactions.50 The reaction that produces CO gas is carried out in the 'CO 
producing Chamber', CO then diffuses into the 'CO consuming Chamber' where it can then 
be used in the carbonylation reaction. 
 
Figure 1.6 COware: glassware designed for carbonylation reactions. 
A wide range of reactions were explored by Skrydstrup et al. For example 
silacarboxylic acid CORMs (15a-c) were shown to be effective CO sources for 
aminocarbonylation reactions, forming amide 20 from aryl iodide 18 and secondary amine 
19 in an 82% yield (Scheme 1.9). 1.5 equivalents of the CO donor was dissolved in 1,4-









Scheme 1.9 Aminocarbonylation of 18 and 19 using silacarboxylic acid CORMs as CO sources.48 
They further demonstrated the versatility of such molecules as CO donors by using 15b as 
the CO source for the double carbonylation of aryl halide 21, a reaction which had 
originally been demonstrated by Kondo.51 Importantly, the reaction was carried out at 
room temperature, which was impressive as many CO sources up until this point required 
elevated temperature to generate CO. When three equivalents of CO donor were used in 
the room temperature reaction of aryl halide 21 with pyrrolidine (22), the doubly 
carbonated product 23 was isolated in good yield (Scheme 1.10).48 
 
Scheme 1.10 Double carbonylation of aryl halide 21 using silacarboxylic acid 15b as a CO source at rt.48 
Hermange and Skrydstrup also developed the acid chloride CO donor molecule, 9-methyl-
9H-fluorene-9-carbonyl chloride (24) (Scheme 1.11), which they also applied to the 
palladium-catalysed aminocarbonylation reactions of aryl iodides, again utilizing their two-
chamber system.50 Chloride 24 undergoes a palladium catalysed decarbonylation reaction 
in the 'CO releasing chamber' to reform its precursor compound (25) and to liberate CO 
which can then be incorporated into the carbonylation reaction occurring in the 'CO 
consuming chamber'.50 This compound is now commercially available under the name 





Scheme 1.11 Acid chloride CO donor molecule 24 used for palladium-catalysed aminocarbonylations. 
Reagents and conditions: 1,4-dioxane, 80 °C; a. Pd(dba)2 (5 mol%), P(tBu)3 (10 mol%), DIPEA (1.5 eq.); b. 
Pd(dba)2 (5 mol%), PPh3 (10 mol%), Et3N (2 eq.).50 
Chloride 24 was also shown to be an effective CO donor for aminocarbonylation reactions 
on a range of 2-pyridyl tosylate substrates affording moderate to good yields of the 
corresponding amides.50 
Cho adapted the norbornadienone-based organic CORM system developed by the Larsen 
group for use in chemical synthesis, specifically in palladium-catalysed carbonylation 
reactions.39 Cho utilised the CO produced from the base-activated cycloadduct 9 in 
palladium-catalysed aminocarbonylation reactions. For example, the reaction of p-
iodoanisole (26) with n-butylamine (27) was performed using cycloadduct 9 and 
triethylamine (Scheme 1.12).  This was done in both a one-chamber and two-chamber 
system similar to that developed by Skrydstrup et al.50 to give N-butyl 4-





Scheme 1.12 Palladium-catalysed aminocarbonylation of p-iodoanisole (26) and n-butylamine (27) using 
organic CORM 9 as the CO source. Reagents and conditions: a. Et3N (2.3 eq.), 1,4-dioxane, 80 °C, 93%; b. 
Pd(dba)2 (5 mol%), PPh3 (10 mol%), Et3N (2.3 eq.), 1,4-dioxane, 80 °C, 99%.52 
Cho further extended this work to examine tolerance and chemoselectivity towards 
different functional groups on the aryl substrate, such as electron-withdrawing nitro 
groups. When 1-iodo-4-nitrobenzene was used as the substrate she obtained N-butyl-4-
nitrobenzamide in a 99% yield. In addition, palladium-catalysed aminocarbonylation of 1-
bromo-4-iodobenzene was performed to examine chemoselectivity towards the aryl halide 
substrate. Full chemoselectivity was observed where the only product arose from insertion 
of CO into the aryl iodide bond.  
1.6 Palladium-catalysed coupling chemistry 
The diversity of palladium-catalysed coupling systems has been exemplified by their 
compatibility with a wide range of functional groups as apparent from the many named 
reactions of this type (Heck-Mizoroki, Suzuki-Miyaura, Sonogashira, and Stille to name a 
few).53 The initial focus of the current research, palladium-catalysed carbonylation of aryl 
halides, was first described more than 30 years ago by Heck and co-workers.54 This type of 
reaction has been widely used in chemical synthesis and the chemical industry. A general 
cycle for palladium-catalysed carbonylation reactions is shown in Figure 1.7. It has five 





Figure 1.7 General reaction cycle for palladium-catalysed carbonylation reactions, where Ln indicates 
unspecified ligands; Ar-X indicates and aryl halide where X = I or Br; and nucleophiles (Nu) can include 
substrates such as amines, organoboron species, alkynes, aryl / vinyl halides and organotin compounds. 
Many different reactions are included in this type of catalytic cycle, all of which are 
initiated by the oxidative addition (Figure 1.7, Step A) of an electrophile, typically an aryl 
or vinyl halide to the active Pd0 species giving rise to an arylpalladiumII species. Under an 
atmosphere of CO coordination of CO to palladium can occur (Figure 1.7, Step B), as CO 
has a high affinity for both palladium0 and palladiumII. This arises from the ability of CO to 
act as both a σ-donor and π-acceptor.55 Rearrangement allows CO to undergo at 1,1-
insertion into the Pd-aryl bond (Figure 1.7, Step C) to form the acylpalladiumII 
intermediate. Following this an insertion reaction with a nucleophile (NuH) with the PdII 
complex occurs (Figure 1.7, Step D). The final step in the catalytic cycle is reductive 
elimination (Figure 1.7, Step E), which provides the carbonylated product and reforms the 
catalytically active Pd0 species.  
Carbonylative palladium catalysis reactions have many advantages, as the carbonyl group 
can be introduced at almost any point in the synthesis due to the mild and selective reaction 




conditions (such as highly basic or nucleophilic reagents) which are often incompatible 
with sensitive functional groups and need to be introduced early on in synthesis. 
1.6.1 Aminocarbonylation 
The amide functional group plays an important role in the elaboration and composition of 
many biological systems.56 It is a key linking moiety in proteins and polymers as well as a 
common feature in many different types of drug molecules, natural products, 
agrochemicals, and biologically active molecules.57 As mentioned above, like most 
palladium mediated carbon-carbon bond forming reactions, aminocarbonylations are 
compatible with a large variety of functional groups, thus avoiding the need for harsh 
reagents and high temperatures which are typically detrimental to the integrity of the 
substrates. The reaction is presumed to follow the mechanistic pathway described in 
section 1.6, with an amine acting as the nucleophilic component in Step D. 
Following their work on the carbonylative cross-coupling of aryl and vinyl halides with 
olefins, Heck and co-workers reported the first examples of palladium catalysed 
aminocarbonylation in the 1970s,54,58 the scope of the reaction has greatly expanded and 
there are now examples of aminocarbonylations of aryl chlorides,59 and tosylates60 as well 
as the more common aryl iodides, bromides and triflates. 
1.6.2 Carbonylative Suzuki-Miyaura cross-coupling  
Another example of widely utilized palladium catalysed reactions is the well-known 
Suzuki-Miyaura carbonylation reaction. This was first reported in 1998 following 
development of the cross coupling reaction of the same name.61 The original report 
involved the three-component reaction of an aryl halide (or triflate), a boronic acid (or 
derivatives of) and carbon monoxide to give corresponding unsymmetrical biaryl ketones 
as products. The reaction is considered to proceed via a pathway similar to that of the 
palladium-catalysed carbonylative coupling reactions previously discussed. The first step 
involves oxidative addition of the aryl halide to a Pd0 complex, followed by insertion of 
CO to give acylpalladiumII halide, and transmetallation of the aryl group from the boronic 




reductive elimination to form the biaryl ketone product. The Suzuki-Miyaura carbonylation 
reaction lends itself to the synthesis of unsymmetrical ketones with various functional 
groups, due to the tolerant character of organoboranes,62 and the wide range of 
commercially available aryl iodides. The main drawback of this reaction is that it is 
directly competing with its non-carbonylative counterpart, via a very similar mechanistic 
pathway through a common acylpalladiumII  halide intermediate (Figure 1.8, Cycle B). 
 
Figure 1.8 Competing reaction cycles. Cycle A: Carbonylative Suzuki-Miyaura; Cycle B: Suzuki-Miyaura 
cross-coupling. 
1.7 The current proposal 
Cho investigated the use of CORM 9 as a CO source for aminocarbonylation reactions of 
aryl iodides such as p-iodoanisole (26) and 1-iodo-4-nitrobenzene (31) with n-butylamine 
(27) (see Scheme 1.12, Page 15).52 Although the use of 9 as a CO source for 
aminocarbonylation reactions developed by Cho was successful, we sought to optimise this 
approach and extend the scope of bromo-norbornadienones as CO donors. Bromo-
maleimides such as 8, used in the synthesis of 9 (see Scheme 1.3, Page 6), are prepared by 
the addition of molecular bromine to substituted maleimides followed by elimination of 
HBr. These steps could be circumvented by reacting commercially available bromomaleic 
anhydride (29) with diene 4 to provide Diels-Alder cycloadduct 30 (Scheme 1.13). Given 




cycloadduct 9, base induced elimination of HBr followed by subsequent cheletropic loss of 
CO from 30 should be more facile.  
 
Scheme 1.13 Proposed synthesis of cycloadduct 30. 
We plan to investigate the use of 30 as a CO donor molecule. This will be achieved by 
repeating the aminocarbonylation reactions carried out by Cho using cycloadduct 30 as the 
CO source. Furthermore, we will examine the scope of this reaction by using iodobenzene 
(33) and 1-iodonapthalene as substrates (34) (Figure 1.9). 


















Figure 1.9 Components for palladium-catalysed carbonylation reactions. 
After optimisation of these reactions to ensure consistent results, attention will then turn to 
the use of secondary amines as the nucleophilic component as such substrates were not 
investigated by Cho. Morpholine (35) will be used for these reactions which should 
provide tertiary morpholinyl amides. This will be carried out with the same aryl iodides as 
shown in Figure 1.9. Once this work has been achieved the use of 30 as a CO donor will be 
applied to other palladium-catalysed carbonylation reactions, such as Suzuki-Miyaura 
carbonylations. We plan to investigate CORM 30 as a CO donor for the formation of the 
cholesterol reducing drug fenofibrate40 (Scheme 1.14). This would involve the 






Scheme 1.14 Proposed reaction scheme for formation of fenofibrate (39) using cycloadduct 30 as the CO 
source for palladium-catalysed carbonylative Suzuki-Miyaura reaction. 
Following the successful synthesis of fenofibrate, the system will be applied to other 
biologically active molecules such as synthetic cannabinoids (SCs) which contain a core 3-
acyl indole backbone (Figure 3.10).  
 
Figure 1.10 3-acyl indole backbone of cannabimimetic indoles. 
Once cycloadduct 30 has be shown to be an effective CO source for various palladium 
catalysed carbonylation reactions and the synthesis of biologically active molecules, 
attention will turn to the synthesis of compounds that will provide more information about 




1.8 Mechanism of CO release 
The lead organic CORM (oCOm-21) synthesised by the Larsen group is currently being 
investigated for its vasorelaxant properties during cardiovascular surgery. These properties 
were investigated by treatment of pre-contracted rat aortic rings with varying doses of the 
CORM which showed a dose dependent relationship. oCOm-21 was found to have an 
EC50 value of 18.0 ± 0.8 µM.
19  
 
Figure 1.11 Structure of oCOm-21. Where A- is Cl-, Br-, or OCOCF3-. 
This compound has also been shown to have tissue preservation properties (Figure 1.12). 
Rat heart tissue samples treated with oCOm-21 appeared to be more viable (b ii) after 
incubation for 48 hours, as evidenced by dehydrogenase activity (red colour), when 
compared to an untreated control (b i). 
 
Figure 1.12 Preliminary experiment showing potential tissue preservation properties of oCOm-21: rat heart 
tissue samples; (a) fresh tissue samples (i) untreated and unstained, (ii) untreated and stained with tetrazolium 
chloride (TTC) stain; (b) tissue samples after incubation (48 hours, 37 °C) (i) control tissue stained with TTC 
stain, (ii) samples incubated with oCOm-21 (3 µM) for 48 hours and stained with TTC stain, (iii) tissue 




It was theorised that by changing the halide leaving group of oCOm-21 we would be able 
to gather more information about how CO release from these compounds is occurring and 
whether this fits with the proposed E1cB mechanism.
23 The chloro- and iodo-analogues of 
oCOm-21 will be synthesised for this purpose. 
 
Figure 1.13 Structure of oCOm-60 and -61. Where A- is Cl-, Br-, or OCOCF3-. 
1.8.1 The E1cB mechanism 
E1cB elimination is a two-step process. The first step involves abstraction of the β-
hydrogen by base to form the carbanion intermediate (the conjugate base of the substrate 
that is giving up the leaving group). Step two comprises the formation of a new double 
bond and concomitant loss of the leaving group (Figure 1.14). It has been found that the 
E1cB mechanism is most likely to occur in substrates that have both a poor leaving group 
and an acidic hydrogen.63  
 
Figure 1.14 The E1cB mechanism.64 
This reaction is considered to be first order with respect to the conjugate base,65 and three 
distinct cases can be described. The first involves deprotonation (step 1) as the rate 
determining step and is termed E1cB(irr). Formation of the product is faster than return of the 
carbanion to starting material and thus the deprotonation step is considered to be 
irreversible. In this case, the acidity of the proton would control the rate of elimination. 




This should produce general trend wherein compounds with chloride leaving groups would 
have more acidic protons compared to those with bromide or iodide leaving groups, 
thereby making it easier to remove. This would increase the rate of CO production.  
If the second step (leaving group leaving) is rate determining, we would expect to see a 
different trend. This could be either an E1cB(rev) or E1cB(anion) mechanism, in both of which 
the second step (leaving group leaving) is rate determining and they differ in behavior of 
the first step. Iodide is a better leaving group than bromide, which in turn is a better 
leaving group than chloride. This is in part due to the relative electronegativities of I, Br 
and Cl, but can be better explained by the relative size and atomic radius of each atom. 
Large atoms have more core electrons shielding their nuclear charge from outer shell 
electrons, meaning they have a poor affinity for bonding electrons. As a result, larger 
atoms have longer bond lengths. It is well known that longer bonds are weaker bonds and 
therefore take less energy to break. This is consistent with the reported bond lengths and 
energies of C-X bonds (Table 1.3).66 
Table 1.3 Average bond distance and energy of carbon to other elements.66 
Bond Bond Length (Å) Bond Energy (kJ mol-1) 
CH3-Cl 1.78 351 
CH3-Br 1.93 293 




















Chapter 2  
Development of organic CORMs: Formation of a norbornadienone 
CO source 
2.1 Synthesis of diene dimer 4 
The first objective in the development of a new CO source for palladium catalysed 
carbonylation reactions was the synthesis of the bridged carbonyl compound 30. This 
would require the synthesis of 2,5-dimethyl-3,4-diphenylcyclopentadienone (4) which can 
be used as the 4πs component in a Diels-Alder reaction with the commercially available 
dienophile, bromomaleic anhydride (29) (Scheme 2.1). 
 
Scheme 2.1 Reaction of diene dimer 4 and bromomaleic anhydride (29) to give corresponding cycloadduct 
30. Reagents and conditions: toluene, reflux, 4 h, 96% 
The synthesis of 4 started with a base promoted double aldol reaction of benzil (40) and 3-
pentanone (41) to give the cyclopentenone intermediate 42 which was used without 
purification in the next step (Scheme 2.2). Elimination of water was then effected by 
treatment with acid activated acetic anhydride to generate diene 4 in a 73% yield over the 
two steps as its dimer. The formation of the dimer is a reversible process and heating 





Scheme 2.2 Synthesis of dimethyldiphenylcyclopentadienone 4 as its dimer via a base promoted double aldol 
condensation of 3-pentanone with benzil. 
The HRMS and NMR data obtained were consistent with the structure of 4 and with those 
previously reported.67 The HRMS spectrum showed an ion at m/z = 543.2278 which was 
consistent with the molecular formula of C38H32O2Na, sodium adduct [M+Na]+ of  4. The 
1H NMR spectrum showed four singlets (0.58, 1.25, 1.64, and 2.25 ppm). Each singlet 
integrated to three protons, which was indicative of four non-equivalent methyl groups of 
the dimer. It also contained multiplets (in the range of 6.70 - 7.29 ppm) which accounted 
for 20 aromatic protons. 
2.1.1 Diels-Alder addition of diene 4 to dienophile 29 
With diene dimer 4 in hand, the Diels-Alder reaction with bromomaleic anhydride (29) 
was undertaken. This proceeded smoothly in refluxing toluene to form the bridged 
cycloadduct 30 as an inseparable 8:1 mixture of the endo and exo isomers in an excellent 




The structure of 30 was confirmed from its spectroscopic data. The HRMS spectrum 
showed a peak at m/z = 459.0202 [M+Na]+ consistent with a molecular formula of 
C23H17BrO4Na, the sodium adduct of 30. The ratio of endo and exo isomers was 
determined from the integration of the signal for the H-7a proton in the 1H NMR spectrum 
(Figure 2.1). 
 
Figure 2.1 Partial 400 MHz 1H NMR spectrum of 30 recorded in CDCl3 at 400 MHz. 
For the major endo isomer two sets of singlets were observed at 1.62 and 1.65 ppm with 
each singlet integrating to three protons. These singlets could be attributed to the two 
methyl groups. These are non-equivalent, due to the asymmetrical nature of the 
cycloadduct. A one proton singlet at 3.74 ppm was assigned as the H-7a proton. The two 
methyl groups of the minor exo isomer were observed as singlets at 1.25 and 1.59 ppm 
which each integrated to three protons. The H-7a proton of the exo isomer resonated at 
3.52 ppm. Further evidence for the formation of cycloadduct 30 was found in the 13C NMR 
spectrum, with a signal at 195.4 ppm, consistent with a bridged carbonyl group. The 
signals for the imide carbonyl groups were present at 166.8 and 167.0 ppm. 
2.1.2 The Diels-Alder reaction 
The 8:1 ratio of endo to exo isomers of the bridged cycloadduct can be explained by the 








[4πs + 2πs] process as it involves the 4π-electrons of the diene and the 2π-electrons of the 
dienophile reacting in a suprafacial manner.68 For a normal electron demand Diels-Alder 
reaction an electron rich diene and electron deficient dienophile are required. This can be 
achieved with electron-withdrawing groups (such as an ester) attached to the double bond 
of the dienophile, which lower the LUMO energy. Conversely, the energy of the HOMO of 
the diene can be raised by electron donating groups. This results in a smaller energy gap 
between the HOMO(diene) and the LUMO(dienophile) (Figure 2.2).
69 
 
Figure 2.2 Substituents effect on the HOMO-LUMO gap.69 
Bromomaleic anhydride is an electron deficient dienophile, due to the combined presence 
of the bromine substituent on the double bond and the electron withdrawing carbonyl 
groups which lower the LUMO by decreasing the electron density of the reacting π system. 
Diene dimer 4 is known to be electron-rich due to the methyl groups at the 2- and 5-
positions which enhance electron density inductively through the σ system.52 The phenyl 
substituents at the 3- and 4- positions would further increase the electron density of the 
diene by resonance; both of these contribute to raising the energy of the HOMO of the 
diene. Thus, the primary orbital interactions for the reaction between bromomaleic 
anhydride and dimer 4 would be between the HOMO of the electron rich diene and the 
LUMO of the dienophile. The reaction is concerted and occurs via a single transition state, 
driven by the conversion of two π-bonds into two σ-bonds. The reactants can approach 





Figure 2.3 Overlap of HOMO of cyclopentadienone 4 and LUMO of bromomaleic anhydride via endo (A) 
and exo (B) approach. Substituents of the diene have been omitted for clarity. 
If the reaction is kinetically controlled, the endo product is favoured. This is due to the 
secondary (non-bonding) orbital interactions (shown as blue wavy lines) between the 
LUMO of the carbonyl groups (blue) and the HOMO of the diene. No bonds are formed 
from these interactions but the energy of the endo transition state is lowered, thereby 
increasing the rate of formation of the endo product. The converse is true for reactions 
under thermodynamic control in which the Diels-Alder reaction is reversible. Under these 
conditions the more stable exo-adduct is favoured. The reactions of maleic anhydride 
derivatives and cyclopentadienones have been shown to proceed under kinetic control 
giving rise to mainly endo products.70 The assignment of the major and minor isomers of 
30 as endo and exo, respectively, was made based on this precedent. 
2.2 Triggering the release of CO from the cycloadduct 30 (CO Source A) 
The ability of cycloadduct 30 to release CO can be indirectly examined via 1H NMR 




as 30 can lose HBr upon treatment with an organic base such as Et3N or DBU (Scheme 
2.3). This is then followed by cheletropic rearrangement and loss of CO, driven by the 
stability of the aromatic product. Bromo-cycloadduct 30 is asymmetrical and non-aromatic, 
hence the two methyl groups are not equivalent. In the 1H NMR spectrum of 30, this is 
apparent from the two singlets around 1.50 ppm (vide supre). After the cheletropic loss of 
CO, it was expected that the 1H NMR spectrum of the aromatised cycloadduct would 
contain one singlet integrating to six protons with a chemical shift between 2.0 and 3.0 
ppm, as the methyl groups are now equivalent and attached to an aromatic ring.  
 
Scheme 2.3 E1cB mechanism for the release of HBr and CO from bromo-cycloadduct 30 to give aromatised 
product 36. 
Treatment of cycloadduct 30 with Et3N gave the corresponding aromatic product 36 in a 
98% yield. Effervescence was observed on addition of base to 30, indicative of gas release. 
The HRMS data supported a molecular formula of C22H16O3, which is consistent with the 
proposed structure of 36, including loss of the characteristic bromine isotope pattern. 
Pleasingly, the 1H NMR spectrum showed a six-proton singlet at 2.43 ppm. This is 
consistent with two equivalent methyl groups attached to an aromatic ring. Furthermore, 
the 13C NMR spectrum of 36 no longer contained a peak at 195.4 ppm of the bridged 




2.3 Investigation of an alternative CO source B 
In addition to cycloadduct 30 (CO source A), a second norbornadienone based CO source 
was also investigated. A Diels-Alder reaction was carried out between cyclopentadienone 4 
and diethyl acetylenedicarboxylate (43) (Scheme 2.4). The two components were heated in 
1,4-dioxane to give hexa-substituted benzene 44 in 91% yield. This reaction proceeds via 
norbornadienone intermediate 43b which undergoes spontaneous cheletropic 
rearrangement, giving rise to the aromatic product (44) and CO. Spectroscopic and 
analytical data for 44 were consistent with those reported in the literature.71 
 
Scheme 2.4 Reaction of diene dimer (4) and diethyl acetylenedicarboxylate (43) to give hexa-substituted 
benzene (44). This reaction is assumed to proceed via the unstable norbornadienone intermediate 43b. 
The 1H NMR spectrum of 44 contained a triplet integrating to six protons (J = 7.1 Hz) at 
1.39 ppm, which was attributed to the two equivalent methyl groups of the ethyl esters. A 
six proton singlet at 2.08 ppm accounted for the two equivalent aromatic methyl groups of 
the hexasubstitued benzene ring. A quartet integrating to four protons at 4.38 ppm was 
indicative of the methylene groups on the ethyl ester side chain.  Most importantly, 
analysis of the 13C NMR spectrum did not show a signal for a bridged carbonyl, providing 




Chapter 3  
Application of CORMs in palladium-catalysed aminocarbonylation 
reactions 
3.1 Initial investigations 
With the synthesis of cycloadduct 30 complete, the next step was to repeat the palladium 
catalysed aminocarbonylation reactions exemplified by Cho,52 using cycloadduct 30 as a 
CO source. To simplify analysis and purification of the products, a similar two-chamber 
system to that of Hermange et al. was used (Figure 3.1).50 This two-chamber system 
circumvents the requirement for purification of the carbonylation reaction product from 
those of the spent CO source.  
 
Figure 3.1 Two-chamber glassware prepared by the Larsen group for palladium-catalysed carbonylation 
reactions.52 
In the CO releasing chamber (Chamber A, Scheme 3.1), 1.5 equivalents of the bromo-
cycloadduct 30 was treated with 2.0 equivalents of Et3N. In Chamber B (Scheme 3.1), p-
iodoanisole (1 eq.), n-butylamine (2.3 eq.) were treated with Et3N (2.3 eq.) and 5 mol% 





Scheme 3.1 In Chamber A (CO generation chamber), 30 was treated with Et3N to give 36 and CO.  26 and 
27 were treated with Et3N and palladium-catalyst at 80 °C in Chamber B (CO consuming chamber) to yield 
28. Reagents and conditions: 80 ˚C, a. Et3N (2.0 eq.), 1,4-dioxane; b. Pd2(dba)3 (5 mol%),  PPh3 (10 mol%), 
Et3N (2.3 eq.), 1,4-dioxane, 88%. 
Initial attempts to produce consistent results gave varying degrees of conversion of the 
starting materials to the corresponding amide products. It was hypothesised that the CO gas 
being produced in Chamber A was escaping from the system, as when the two-chamber 
system was opened after reaction for 20 hours it was often no longer pressurised. As 1.5 
equivalents of CO gas should be produced, not all of it would be incorporated, even in the 
case of full conversion to the amide product. It is most likely that the caps for the two-
chamber system were not completely sealing leading to loss of CO gas from the apparatus. 
To overcome this problem, the caps were fitted with silicon seals that proved very 
effective. In almost every reaction where the silicon seals were employed the system was 
still pressurised after the reaction was complete. 
The 1H NMR spectrum of the crude reaction mixture from Chamber B showed full 
conversion to the amide 28 with no traces of p-iodoanisole evident (Figure 3.2). The 








Figure 3.2 Comparison of the aromatic region in the 1H NMR spectra of the crude reaction mixture of 28 
(blue) and p-iodoanisole (26) (red). No traces of starting material p-iodoanisole (26) are present in the 
reaction mixture. 
The 1H NMR data of 28 were consistent with those in the literature.48 A three proton triplet 
at 0.94 ppm was assigned to the δ methyl protons of the side chain. Three multiplets at 
1.35 – 1.38, 1.54 – 1.61 and 3.40 – 3.45 ppm consisting of two protons each were assigned 
to H-9, H-8 and H-7 respectively. A signal for the methoxy protons was evident as a 
singlet at 3.83 ppm. A broad singlet at 6.15 ppm was indicative of an amide proton. A pair 
of two proton doublets (J = 8.9 Hz) were observed at 6.89 and 7.72 ppm, accounting for H-
2/H-6 and H-3/H-5. The 13C NMR spectrum contained a peak at 167.1 ppm, which was 
assigned to the amide carbonyl carbon. These data were further confirmed by HRMS 
which gave an m/z value consistent with a molecular formula of C12H17NO2, as well as IR 
absorptions characteristic of an amide bond. The 1H NMR spectrum of the crude reaction 














aromatic by-product 36, with by the absence of the two singlets around 1.50 ppm and the 
presence of a singlet at 2.43 ppm which integrated to six protons. 
3.1.1 Palladium-catalysed aminocarbonylation using the alternative CO source B 
The alternative CO source as described in section 2.3 was also applied to the 
aminocarbonylation reaction using the two-chamber system. Using cyclopentadienone 4 
and diethyl acetylenedicarboxylate (43) as the CO source in Chamber A, p-iodoanisole and 
n-butylamine were treated with Et3N and 5 mol% palladium catalyst in Chamber B 
(Scheme 3.2).  
 
Scheme 3.2 Reaction of 4 and diethyl acetylenedicarboxylate (43) to give 44 and CO. Reagents and 
conditions: a. 1,4-dioxane; b. Pd2(dba)3 (5 mol%),  PPh3 (10 mol%), Et3N (2.3 eq.), 1,4-dioxane, 80 ˚C, 95%. 
As previously determined, the CO releasing reaction of cyclopentadienone 4 and diethyl 
acetylenedicarboxylate does not proceed until the reagents are heated. This is 
advantageous, as all reactants can be added and the system properly sealed before any CO 
is released. This is in contrast to the system described in section 2.1.1, where CO begins to 
be released immediately upon addition of base. The amide product, N-butyl-4-
methoxybenzamide (28), was obtained in a 95% yield after purification from the reaction 
mixture by column chromatography. The analytical and spectroscopic data were identical 





3.2 Investigating the tolerance of and chemoselectivity of the 
aminocarbonylation reaction towards different functional groups  
The aminocarbonylation reaction employing cycloadduct 30 as previously described was 
carried out using selected aryl iodides as reactants to investigate tolerance and 
chemoselectivity towards different functional groups (Scheme 3.3, Table 3.1).   
Table 3.1 Palladium-catalysed aminocarbonylation reactions carried out with selected aryl iodides and n-
butylamine. All reactions were carried out at 80 °C for 20 hours.  
 
Scheme 3.3 General reaction scheme using 30 as the CO source for aminocarbonylation reactions with n-
butylamine in 1,4-dioxane. Reagents and conditions: 80 ˚C, 20 hours. a. Et3N (1.5 eq). b. Pd2(dba)3 (5 
mol%), PPh3 (10 mol%), Et3N (2.3 eq.). 
Entry Aryl iodide Product 
Conversion a  
[%] 



































a measured by 1H NMR of the crude reaction mixture 
b isolated yields after column chromatography. Yields in brackets are for reactions covered by note c 
c reaction also carried out using the alternative CO source in Chamber A 
Firstly, 1-iodo-4-nitrobenzene (31) was reacted as the limiting reagent in Chamber B with 
n-butylamine (27), and cycloadduct 30 was treated with Et3N in Chamber A. 100% 
conversion to the corresponding amide product N-butyl-4-nitrobenzamide (45) was 
observed and the purified product was obtained in almost quantitative yield (99%) (Table 
3.1, Entry 2). Once again, the spectroscopic data were consistent with those reported in the 
literature.72 The 1H NMR spectrum for the amide product 45 was very similar to that of 28 
as it contained a three proton triplet at 0.98 ppm accounting for the methyl protons. Three 
two proton multiplets were present at 1.39 - 1.48, 1.60 - 1.67 and 3.47 - 3.52 ppm, from H-
10, H-9 and H-8, the same pattern as previously seen in the spectrum for 28. The amide 
proton was present as a broad singlet at 6.12 ppm. The two doublets (J = 8.7 Hz) at 7.92 
and 8.29 ppm again accounted for H-2/H-6 and H-3/H-5 respectively. The 13C NMR 
spectrum contained a peak at 165.4 ppm, characteristic of the amide carbonyl group. 
The alternative CO source of cyclopentadienone 4 and diethyl acetylenedicarboxylate (43) 
was also applied to the carbonylation reaction of 1-iodo-4-nitrobenzene (31) and n-
butylamine (27). Full conversion of the limiting reagent to the corresponding amide 
product 45 was achieved, with an 82% isolated yield following column chromatography. 
1-Bromo-4-iodobenzene (32) was used as a substrate to examine the chemoselectivity of 
the palladium-catalysed aminocarbonylation reaction (Table 3.1, Entry 3,). The formation 
of 46 was evident by comparison of the 1H NMR data of the isolated compound with those 
reported in the literature.73 The 1H NMR spectrum of the crude reaction mixture in 
Chamber B showed full conversion of starting material to the corresponding amide, and no 
evidence of insertion of CO into the Ar-Br bond.  
The versatility of the aminocarbonylation reaction utilising cycloadduct 30 as the CO 




(34) as substrates. Reaction of iodobenzene and n-butylamine again resulted in 100% 
conversion of the aryl iodide substrate as confirmed by the 1H NMR spectrum of the crude 
reaction mixture. The product was isolated in 97% yield (Table 3.1, Entry 3). The 1H NMR 
spectrum of secondary amide 47 was again similar to those described previously, and 
consistent with that reported in the literature.74 When 1-iodonapthalene was used as the 
limiting reagent, the 1H NMR spectrum of the crude reaction mixture showed only 90% 
conversion of starting material to the corresponding amide product 48 (Table 3.1, Entry 5). 
This is thought to be due to the steric interactions from the hydrogen atom peri to the 
position of carbonyl insertion (Figure 3.3), which possibly makes it more difficult to form 
the PdII species in the oxidative addition step of the catalytic cycle. 
 
Figure 3.3  Steric interactions between peri-hydrogen atom and the carbonyl group of secondary amide 48. 
Amide product 48 was obtained in an 88% yield after column chromatography (Table 3.1, 
Entry 4), and the structure was confirmed by comparison with 1H NMR data reported in 
the literature.74-75 As expected a triplet integrating to three protons was present at 0.99 
ppm, arising from the methyl group. The multiplets at 1.46, 1.65 and 3.56 were assigned as 
protons H-11 through to H-9. The amide proton appeared at 5.95 ppm and four multiplets 
in the aromatic region (7.45, 7.56, 7.89 and 8.30 ppm) accounted for the seven aromatic 
protons of the naphthalene moiety.  
3.3 Palladium-catalysed aminocarbonylation reactions of aryl iodides with the 
secondary amine morpholine 
Having determined that cycloadduct 30 was a suitable source of CO for palladium 
catalysed aminocarbonylation reactions with a wide range of aryl iodides, attention then 
turned to applying the system to more complex structures such as the synthesis of tertiary 
amides. Secondary amine morpholine was chosen as an alternative nucleophile for these 




Table 3.2 Palladium-catalysed aminocarbonylation reactions of selected aryl iodides and morpholine.  
 
Scheme 3.4 General reaction scheme using 30 as the CO source for aminocarbonylation reactions of aryl 
iodides with morpholine. Reagents and conditions: a. Et3N (1.5 eq). b. Pd2(dba)3 (5 mol%), PPh3 (10 mol%), 
Et3N (2.3 eq.). 100 °C, 25 h. 









































a measured by 1H NMR 
b isolated yields after purification by column chromatography 




A trial reaction was carried out using 1.5 equivalents of 30 as the CO source in Chamber 
A. In Chamber B; p-iodoanisole (1 eq.), and morpholine (35) (2.3 eq.) were treated with 
Et3N and 5 mol% palladium catalyst. The reaction mixture was heated to 80 °C (Table 3.2, 
Entry 1c). After 20 hours, the 1H NMR spectrum of the crude reaction mixture indicated 
that 80% of p-iodoanisole starting material had been converted into the amide product. In 
order to achieve full conversion, the reaction repeated and the system was heated to 100 °C 
for 25 hours (Table 3.2, Entry 1).  
The structure of 49 was confirmed by comparison of spectroscopic data with those 
reported in the literature.76 The 1H NMR aromatic signals arising from p-iodoanisole were 
much the same as for compound 28, with two multiplets at 6.90 – 6.94 and 7.37 – 7.41 
ppm accounting for the H2/H6 and H3/H5 protons respectively. A triplet integrating to 
three protons at 3.83 ppm was indicative of the methoxy substituent. A broad multiplet 
from 3.64 – 3.70 ppm accounted for the eight protons arising from the morpholino group 
(this signal was found to be characteristic for the other tertiary amides 50, 51, 52 and 53 
which were prepared in this study). The 13C NMR spectrum contained a signal at 170.5 
ppm, indicative of an amide carbonyl carbon. The structures for Entries 2 through 5 (Table 
3.2), were also confirmed by comparison of their spectroscopic data with literature those 
reported in the literature.76-77 Once again, when the aminocarbonylation was attempted 
using 1-iodonapthalene as the limiting reagent (Entry 5), the 1H NMR spectrum of the 
crude reaction mixture showed lower conversion (80%) of starting material to the amide 
product; nevertheless the product was isolated in an acceptable yield of 75% following 
column chromatography so no attempt to alter reaction conditions to increase the yield of 
53 was made. 
3.4 Double carbonylation reactions 
Following the successful synthesis of both secondary and tertiary aryl amides, the protocol 
was adapted and applied to a palladium catalyzed double carbonylation reaction, originally 
reported by Yamamoto et al. in 1982.78 This is mechanistically similar to the mono-
carbonylation reaction but instead gives rise to compounds with an α-ketoamide functional 




fragments in biologically active molecules, synthetic drugs, and pharmaceutically 
interesting compounds.82-83  
 
Figure 3.4 α-Ketoamide functional group. 
The first step, common to both the double and monocarbonylation catalytic cycles, is 
oxidative addition of the Pd0 species to the aryl halide bond, giving rise to an arylpalladium 
species A (Figure 3.5). Coordination of CO to this intermediate provides CO-complex B. If 
insertion of CO into the aryl–palladium bond takes place, acylpalladium complex C is 
produced, which drives the double carbonylation cycle (Figure 3.5, Cycle A). If this does 
not occur, Cycle B will be favoured and attack of the nucleophile on the carbonyl ligand 
followed by reductive elimination will generate amide D'. Once complex C is formed, 
another molecule of CO can coordinate to the acylpalladium complex. Subsequent attack 
of the nucleophile (in this case an amine) on the carbonyl ligand produces the 
aroyl(carbamoyl)palladium species E as the bis-acyl-type intermediate. The final step in 
the catalytic cycle is reductive elimination of the α-ketoamide (F) which regenerates the 
active Pd0 catalytic species.84 As the scope of this type of carbonylation reaction has 
expanded, many factors favouring Cycle A over Cycle B have been examined including 





Figure 3.5 Proposed mechanism of the Double carbonylation reaction.  This reaction comprises two 
competing catalytic cycles A and B with common intermediates A and B. Cycle A gives a-ketoamide, the 
double carbonylation product, whereas cycle B affords amide, the single carbonylation product. Diagram 
adapted from Yamamoto and Lin.84  
As mentioned above, organic CORMs have been successfully applied to double 
carbonylation reaction of various substrates as demonstrated by both Kondo et al.51 and 
Skrydstrup et al.48  
 
Scheme 3.5  Double carbonylation of aryl halide 21 using silacarboxylic acid CORM 15b as a CO source at 
rt.48 
Skrydstrup and co-workers showed that higher CO pressures favoured Cycle A over Cycle 
B, when three equivalents of their silacarboxylic acid CORM (15b) were used for the 




corresponding α-ketoamide product 23 was obtained in 91% yield following purification with 
no trace of the single carbonylated amide product. The choice of ligand is also important. 
Kondo et al. have shown that PtBu3, a bulky, electron-rich ligand has extremely good 
selectivity for doubly carbonylated products over mono-carbonylated counterparts.51 
However, the free phosphine ligand is sensitive to air and therefore the more stable tri-tert-
butylphosphonium tetrafluoroborate salt ([(t-Bu)3PH]BF4) is more commonly used.
85 The 
choice of base has also been shown to be important for the selectivity. DBU is known to 
favour the formation of single carbonylation products.86 However, when used in 
conjunction with [(t-Bu)3PH]BF4, rather than PPh3, a change in the selectivity is observed 
where the double carbonylated α-ketoamide product is formed preferentially over the amide 
product.51, 87  
 
Scheme 3.6 The double carbonylation of p-iodoanisole and butylamine using cycloadduct 30 as a CO source. 
Reagents and conditions: toluene, 100 °C a. DBU (3.0 eq.), b. Pd2(dba)3 (5 mol%), [(tBu)3PH]BF4 (10 mol%), 
DBU (2.0 eq.), 64%. 
In the current research similar reagents and reaction conditions to that of Skrydstrup were 
applied to the double carbonylation reaction of 26 and 27, with cycloadduct 30 as a source 
of CO (Scheme 3.6). Three equivalents of the CO donor molecule were used in order to 
enhance both the rate of the reaction and the selectivity for α-ketoamide formation. The 
ligand [(t-Bu)3PH]BF4 and base DBU was also used. After 20 hours of reaction at room 
temperature, the 1H NMR spectrum of the crude product from Chamber B showed no 




product was obtained in a 64% yield after purification by column chromatography. As 
expected, the 1H NMR spectrum for the doubly carbonylated product was very similar to 
that of the singly carbonylated amide; a three proton triplet at 0.94 ppm accounted for the 
side chain methyl protons. Three multiplets at 1.34 – 1.44, 1.54 – 1.61 and 3.34 – 3.40 ppm 
consisting of two protons each were assigned to H-11, H-10 and H-9 respectively, A signal 
for the methoxy protons was evident as a three-proton singlet at 3.83 ppm. The broad 
singlet arising from the N-H was apparent at 7.15 ppm. The main difference between the 
1H NMR spectra of the doubly carbonylated product and that of the singly carbonylated 
amide (28) was in the signals corresponding to aromatic protons. These were observed as a 
pair of doublets of triplets at 6.93 and 8.40 ppm which both integrated to two protons. The 
latter signal is shifted further downfield due to proximity to the α-ketoamide moiety. 
Furthermore the 13C NMR spectrum gave conclusive evidence for formation of the α-
ketoamide over the amide as it showed two carbonyl peaks at 164.8 and 186.0 ppm 
corresponding to C-7 and C-8. These data were further supported by HRMS data which 
gave a parent ion peak of m/z 258.1118 which is consistent with a molecular formula of 
C13H17NO3, corresponding to the [M+Na]
+ adduct. A small amount (<10%) of the 
corresponding amide (arising from the mono-carbonylative reaction) was also isolated 
from the crude reaction mixture. 
3.5 Suzuki-Miyaura carbonylation reactions 
As discussed in section 1.6.2, the carbonylative Suzuki-Miyaura cross-coupling is the 
three-component reaction of an aryl halide (or triflate), a boronic acid (or derivatives of) 
and CO to give corresponding unsymmetrical biaryl ketones as products (Scheme 3.7). 
These unsymmetrical biaryl ketones are common features of many biologically active 
molecules. As with all palladium cataylsed carbonylation reactions, there are many factors 
that can be explored in order to optimize the reaction and suppress unwanted competitive 
direct cross-coupling. Solvent, reaction temperature, as well as bidentate phosphine ligands 
versus a ligand free system were all investigated to find reaction conditions that could be 
applied to a wide range of substrates before being applied to the synthesis of biologically 





Scheme 3.7 Three-component carbonylative Suzuki-Miyaura cross-coupling. 
3.5.1 Optimization of reaction conditions 
Initial attempts to consistently produce the carbonylative over the non-carbonylative cross-
coupled product gave mixed results. A trial reaction of iodobenzene with phenylboronic 
acid was chosen to study substrates without the influence of electronic effects from 
substituents on either the aryl halide or boronic acid component. The crude reaction 
mixtures were analysed for the desired product benzophenone (56), the direct coupling 
product biphenyl (57), and the overall conversion of starting material (Scheme 3.8, Table 
3.3).  
The first reaction was carried out using similar conditions to those utilized for 
aminocarbonylations; two equivalents of the bromo-cycloadduct 30, were treated with 2.3 
equivalents of Et3N in Chamber A. In Chamber B iodobenzene (32) (1 eq.), and 
phenylboronic acid (55) (1.5 eq.) were treated with three equivalents of K2CO3, 2 mol% 
palladium catalyst and 10 mol% PPh3. The reaction mixture was heated to 80 °C (Table 3.2 
Entry 1). After 25 hours, the 1H NMR spectrum of the crude reaction mixture indicated 
that no p-iodoanisole starting material remained. However, following purification it was 
clear that both carbonylated product 56 and the non-carbonylated product 57 were present. 
Further examination of the 1H NMR spectrum showed a 3:2 ratio of the benzophenone (56) 







Table 3.3 Effects of reaction parameters on the carbonylative Suzuki-Miyaura reaction versus the direct 
Suzuki-Miyaura cross-coupling of 4-iodobenzene with phenylboronic acid. 
 
Scheme 3.8 General reaction scheme using 30 as the CO source for the carbonylative Suzuki-Miyaura 
reaction of iodobenzene with phenylboronic acid. Reagents and conditions: a. Et3N (2.5 eq) 1,4-dioxane, 
b. Pd2(dba)3 (2 mol%), ligand (5 mol%), 25 h, solvent, temp.  






Solvent Ligand Ratioa 
Yieldb 
[%] 




PPh3 3:2 51 




Xantphos 1:4 0 




Xantphos 1.2:1 42 




- 1.7:1 50 




- 1.3:1 46 




- 1.6:1 59 




- 3.2:1 78 
a Ratio of product (56) to non-carbonylative Suzuki cross coupled by byproduct (57) 
b isolated yield of product 56 
c formation of third product (benzoic acid) present 
 
The next step was to investigate an alternative ligand to the monodentate PPh3. Xantphos 
(58) (Figure 3.6) is a relatively cheap bidentate phosphine ligand (bite angle: 97–133°) and 
previous work within the literature has shown it to be an effective ligand for various types 




bite angle e.g. ≥110°) favour the carbonylative Suzuki reaction cycle whereas monodentate 
or cis-chelating ligands (smaller bite angle) favour the direct Suzuki cross coupling.88-89  
 
 
Figure 3.6 Bidentate ligand 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos). 
Despite many reports of Xantphos favouring the carbonylative Suzuki reaction cycle, when 
employed in the reaction of p-iodoanisole (1 eq.), and phenylboronic acid (1.5 eq.) in 
anhydrous toluene,  the 1H NMR spectrum of the reaction mixture showed a 1:4 ratio of 56 
to the undesired byproduct 57 (Table 3.3, Entry 2). A third product was also present in the 
crude reaction mixture, which following purification by column chromatography was 
identified as benzoic acid. This product can arise from attack of water as a nucleophile in 
the catalytic cycle. Given this result, it was proposed that water could be formed by 
dimerization or trimerisation of the boronic acid. This has been shown to occur by heating 
a boronic acid in toluene by Chaudhari et al. (Figure 3.7).90 It has also been shown that the 
presence of water, or even employing  water as a solvent can accelerate the direct cross-
coupling reaction91 since the anion ArB(OH)3ˉ is 10
6 times more reactive than the neutral 
boronic acid.92 The trimerisation of the boronic acid would explain both the high ratio of 
undesired biphenyl (57) to benzophenone (56), and also the presence of benzoic acid as a 
second byproduct.  
 





The reaction was then repeated, with anisole as the carbonylation solvent in Chamber B. 
This solvent is commonly used for carbonylative Suzuki-Miyaura reactions, and has been 
shown to improve selectivity over the direct coupling reaction.93 The ratio of the 
carbonylative product 56 to cross coupled by-product 57 improved to 1.2:1, however, there 
was still a small amount of benzoic acid byproduct present and so a ligand free system was 
investigated (Table 3.3, Entry 3). There have been previous reports of ligand-free 
carbonylation reactions, although many have used very high pressures of CO in order to 
achieve this.94 Li et al reported a ligand-free system for Suzuki-Miyaura carbonylation 
reactions utilizing Pd2(dba)3 (2 mol%) as the catalyst, K2CO3 (3 eq.), and anisole as the 
solvent without using high pressures of CO.95 This system showed good selectivity for 
carbonylated products over non-carbonylated and as such was applied to our system. Once 
again an improvement was seen in the ratio of 56 to 57 which increased to 1.7:1. No 
benzoic acid byproduct was identified in the 1H NMR spectrum of the crude product 
(Table 3.3, Entry 4). 
The next step in the optimisation of the reaction was to investigate the effects of 
temperature. The reaction was carried out under the same conditions at both 50 °C and 100 
°C. For the reaction at 50 °C the 1H NMR spectrum of the crude product showed 
incomplete conversion, with a small amount of unreacted iodobenzene starting material 
observed, and a ratio of 1.3:1 of 56 to 57 (Table 3.3, Entry 5). The reaction carried out at 
100 °C showed full conversion of starting material; but the ratio of the product to biphenyl 
did not show much improvement (1.6:1) (Table 3.3, Entry 6). The final investigated 
condition was the amount of CO donor used, as a greater quantity of CO would hopefully 
increase the amount of CO dissolved in the reaction mixture and also raise the Pd/CO ratio 
which is known to directly affect the selectivity for the carbonylative reaction over the 
competing cross coupling reaction.96 When the number of equivalents of cycloadduct 30 
was raised from two to three, a greatly improved ratio of benzophenone (56) to biphenyl 
(57) to 3.2:1 was seen and an isolated yield of 78% of benzophenone was obtained (Table 
3.3, Entry 7). Although this reduces the overall atom efficiency of the reaction, it was 
deemed necessary in order to obtain good yields and selectivity for the carbonylative 




Thus, it was found that the optimal reaction conditions to be used in the Suzuki-Miyaura 
carbonylation reaction were as follows; Pd2(dba)3 (2 mol%) as the catalyst, anisole as the 
solvent, and K2CO3 as the base at 80 °C with three equivalents of CO donor molecule 30 
as the CO source. These conditions were used for all subsequent carbonylative Suzuki-
Miyaura reactions. 
3.5.2 Electronic effects of substituents 
With optimized conditions in hand, the system was applied to Suzuki-Miyaura 
carbonylations of substrates with different electronic properties in order to investigate the 
effects of both electron withdrawing and donating groups. Initial investigations into 
reactions of p-nitro-iodobenzene (31) and phenylboronic acid (55) were not successful 
with large amounts of the biaryl product obtained from the competing non-carbonylative 
Suzuki coupling. Nitro groups are highly electron withdrawing and when bonded to an 
aromatic ring they decrease the electron density of the ring through inductive and 
mesomeric effects. It is thought that electron-withdrawing substituents of the aryl iodide 
component enhance the rate of the non-carbonylative reaction by facilitating the rate 
limiting oxidative addition step.  
When p-iodoanisole (26), an aryl iodide with an electron donating para-substituted 
methoxy group was applied to the reaction a change in the general trend was observed and 
the main product isolated was the carbonylated biaryl ketone; (4-
methoxyphenyl)(phenyl)methanone (59) in 74% yield following column chromatography 
(Scheme 3.9). A small amount of the competing biphenyl cross coupled product was also 
detected in the reaction mixture by 1H NMR (approx. 10 %) but not isolated. The HRMS 
and NMR data were consistent with the structure of 59 and with those previously 
reported.97 The HRMS spectrum showed an ion at m/z = 235.0730 [M+Na]+ which 
confirmed 59 had the molecular formula C14H12O2Na. The 
1H NMR spectrum contained a 
singlet at 3.89 ppm which was indicative of the methoxy group; it also contained four sets 
of doublets at 6.97, 7.47, 7.76 and 7.83 ppm, each integrating to two protons and a one 
proton triplet at 7.57 ppm accounting for all of the aromatic protons of the biaryl ketone. 
The 13C NMR spectrum contained a peak at 195.8 ppm, which was assigned to the 





Scheme 3.9 Reaction of p-iodoanisole (26) and phenylboronic acid (55) to give (4-methoxyphenyl)(phenyl) 
methanone (59). Reagents and conditions: 80 ˚C, Chamber A: cycloadduct 30 (3.0 eq.), Et3N (3.5 eq.), 1,4-
dioxane; Chamber B: Pd2(dba)3 (2 mol%), K2CO3 (3.0 eq.), anisole, 74%. 
In terms of the carbonylative versus the direct cross-coupling reactions it is clear that 
electron donating substituents in the para position of the aryl halide decrease the reaction 
rate for the competing direct cross-coupling reaction allowing time for the coordination of 
CO to the acylpalladiumII complex. In turn this allows the carbonylative reaction to 
proceed. Conversely, electron withdrawing groups increase the rate of the direct cross-
coupling reaction compared with their unsubstituted counterparts.98 Substituents on the 
boronic acid substrate also have an effect on the outcome of the reaction. It has been 
shown that electron-rich aryl boronic acids are good substrates for the direct cross-coupling 
reaction relative to non-substituted phenylboronic acids.99-100 It was hoped that a boronic 
acid with an electron withdrawing substituent would favour the carbonylative reaction 
cycle over the direct Suzuki-Miyaura cross-coupling reaction. 4-Chlorophenylboronic acid 
(38) was reacted with p-iodoanisole (26) under the optimised reaction conditions described 
in Section 3.5.1, Page 44. After heating the reaction for 25 hours, the 1H NMR spectrum of 
the crude product from Chamber B showed only one compound; the desired product, biaryl 
ketone (4-chlorophenyl)(4-methoxyphenyl)methanone (60) (Figure 3.8) which was 
obtained in a 94% yield after purification by column chromatography.  
 
Figure 3.8 Structure of (4-chlorophenyl)(4-methoxyphenyl)methanone (60). 
The HRMS and NMR data obtained for ketone 60 were consistent with those previously 




methoxyphenyl)(phenyl)methanone. The HRMS contained a peak at m/z = 269.0340 
[M+Na+] which was consistent with a molecular formula of C14H11
35ClO2 and the 
13C 
NMR spectrum contained a signal for the carbonyl carbon at 194.5 ppm. This result 
demonstrated that an electron deficient boronic acid (such as 4-chlorophenylboronic acid) 
is a preferable coupling partner than either a non-substituted or electron-rich boronic acid 
for carbonylative Suzuki-Miyaura reactions, favouring this reaction pathway over the 
direct cross-coupling path. This was ideal, as the next step in the investigation was to apply 
the system to the synthesis of the biologically active compound fenofibrate which has a 
similar structure to compound 60. 
3.6 Application of cycloadduct 30 as a CO source for the synthesis of biologically 
active compounds 
3.6.1 Synthesis of fenofibrate 
An example of a biologically active unsymmetrical biaryl ketone that can be synthesised 
using this protocol is fenofibrate (Figure 3.9), sold under the brand name Tricor®. 
Fenofibrate is a cholesterol and triglyceride regulator (fibrate) which has been used since 
1975, and is one of the most commonly prescribed fibrates.102 Following oral 
administration, fenofibrate is rapidly hydrolysed by esterases in the intestinal wall and liver 
to its active metabolite, fenofibric acid. This active compound activates the Peroxisome 
Proliferator-Activated Receptor α (PPARα) which in turn increases lipolysis and 
elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and 
reducing production of inhibitors of these lipases.103 
 
Figure 3.9 Structure of the cholesterol reducing drug fenofibrate (39) sold under the brand name Tricor®. 
This compound has been previously synthesised via a Suzuki-Miyaura carbonylation 
reaction,93 from an aryl iodide that itself can be synthesised in one step; and 4-




A model system was investigated. This involved the synthesis of a less complicated aryl 
iodide (63). p-Iodophenol (61) was refluxed with ethyl bromoacetate (62) in acetone, to 
give ethyl 2-(4-iodophenoxy)acetate (63) via an SN2 reaction (Scheme 3.10). The product 
was obtained in quantitative yield following column chromatography and the 1H NMR data 
of 63 were consistent with those found in the literature.104 The 1H NMR spectrum of aryl 
iodide 63 contained a three proton triplet at 1.29 ppm, accounting for the methyl group of 
the ester side chain. A two proton quartet at 4.27 ppm accounted for the neighbouring CH2 
group and a two proton singlet at 4.58 ppm correlated to the C7 methylene protons. A pair 
of two proton doublets at 6.69 and 7.57 ppm was attributed to the protons attached to the 
aromatic ring. This was further supported by the HRMS spectrum which contained a peak 
at m/z 328.9645, consistent with a molecular formula of C10H11IO3 for the [M+Na]
+ adduct. 
 
Scheme 3.10 Synthesis of aryl iodide 63 from p-iodophenol and ethyl 2-bromoacetate. Reagents and 
conditions: acetone, K2CO3, reflux, 18h, quantitative. 
Next, iodide 63 was reacted with 4-chlorophenylboronic and Pd2(dba)3 in the presence of 
CO generated by reaction of cycloadduct 30 with Et3N in the two-chamber setup (Scheme 
3.11). Both reaction chambers were heated to 80 °C and the reaction was allowed to 
proceed for 30 hours. The corresponding biaryl ketone 64 was isolated in an 80% yield 
following column chromatography and the structure confirmed by the spectroscopic data. 
The 1H NMR spectrum was similar to that of aryl iodide 63. It contained a triplet 
integrating to three protons at 1.31 ppm again arising from the CH3 group of the side chain, 
and a quartet at 4.29 ppm arising from the neighbouring CH2 group. It also contained a 
singlet at 4.71 ppm attributed to the C-7 methylene group. Four doublets between 6.98 and 
7.80 ppm accounted for all eight aromatic protons of the biaryl ketone moiety. The 13C 
NMR spectrum contained a peak at 194.4 ppm arising from the carbonyl carbon. This was 







Scheme 3.11 Synthesis of 64 using cycloadduct 30 as the CO source for palladium-catalysed carbonylative 
Suzuki-Miyaura reaction. Reagents and conditions: 80 ˚C, a. cycloadduct 30 (3.0 eq.), Et3N (3.5 eq.), 1,4-
dioxane; b. Pd2(dba)3 (2 mol%), K2CO3 (3.0 eq.), anisole, 80%. 
Having established a model system, we then moved to the synthesis of fenofibrate. The 
first step was the formation of the aryl iodide component (37). Initially, p-iodophenol (61) 
was reacted with isopropyl 2-bromo-2-methylpropanoate (65) and potassium carbonate in 
methyl ethyl ketone (MEK), but the reaction was unsuccessful and only starting material 
was recovered. Changing solvents from MEK to acetonitrile resulted in formation of the 
desired aryl iodide 37 in in 55% yield following purification by column chromatography 
(Scheme 3.12).  
 
Scheme 3.12 Synthesis of aryl iodide 37 from p-iodophenol and 2-bromo-2-methylpropanoate. Reagents and 
conditions: MeCN, K2CO3, reflux, 18h, 55% 
The 1H NMR spectrum of 37 showed two distinct signals which integrated to six protons 
each. A doublet at 1.21 and a singlet at 1.57 ppm which accounted for the C-9 methyl 
substituents and two methyl groups attached to C-7 respectively. A septet at 5.07 ppm was 
indicative of H-9. Furthermore, a pair of two proton multiplets were apparent at 6.59 - 6.63 




further supported by HRMS which gave m/z value of 371.0111 supporting a molecular 
formula of C13H17IO3 for the [M+Na]
+ adduct, as well as IR absorptions characteristic of 
C=O and ether stretches.  
Aryl iodide 37 was then reacted as the limiting reagent in Chamber B with 4-
chlorophenylboronic acid (38) under the optimised carbonylation reaction conditions (see 
section 3.5.1). Both reaction chambers were heated to 80 °C for 65 hours. Following 
purification of the crude reaction mixture by column chromatography, fenofibrate (39), 
was obtained in 80% yield (Scheme 3.13). The spectroscopic data were consistent with 
those reported in the literature.96 The 1H NMR spectrum for the product 39 showed signals 
consistent with the aryl iodide component, with a six-proton doublet at 1.20 ppm 
accounting for the C-9 methyl substituents, and a six proton singlet at 1.66 ppm 
corresponding to the two methyl groups attached to C-7. Pleasingly there were now four 
aromatic doublets at 6.86, 7.45, 7.70 and 7.73 ppm each integrating to two protons, arising 
from the biaryl ketone moiety. The 13C NMR spectrum showed a peak 194.4 ppm which is 
characteristic of the carbonyl group of a biaryl ketone. This was further supported by 
HRMS data which was consistent with a molecular formula of C20H21ClO4 for the 
[M+Na]+ adduct of fenofibrate (39). 
 
Scheme 3.13 Synthesis of fenofibrate (39) using cycloadduct 30 as the CO source for palladium-catalysed 
carbonylative Suzuki-Miyaura reaction. Reagents and conditions: 80 ˚C, a. cycloadduct 30 (3.0 eq.), Et3N 




3.6.2 Synthesis of model synthetic cannabinoids  
As the synthesis of fenofibrate (39) via a Suzuki-Miyaura carbonylation has been 
previously described in the literature,93 examples of different biologically active and more 
complex systems that could be synthesised using this method were sought. It was proposed 
that our system could provide access to synthetic cannabinoid (SC) structures containing 
an indol-3-yl aryl ketone backbone (Figure 3.10). SCs were first synthesized in the early 
1990s in academic research centres and the pharmaceutical industry as investigational 
drugs.105 Many are full agonists for cannabinoid receptor type-1 (CB1) (as well as 
cannabinoid receptor type-2 (CB2)) compared to Δ
9-tetrahydrocannabinol (THC), which is 
a partial agonist.106 The psychoactive effects of these compounds is mostly derived from 
agonistic this activity at CB1 receptors, which are predominantly found in the central 
nervous system. The first work in this field was spurred by the discovery in 1990 that the 
known compound pravadoline (72) had potent analgesic effects which proceeded via a 
different mechanism to that of opioids.107 It was later discovered that pravadoline had high 
binding affinity for CB1 receptors and is now considered to be the first example of the 
aminoalkylindole class of SC compounds.108 Many of the most commonly reported 
examples of these compounds were originally developed by John W. Huffman, an emeritus 
professor of organic chemistry at Clemson University. To date his research group have 
synthesised over 400 examples of various SCs known as JWH cannabinoids, many of 
which contain the acyl indole moiety. Recent literature preparations have shown only a few 
examples of cannabimimetic indoles that have been synthesised via carbonylation 
reactions. The most relevant of which involved tandem C−H bond iodination and 
carbonylative Suzuki-Miyaura cross-coupling.109 However, their process used gaseous CO 
and additives such as pyridine and CsF to facilitate the reaction. 
 
Figure 3.10 The structure of the 3-acyl indole backbone of cannabimimetic indoles. 
In order to investigate cycloadduct 30 as a suitable CO source for carbonylation reactions 




Iodo-1H-indole (66) was prepared in 77% yield following a literature procedure (Scheme 
3.14).110 (Warning: the odour associated with this compound is similar to that of skatole). 
The 1H NMR data of 66 were consistent with those reported in the literature. 
 
Scheme 3.14 Iodination of indole to give 66. Reagents and conditions: I2, KOH, DMF, 1 h, rt, 77%. 
A trial carbonylation reaction of 3-iodo-1H-indole (66) with phenylboronic acid (55) was 
carried out under the same conditions as described in section 3.5.1 (Scheme 3.15). 
Following column chromatography, the desired product 3-acyl indole 1H-indol-3-
ylphenylmethanone (67) was isolated in 50% yield. The spectroscopic data was consistent 
with those reported in the literature.111 The 1H NMR spectrum contained a broad singlet at 
12.06 ppm accounting for the NH proton and a singlet at 7.79 ppm characteristic of H-2 of 
indole. There was a doublet at 7.79 ppm, which accounted for two of the protons of the 
phenyl ring and three multiplets between 7.22 and 7.64 ppm accounting for the other six 
aromatic protons. The 13C NMR spectrum contained a peak at 189.9 ppm correlating to the 
carbonyl carbon.  
 
Scheme 3.15 Synthesis of SC-67. Reagents and conditions: 80 ˚C, a. cycloadduct 30 (3.0 eq.), Et3N (3.5 eq.), 
1,4-dioxane; b. Pd2(dba)3 (2 mol%), K2CO3 (3.0 eq.), anisole, 50%. Includes numbering system of indole 




2-Napthylboronic acid was then also used as the coupling partner in conjunction with 3-
iodo-1H-indole giving napthoylindole (1H-indol-3-yl)(naphthalen-2-yl)methanone (68) in 
44% yield following column chromatography. This compound is known but spectroscopic 
data have not been reported. The spectroscopic data collected was consistent with the 
proposed structure and similar to that of 1H-indol-3-ylphenylmethanone. The 1H NMR 
spectrum contained a broad singlet at 8.62 ppm arising from the NH proton of the indole 
moiety. Multiplets between 7.33 and 8.48 ppm integrated to a total of 12 protons. The 13C 
NMR spectrum again contained a peak at 189.9 assigned to the carbonyl carbon. The NMR 
data was further supported by the HRMS data which contained a peak at m/z 294.0868 for 
[M+Na]+ which is consistent with a molecular formula of C19H13NONa. Both 67 and 68 
are examples of 'model' SCs in that they contain the core 3-acyl indole structure but have 
not been specifically reported as having effects on either the CB1 or CB2 receptors (Figure 
3.11). This work is also novel in that there are very few examples of Suzuki-Miyaura 
carbonylations with indole derivatives that are not functionalised at the nitrogen. 
 
Figure 3.11 Model 3-acyl indole SC's synthesised via Suzuki-Miyaura carbonylation reaction. 
Indoles 67 and 68 both contain free indole nitrogen's, in contrast to the JWH SCs which are 
commonly functionalised at the indole nitrogen. Not only can this change the physical 
properties of the molecule, but it also protects the indole nitrogen. One particularly 
interesting side chain that is a common feature of many pharmaceuticals is the 
ethylmorpholine side chain. This confers water solubility to a molecule when protonated. 
Early work into the structure activity relationship (SAR) of SCs found that the 
ethylmorpholine substituent had optimal binding activity at the CB1 receptor.
112 N-
alkylation of 3-iodo-1H-indole (66) was accomplished by formation of an active indole 
anion using a stoichiometric amount of sodium hydride followed by reaction of the 





Scheme 3.16 Reaction of 3-iodo-1H-indole (66) with 2-morpholinoethyl methanesulfonate (69) to give 
iodoindole 70. Reagents and conditions: DMF, NaH, 4 h, rt, 90%. 
Following column chromatography, 4-(2-(3-iodo-1H-indol-1-yl)ethyl)morpholine (70) was 
isolated in 90% yield and the spectroscopic data were consistent with those reported in the 
literature.113 The 1H NMR spectrum contained a four proton multiplet at 2.45 – 2.55 ppm 
attributed to H-10, a two proton triplet at 2.74 ppm accounting for the H-9 methylene 
protons, and another four proton multiplet at 3.67 – 3.77 arising from H-11. A second two 
proton triplet at 4.25 ppm accounted for the H-8 methylene protons. Four signals between 
7.20 and 7.45 ppm could be attributed to the 5 indole protons. The 13C NMR spectrum was 
similar to that of 3-iodo-1H-indole (66) but contained four extra signals at 44.3, 54.0, 58.3 
and 67.0 ppm arising from C-8, C-10, C-9 and C-11 of the ethylmorpholine sidechain 
respectively. The structure was further confirmed by HRMS data which supported a 
molecular formula of C14H17N2OI for the [M+H]
+ adduct of 70.  
With the successful preparation of iodoindole 70, the Suzuki-Miyaura carbonylative cross 
coupling was attempted.  Phenylboronic acid was initially used as the boronic acid 
coupling partner, and the corresponding carbonylative cross-coupled product 71 was 
isolated in 59% yield (Scheme 3.17). The 1H NMR spectrum of 1-(2-morpholinoethyl)-1H-
indol-3-ylphenylmethanone (71) contained signals characteristic of the ethylmorpholine 
side chain. A four proton multiplet at 2.50 ppm from the H-10 protons, a triplet at 2.78 
ppm for H-9, a four proton triplet at 3.68 ppm correlating to H-11. Finally, a doublet 
integrating to two protons was observed 4.26 ppm, arising from the H-8 protons of the side 
chain. Six distinct signals between 7.32 and 8.47 ppm integrated to ten protons, accounting 
for the remaining phenyl and indole protons. The 13C NMR spectrum contained a signal at 








Scheme 3.17 Synthesis of 71 from 70 and 55. Reagents and conditions: 80 ˚C, a. cycloadduct 30 (3.0 eq.), 
Et3N (3.5 eq.), 1,4-dioxane; b. Pd2(dba)3 (2 mol%), K2CO3 (3.0 eq.), anisole, 59%. 
Although 71 is a known compound, its spectroscopic data have not been reported in the 
literature. Data for the known compound pravadoline (2-methyl(4-methoxyphenyl)(1-(2-
morpholinoethyl)-1H-indol-3-yl)methanone) (72) (Figure 3.12) has been reported by 
D'Ambra et al.108 and comparison with the data reported for this compound was used to 
help assign those of 71 as the two share the same core structure. 
 
Figure 3.12 Structure of pravadoline. The first example of an aminoalkylindole SC. 
4-Methoxyphenylboronic acid (73) was reacted as a coupling partner with iodoindole 70 to 




(Scheme 3.17). The corresponding carbonylated product 4-methoxyphenyl(1-(2-
morpholinoethyl)-1H-indol-3-yl)methanone (74) was isolated in 43% yield. The lower 
yield is thought to be due to the electron-donating substituent of the boronic acid 
component which makes it a less ideal coupling partner for carbonylative Suzuki-Miyaura 
reactions. The spectroscopic data collected were consistent with the proposed structure of 
74, and very similar to that of the previously synthesised 71. The 1H NMR spectrum 
contained characteristic signals of the ethylmorpholine side chain, two doublets at 6.99 and 
7.85 ppm accounted for the aromatic protons of the 4-methoxyphenyl moiety. The 
spectrum also contained three further aromatic signals accounting for the four remaining 
indole protons. The 13C NMR spectrum displayed a signal corresponding to the carbonyl 
carbon at 189.9 ppm. These data were supported by HRMS which gave a m/z value of 
365.1837 which was consistent with the molecular formula of C22H24N2O3 for the [M+H]
+
 
adduct of 74. This compound is similar to Pravadoline (72), and the two differ at only the 
2-position where 72 has a methyl group. This change from –CH3 to –H has been shown to 
enhance the potency in central cannabinoid receptor binding assays and corresponding 
activity in functional assays.112 
 
Scheme 3.18 Synthesis of 74 from 70 and 73. Reagents and conditions: 80 ˚C, Pd2(dba)3 (2 mol%), K2CO3 
(3.0 eq.), anisole, 43%. 
The final reaction was carried out with 1-napthylboronic acid (75) to form the known 
aminoalkylindole SC JWH-200 (76) (Scheme 3.19). The carbonylative cross-coupling was 
performed using the optimised conditions described in section 3.5.1 to obtain SC JWH-200 
(76) in 63% yield following column chromatography. The spectroscopic data acquired for 
76 were similar to the data acquired for the SCs previously synthesised in this study and 
were consistent with that reported in literature.114 The 1H NMR spectrum of 76 contained 




aromatic signals accounting for the four remaining indole protons and the protons of the 
naphthalene group. The 13C NMR spectrum again contained a signal for the carbonyl 
carbon at 192.3 ppm. This was further supported by HRMS data which gave a m/z value of 
358.1882 which was consistent with the molecular formula C21H24N2O2 for the [M+H]
+ 
adduct. JWH-200 has a similar binding affinity (Ki) for CB1 as THC,
115 but in vivo studies 
demonstrated stronger analgesic effects than that of THC and other analogues.116  
 
Scheme 3.19 Synthesis of 76 from 70 and 75. Reagents and conditions: 80 ˚C a. cycloadduct 30 (3.0 eq.), 










Chapter 4  
Mechanism of CO release 
Having shown cycloadduct 30 to be an effective CO source for various palladium 
catalysed carbonylation reactions, attention then turned to investigating the mechanism of 
CO release under slightly basic (pH 7.4), aqueous conditions. Cycloadduct 30 is not water 
soluble, so a water soluble CORM was needed.  Previous studies by our research group 
demonstrated that the water soluble oCOM-21 releases CO at pH 7.4.19 The first step was 
to synthesise two analogues of oCOm-21 which differ in their halide leaving group. It was 
envisioned that an investigation of the CO release profiles of oCOm-21 and these 
analogues would provide more information on the mechanism of CO release from these 
compounds and whether it fits with the proposed E1cB mechanism discussed in Chapter 1, 
section 1.8.1. 
The E1cB mechanism was proposed over either an E1 or E2 elimination to explain the loss 
of HX and subsequent cheletropic loss of CO. CO release from norbornadienone-based 
CORMs occurs under weakly basic conditions (pH 7.4). This effectively rules out an E2 
mechanism, which is a bimolecular concerted elimination where strong bases are normally 
required to remove a weakly acidic proton. It has also been shown that in an E2 
elimination, anti-elimination (when H and X are anti-periplanar) is greatly favoured over 
syn-elimination (Figure 4.1).63 In the case of these norbornadienone-based CORMs, the 
proton and the halide leaving group (X) are always syn-periplanar, making E2 elimination 
less likely. 
 




An E1 mechanism was also deemed unlikely. Like the E1cB mechanism, this is a two-step 
process. However in this case the leaving group leaves first, forming a carbocation 
intermediate. The second step in the mechanism is deprotonation of a carbon adjacent to 
the newly formed carbocation. Carbocation formation would be disfavoured in compounds 
such as oCOm-21 and its analogues as it would be destabilised by the adjacent electron 
withdrawing imide carbonyl group. 
4.1  Synthesis of oCOm-21 and analogues 
4.1.1 Synthesis of oCOm-21 
The dienophile component of oCOm-21 was synthesised following literature procedures 
reported by Burkart et al.117 Maleimide (77) was converted into carboethoxymaleimide 78 
which was then reacted with tert-butoxycarbonyl (Boc) protected ethylene diamine 79 to 
afford Boc-protected maleimide 80 (Scheme 4.1). 
 
Scheme 4.1 Synthesis of the dienophile component of oCOm-21. Reagents and conditions: a. N-
methylmorpholine, EtO-COCl, 0 °C, 1 hr, 72%. b. sat. NaHCO3, 0 ºC, 15 min, rt, 45 min, 50%. 
The spectroscopic data of 80 were consistent with those found in the literature and reported 
previously with the Larsen group.19, 117 The 1H NMR spectrum of 80 contained a nine 
proton singlet at 1.40 ppm, characteristic of the nine equivalent protons of the Boc-
protecting group. A multiplet at 3.33 ppm and a triplet at 3.66 ppm both integrated to two 
protons each,  accounted for the H-2' and H-3' protons respectively. A broad singlet at 4.71 
was attributed to the NH proton and a two proton singlet at 6.71 ppm which accounted for 
H-4 and H-5. The 13C NMR spectrum contained two distinct carbonyl signals; one at 156.1 
ppm arising from the carbonyl of the Boc protecting group and the other at 170.9 ppm 
arising from the two identical maleimide carbonyl carbons. The mass spectrum showed a 
peak at m/z 295.1261, consistent with the proposed molecular formula, C12H20N2O5Na
+, 




product proved to be extremely persistent and could not be completely separated at this 
stage by column chromatography. From 80, dibromination and subsequent 
dehydrobromination following literature procedures118 gave the Boc-protected 
bromomaleimide 81 in a 98% yield over the two steps (Figure 4.1).  
 
Scheme 4.2 Bromination of 80 followed by elimination of HBr to yield Boc-protected bromomaleimide 81. 
Reagents and conditions: a. Br2, CH2Cl2, 1 h, reflux. b. Et3N, THF, 2 h, 0 °C. 98% over two steps. 
The structure of 81 could be confirmed by comparison of the spectroscopic data with those 
reported in the literature and previously obtained within our research group.19 Most 
importantly, the 1H NMR spectrum no longer contained a two proton singlet at 6.71 ppm, 
but instead contained a one proton singlet at 6.88 ppm, consistent with loss of one proton 
from the alkene. The HRMS data further confirmed attachment of a bromine atom as it 
contained a peak at m/z 373.0345 which was consistent with the formula 
C12H19N2O5
79BrNa+ for the [M + Na]+ adduct of 81 and had the characteristic isotope 
pattern of a molecule containing one bromine atom. Bromomaleimide 81 was then reacted 
with diene dimer 4 in toluene at 70 °C to give the Boc-protected cycloadduct 82 (Scheme 
4.3).  Column chromatography gave the Boc-protected cycloadduct 82 in 98% yield as a 
white foam in two fractions: the pure endo-cycloadduct and a 2:1 mixture of endo- and 
exo-cycloadducts. The spectroscopic data matched those previously reported by our 
group.19  
 




The pure endo-fraction was dissolved in 1,4-dioxane and treated with 6 M HCl to remove 
the Boc-protecting group. The crude product was then lyophilised and purified by C18 
reverse phase chromatography to give pure endo-oCOm-21 in 90% yield (Scheme 4.4).  
 
Scheme 4.4 Boc-deprotection of 82 to oCOm-21. Reagents and conditions: 6 M HCl, 1,4-dioxane, rt, 4 h, 
90%. 
This deprotection is carried out in 1,4-dioxane with excess HCl, which in the first step 
protonates the tert-butylcarbamate (Scheme 4.5). In the next step, the loss of the tert-butyl 
group results in a carbamic acid species, which undergoes a decarboxylation resulting in 
the free amine. The final step in this deprotection is protonation of the amine due to the 
acidic conditions; this gives the product as the HCl salt. 
 
Scheme 4.5 Boc-deprotection mechanism. 
The 1H NMR spectrum of oCOm-21 in deuterated DMSO showed the loss of the 
characteristic signals arising from the Boc-protecting group. Two three proton singlets at 
1.45 and 1.52 ppm could be attributed to the two methyl groups, similar to those seen in 
the spectrum of cycloadduct 30. A pair of two proton multiplets between 2.88 – 3.09 and 
3.77 – 3.80 ppm accounted for the two CH2 groups of the amine side chain. A one proton 
singlet at 3.93 ppm was assigned as H-7a. Two multiplets between 6.81 and 7.26 ppm 
accounted for the ten aromatic protons and a broad singlet at 8.04 ppm was indicative of 
the amine protons. The 
13C NMR spectrum contained a peak at 196.7 ppm, characteristic of 
the bridged carbonyl carbon, and no longer contained the signal at 156.1 ppm arising from 




m/z, consistent with the proposed molecular formula, C28H29
79BrN3O4, for which the 
calculated mass for [M-Cl]+ was  550.1336 m/z.  
4.1.2 Synthesis of oCOm-60 and -61 
The synthesis of the oCOm-21 analogues containing a different halogen requires an extra 
step in the synthesis of the dienophile component. A halide exchange reaction can be used 
to replace bromine with other halogens. This is an equilibrium process which can be driven 
to completion by exploiting the solubilities of halide salts.63 Coleman et al.119 synthesised 
trimethylsilylethoxymethyl (SEM) protected iodomaleimide 84 from the corresponding 
bromo compound 83 by treatment with an excess of sodium iodide in acetone (Scheme 
4.6). 
 
Scheme 4.6 Synthesis of 84 by substitution of bromine for iodine in 83.119 Reagents and conditions: NaI, 
acetone, reflux. 
We applied this procedure to the synthesis of novel compound tert-butyl 3-(4-iodo-1,3-
dioxo-1,3-dihydro-1H-pyrrol-1-yl)ethylcarbamate (85), where the Boc-protected 
bromomaleimide 81 was dissolved in dry acetone and five equivalents of NaI were added 
(Scheme 4.7). Sodium iodide is very soluble in acetone (50.4 g per 100 g of solvent), 
whereas the corresponding bromide salt is sparingly soluble. Therefore, sodium bromide 
precipitates from the reaction mixture, and the reaction is forced to the right. The 
iodomaleimide product 85 was isolated in 91% yield following column chromatography. 
 
Scheme 4.7 Synthesis of 85 by substitution of bromine for iodine in 81. Reagents and conditions: NaI, 




The spectroscopic and HRMS data for the iodomaleimide 85 was similar to that of the 
corresponding bromomaleimide 81. However, in the 1H NMR spectrum there was a 
significant downfield shift of the H-5 signal. In the spectrum of 81 this was present as a 
one proton singlet at 6.88 ppm, whereas in the spectrum of 85 this proton is shifted 
downfield to 7.18 ppm (Figure 4.2).  This shift can be attributed to the deshielding effect of 
the iodine. Iodine is a ‘soft’ atom compared to bromine as the outer-shell electrons are 
more loosely held making it more polarisable. The NMR data was further supported by 
HRMS which contained a peak at m/z 388.9984, consistent with a molecular formula of 
C11H15IN2O4. The mass spectrum no longer contained the characteristic bromine isotope 
pattern.  
 
Figure 4.2 Stacked partial 1H NMR spectra of Boc-protected bromomaleimide 81 (blue) and Boc-protected 
iodomaleimide 85 (red) recorded in CDCl3 at 400 MHz. 
The mechanism by which this substitution occurs is presumed to be either a nucleophilic 














Mechanism A: Nucleophilic ipso-substitution 
 
Mechanism B: Nucleophilic cine-substitution. 
Scheme 4.8 Proposed mechanisms for the halogen exchange of bromine to iodine. R = CH2CH2NHBoc 
In the ipso-substitution, the nucleophile (the iodide ion) attacks the carbon containing the 
bromine substituent, to give intermediate A. Loss of the bromide in a second step provides 
the substitution product 85 (Scheme 4.8, Mechanism A). In the cine-substitution process 
(Scheme 4.8, Mechanism B), the iodide ion attacks the carbon atom adjacent to the carbon 
bonded to the bromine leaving group to give intermediate B. Proton transfer is required to 
provide the second intermediate C which is stabilised compared to the former. This 
intermediate then rearranges and loss of the bromide leaving group gives the 
iodomaleimide product 85.  
The subsequent reaction of iodomaleimide 85 with diene dimer 4, gave the Boc-protected 
CORM-86. Following column chromatography this was isolated as a white foam in two 
fractions: the pure endo-cycloadduct and a 3.5:1 mixture of endo- and exo-cycloadducts 
with an overall yield of 84% (Scheme 4.9). The endo-fraction was deprotected in the same 





Scheme 4.9 Reaction of iodomaleimide 85 with diene dimer 4 to give Boc-protected CORM-86, followed by 
deprotection with 6 M HCl to give oCOm-60 as the HCl salt. 
The 
1H NMR spectrum of oCOm-60 showed signals at the appropriate chemical shifts for 
the methyl groups (1.47 and 1.49 ppm), as well as a pair of two proton multiplets between 
2.86 and 3.79 ppm which again were attributed to the two CH2 groups of the amine side 
chain. A singlet at 3.89 ppm for H-7a, was shifted downfield compared to the equivalent 
proton of oCOm-21, this was as expected as a similar shift was also seen in the H-5 proton 
of the dienophile as previously discussed. Two characteristic multiplets in the aromatic 
region accounted for all ten of the phenyl protons and a signal for the amine protons was 
present at 8.02 ppm. The mass spectrum showed a peak at m/z 527.0822, consistent with 
the proposed molecular formula, C25H23IN2O3, for which the calculated mass for [M+H]
+ 
was m/z 527.0826.  
Chloromaleimide 87 was synthesised using an analogous halogen exchange approach. 
Reaction of bromomaleimide 81 and tetrabutylammonium chloride (TBAC) in refluxing 





Scheme 4.10 Synthesis of 87 by substitution of bromine for chlorine in 81. Reagents and conditions: TBAC, 
acetone, reflux, o/n, 89%. 
The 1H NMR spectrum of chloromaleimide 87 contained a one-proton singlet at 6.64 ppm 
attributed to H-5. The upfield shift of this signal in the spectrum of 87 compared to that of 
81 was attributed to chlorine being less polarisable, thus deshielding H-5 to a lesser extent 
compared to bromine (Figure 4.3). Other signals in the 1H NMR spectrum were as 
previously observed in the spectra of 81 and 85. 
 
Figure 4.3 Stacked aromatic region of 1H NMR of Boc-protected bromomaleimide 81 (red) and Boc-













The 1H NMR chemical shifts attributed to the H-7a protons of bromide 81, iodide 85 and 
chloride 87 are summarised in Table 4.1. These data show that the iodine substituent 
deshields H-7a to a greater extent than bromine, which in turn has more of a deshielding 
effect than chlorine. This is consistent with the halogens' relative sizes and polarisabilities.  
Table 4.1 Relative chemical shifts of H-5 proton in dienophiles 81, 85 and 87. 
Boc-protected dienophile 











It was envisioned that a fluorine derivative could also be synthesised using a similar 
approach and this was briefly investigated. A mixture of tetra-n-butylammonium fluoride 
(TBAF) and 81 was refluxed in acetone but unfortunately this gave a complex mixture of 
products (Scheme 4.11) with none of the desired fluoromaleimide 88 observed in the 1H 
NMR spectrum. Given this unsuccessful attempt to synthesise fluoromaleimide 88, our 





Scheme 4.11 Attempted synthesis of 88 from 81. Reagents and conditions: n-Bu4NF, acetone, reflux, o/n. 
Chloromaleimide 87 was reacted with diene dimer 4 to give Boc-protected CORM-89 
(Scheme 4.12). Following column chromatography this was isolated as an inseparable 3:1 
mixture of the endo- and exo-isomers as a white foam in 99% yield. The 1H NMR 
spectrum of 89 contained a singlet at 1.41 ppm, which integrated for nine protons and is 
consistent with the Boc-protecting group. There were two three-proton triplets, which 
accounted for the two methyl groups of the cycloadduct. A two proton multiplet between 
3.36 – 3.40 ppm and a two proton triplet at 3.72 ppm accounted for the two CH2 groups of 
the side chain. A singlet at 3.37 ppm was attributed to H-7a and a broad singlet at 4.73 
ppm accounted for the NH proton. Two multiplets between 6.82 and 7.19 ppm accounted 
for the ten aromatic protons. This was further supported by HRMS data which contained a 
peak at m/z 557.1807 which is consistent with a molecular formula of C30H31
35ClN2O5 and 
contained a characteristic isotope pattern of a molecule containing one chlorine atom. 
 
Scheme 4.12 Reaction of chloromaleimide 87 with diene dimer 4 to give boc-protected CORM-89, followed 




Boc-protected CORM 89 was then deprotected using 6 M HCl. Following purification by 
C18 reverse phase chromatography oCOm-61 was isolated in 92% yield, as a 3:1 mixture 
of the endo- and exo-isomers. The 
1H NMR spectrum of oCOm-61 contained two singlets 
at 1.53 and 1.57 ppm accounting for the endo-isomer methyl groups. The corresponding 
methyl signals for the exo-isomer were present at 1.33 and 1.38 ppm. A singlet at 3.76 ppm 
was attributed to the H-7a proton of the endo-isomer, which, as predicted, was shift upfield 
compared to the H-7a signal in oCOm-21 which was seen at 3.93 ppm. Two characteristic 
multiplets in the aromatic region accounted for all ten of the phenyl protons. The mass 
spectrum showed a peak at m/z 435.1439, consistent with the proposed molecular formula, 
C25H23
35ClN2O3, for which the calculated mass for [M+H]
+ was m/z 435.1470.  
When oCOM-21, -60 and -61 release CO gas, they all undergo subsequent rearrangement 
to form a common aromatic byproduct, 2-(4,7-dimethyl-1,3-dioxo-5,6-diphenylisoindolin-
2-yl)ethanaminium chloride (BP-oCOm) (Scheme 4.13). This compound was accessed by 
subjecting oCOm-60 to treatment with DBU, followed by purification by C18 reverse 
phase chromatography to give the BP-oCOm in 94% yield.  
 
Scheme 4.13 Formation of BP-oCOm.  
The 1H NMR spectrum of BP-oCOm contained a singlet at 2.32 ppm which integrated to 
six protons and was attributed to the now equivalent methyl groups attached to the 
aromatic ring. Two, two proton triplets at 3.10 and 3.86 ppm accounted for the two CH2 
groups of the side chain. Two multiplets between 6.91 and 7.29 ppm were characteristic of 
the ten aromatic protons and a broad singlet at 7.86 ppm accounted for the amine protons. 
It was also noted that there was an absence of the one proton singlet seen between 3.75 – 
3.95 ppm indicating H-7a was no longer present in BP-oCOM. Furthermore, the 13C NMR 





As previously discussed in Section 1.8, it was thought that investigation into the CO 
release profiles of oCOms 21, 60 and 61 would provide more information about the 
mechanism of CO release.23 In order to compare the release profiles of oCOm-21 and 
analogues in aqueous media their solubilities in tissue culture water were investigated. 
4.2 Water solubility 
The solubility of oCOM-21 was previously determined to be 18.2 mM (10.8 mg mL-1).19 
The solubility of oCOm-60 and -61 was determined by measuring the UV absorption (λmax 
254 nm) of a saturated solution of each CORM in tissue culture water at rt (approx. 20 °C). 
The saturated solution was prepared by the addition of tissue culture water (1 mL) to a 
sample of CORM. The resulting suspension was then centrifuged (3500 rpm, 15 min) and 
the supernatant was carefully passed through a syringe filter (0.45 μM, nylon membrane) 
to remove undissolved material and the filtrate was then analysed by UV-HPLC. 
Extrapolation of the UV absorption with a calibration curve generated from a series of 
standard solutions in MeCN (ranging from 0.5 to 20 mM).  
These studies indicated that the solubility of oCOm-60 was 9.3 mM (5.2 mg mL-1). 
However, initial results had indicated that this value was much higher, but over about 30 
minutes oCOm-60 was precipitating from solution as a fine white powder indicating that 
the solution had either been super-saturated or that this analogue had two forms in water, 
one which was less soluble that the other. oCOm-61 was found to have a solubility of 15.8 
mM (7.4 mg mL-1) under the same conditions. These solubilities are comparable to the 
solubilities of oCOm-21 and oCOm-23: 18.2 mM (10.8 mg mL-1) and 24.3 mM (18.2 mg 








Table 4.2 Water solubilities of oCOm-21, -23, -60, and -61 at room temperature in tissue culture water. 
Samples were analysed by RP-HPLC (3 μL injection, 3 replicate injections). Solubilities were based on the 
integrated peak area at 254 nm. a determined by Kueh et al.19 b 3:1 mixture of endo and exo isomers. 
















4.3 Biological activity of oCOm-60 and -61 
Preliminary investigations into the biological profiles of oCOm-60 and oCOm-61 were 
carried out by Harrison et al. (Department of Pharmacology, University of Otago). AC16 
cardiomyocyte cells were exposed to CO donor compounds or vehicle control solution for 
1 hour at 37 °C prior to washing with PBS and incubating for a further 23 hours in fresh 
complete media. The loss of cell adhesion for anchorage-dependent cell lines, such as 
AC16 cardiomyocyte cells, represents a surrogate marker of cell death which can be 
measured by the crystal violet cell adhesion (CVCA) assay. Cell survival was reported as a 
percentage of the value obtained for cells exposed to vehicle only and used to plot a 
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Figure 4.4 Concentration-response curve for oCOm-21, -60 and -61. Supplied by Joanne Harrison 
(Department of Pharmacology, University of Otago). 
It is apparent from the concentration-response curve that all three analogues have similar 
toxicity profiles and an EC50 of ranging from 50 – 60 µM.  
4.4 CO Release Profiles 
The comparative CO release profiles of these CORMs (oCOm-21, -60 and -61) were 
investigated indirectly by the HPLC-MS method fully detailed in Section 6.1. Briefly: ~2.5 
mg of each CORM was dissolved in 5 mL aqueous buffer at 37 °C at the specified pH. The 
first of the comparative studies compared the release profiles of oCOm-21 and -60 and the 
second compared oCOm-60 and -61. Aliquots were removed at the specified time points 
and quenched with 2 M HCl before analysis by HPLC. This allows indirect observation of 
the rate of CO release by monitoring the conversion rate of the CORM to its aromatic by-
product (BP-oCOm). Figure 4.5 shows HPLC-MS chromatograms recorded for a typical 
conversion of oCOm-21 to BP-oCOm at pH 7.4 and 37 °C. The conversion occurs over 
approximately 90 minutes and it can be inferred that CO is being lost at the same rate. 
m-21 (endo) 
m-60 (endo) 





Figure 4.5 Partial HPLC-MS TIC chromatograms showing conversion of CORM (oCOm-21, tR = 10.4) to 
its by-product (BP-oCOm, tR = 11.1) over time in PBS buffer at pH 7.4, 37 °C. Vertical scale is ion current. 
For column, solvent and method details see page 85, section 6.1. 
Figure 4.6 shows the CO-release data at pH 7.4 for oCOm-21 and -60 in phosphate 
buffered saline (PBS) at 37 °C displayed as plots of percentage peak area against time. 
Both CORMs convert to the same spent by-product as discussed in section 4.1.2. As 
evidenced by the steeper slope, it can be seen that the bromo adduct oCOm-21 (♦) releases 
CO faster than the iodo adduct oCOm-60 (■) under these conditions in PBS. Previous 
work in the Larsen group by Seifert-Simpson showed that the release of CO from this class 












of compounds is pH dependent, where increasing the pH results in an increased rate of 
formation of the aromatic by-product.120 
 
Figure 4.6 The CO release profiles of oCOm-21 (♦) and oCOm-60 (■) (pH 7.4, 37 °C, PBS buffer). Dashed 
lines are added to guide the eye. 
A similar trend can be seen in Figure 4.7 which shows the comparative CO-release data at 
pH 7.4 for oCOm-60 and -61 in PBS buffer, again displayed as plots of percentage peak 
area against time. In this plot it can be seen that the chloro adduct oCOm-61 releases faster 
than the iodo. 
 
Figure 4.7 The CO release profiles of oCOm-60 (■) and oCOm-61 (●) (pH 7.4, 37 °C, PBS buffer). Dashed 
























































This exponential decay seen in the release profiles of all three analogues is indicative of a 
first-order reaction. The differential rate law of such reactions is as follows, [A] is the 
concentration of the CO releasing molecule (oCOm-21, -60 or -61). The units of k are s-1: 
 𝑅𝑎𝑡𝑒 =  −
∆[𝐴]
∆𝑡
 = 𝑘[𝐴] Equation 1 
In order to compare the relative rates of CO release for each analogue it is necessary to 
determine the rate constant; k. This is done by plotting the natural log of the concentration 
decrease against time (in seconds). A straight line is obtained, which confirms that the 
reaction is indeed first order (Figure 4.8). This is consistent with an E1cB mechanism which 
is known  to be first order with respect to the conjugate base.65 An integrated rate law can 
be derived from these graphs.121 
 𝑙𝑛[𝐴] = 𝑙𝑛[𝐴0] − 𝑘𝑡 Equation 2 
  
Figure 4.8 Plot of ln[oCOm-21] (♦) against time (in seconds). This gives a straight line with equation -
0.0009x - 9.3208 and R²values of 0.9967. Starting concentration calculated from the linear regression fitted 
to the calibration curve using the absorbance at 254 nm.  
Similar graphs were obtained for both oCOm-60 and -61 which are shown in Figure 4.9. 




















versus time is a straight line with a slope of −k. This value of k obtained from such graphs 
can then be used in Equation 1 to determine the rate.  
 
Figure 4.9 Plot of ln[oCOm-60] (■) and ln[oCOm-61] (●)  against time. Equation for oCOm-60: y = -
0.0007x - 9.1172 with R² = 0.9959. oCOm-61: y = -0.0006x - 10.003 and R² = 0.9914. 
It was theorised that this data should give us more insight into the mechanism of CO 
release. A comparison of the values of k obtained experimentally with the relative carbon – 
halogen bond lengths and the electronegativities of each halogen atom should provide 
information about the rate determining step. As discussed in section 1.8.1, page 22, there 
are three distinct cases for the E1cB mechanism that can be described.  
The first case, termed E1cB(irr), describes a reaction where step 1 is essentially irreversible. 
This first step is rate determining as the deprotonation is slow and formation of the product 
is faster than return of the carbanion to starting material. If this is the case, then the acidity 
of the H-7a proton would control the rate of elimination. The electronegativity of the 
leaving group has a direct effect on the acidity of this proton. By this logic, we would 
expect oCOm-61 with its chloride leaving group making it's H-7a proton the most acidic 
to release CO fastest, followed by the bromo adduct oCOm-21 and then the iodo adduct 































oCOm-60 7 x 10-4 2.14 2.66 
oCOm-21 9 x 10-4 1.93 2.96 
oCOm-61 6 x 10-4 1.78 3.16 
In the other two cases which can be considered, E1cB(rev) and E1cB(anion), the second step 
(leaving group leaving) is rate determining but they differ in behaviour of the first step. In 
the case of E1cB(rev), the carbanion returns to starting material faster than the product is 
formed. E1cB(anion) only occurs in substrates with very stable carbanions, where the product 
forms slowly. In order to distinguish between these two cases, an isotope study where H-7a 
is replaced with deuterium would need to be undertaken. However, in the case where the 
second step (leaving group leaving) is rate determining, we would expect the ability of the 
leaving group to control the rate of elimination. Iodine is a better leaving group than 
bromine, which in turn is a better leaving group than chlorine and this leaving group ability 
can be directly related to the bond length. And we would expect oCOm-60 to release CO 
fastest, followed by oCOm-21 then oCOm-61. 
 
Scheme 4.14 (E1cB)irr mechanism for the release of HX and CO from oCOm-21 and -60 to give BP-oCOm. 




However, the observed trend is not consistent with either argument. The experimental data 
shows that CO is released fastest from oCOm-21, followed by oCOm-61 then -60. This 
result suggests that oCOm-21 and -60 are examples of the E1cB(irr) mechanism (Scheme 
4.14), whereas oCOm-61 does not follow this mechanism. This suggests that for oCOm-
61 the leaving group is involved in the rate determining step of this process and that the 
mechanism for the loss of HCl would be an (E1cB)rev process as shown in Scheme 4.15.  
 
Scheme 4.15 Proposed (E1cB)rev mechanism for the release of HCl and CO from oCOm-61 to give BP-
oCOm. R = CH2CH2NH3Cl 
This is further complicated as oCOm-61 was a 3:1 mixture of the endo- and exo-isomers 
and was not able to be isolated as an individual isomer. oCOm-21 and -60 were both 
isolated as the pure endo-isomer. It would also be expected that there would be a small 
difference in the release rates of the different isomers of each CORM as there would be 
different steric interactions between the H-7a proton and the methyl substituents of the 
diene and the carbonyl groups of the dienophile (Figure 4.10).  
 




Chapter 5  
Conclusions and Future Work 
5.1 Carbonylations using CORMs as a CO source 
Cycloadduct 30 was successfully used as a CO source for the palladium-catalysed 
aminocarbonylation of both primary and secondary amines to generate secondary and 
tertiary amides. The reaction was performing using a two-chamber system in which 
cycloadduct 30 is kept separate from the aminocarbonylation reaction mixture, thus 
allowing easier isolation of the products.  Such transformations proved to be synthetically 
useful, and high yields of product were obtained using only a slight excess of CO donor in 
one Chamber A. 
 
Scheme 5.1 Synthesis of various secondary and tertiary amides using cycloadduct 30 as a CO source. 
Reagents and conditions: 1,4-dioxane, 80 ˚C, 20 hours. a. Et3N (1.5 eq). b. Pd2(dba)3 (5 mol%), PPh3 (10 
mol%), Et3N (2.3 eq.). R = OMe, NO2, Br, H, or napthyl. 
When this system was applied to palladium-catalysed Suzuki-Miyaura carbonylations, 
synthesis of biologically active compounds such as fenofibrate and JWH-200 (76) were 




order to achieve good yields and favour the carbonylative reaction over its cross-coupled 
counterpart, three equivalents of CORM 30 were needed to generate high pressures and a 
good CO/Pd ratio. This leaves obvious room for improvement and there are a myriad of 
factors that could be investigated in order to optimise the system further, such as different 
catalysts, ligands or solvent systems. 
 
Scheme 5.2  Synthesis of 76 from 70 and 75. Reagents and conditions: 80 ˚C a. cycloadduct 30 (3.0 eq.), 
Et3N (3.5 eq.), 1,4-dioxane; b. Pd2(dba)3 (2 mol%), K2CO3 (3.0 eq.), anisole. 
Since the first report of palladium-cataylsed carbonylation reactions by Heck and co-
workers in the 1970s,54 the scope of carbonylation chemistry has increased dramatically 
and there are many other named reactions of this type (Sonogashira, Stille, Kumada, 
Negishi, Buchwald-Hartwig, and others). These reactions have allowed the parallel 
synthesis and coupling of suitable components at any stage in the process. This approach is 
often more efficient and flexible and allows access to compounds such as amides, acids, 
esters and other carbonyl-containing compounds and have been used in the preparation of 
active pharmaceutical ingredients. Given the scope of products accessible through 
carbonylative cross coupling reactions, cycloadduct 30 could prove to be a safe, solid CO 






5.2 Mechanism of CO release 
The trend seen in the CO release profiles of oCOms-21, -60 and -61 provided some 
information about the mechanism of CO release from this class of compounds. The 
experimental HPLC-MS data showed that oCOm-21 released CO fastest, followed by 
oCOm-61 then oCOm-60 indicating that the bromo-cycloadduct undergoes loss of CO 
more quickly than either the chloro or iodo adducts. This did not fit either of the trends that 
were expected and more information is needed before specific conclusions can be made. 
 
Figure 5.1 Structures of oCOm21, -60 and -61. The latter two were synthesised as iodo and chloro analogues 
of the Larsen group's current lead compound in order to provide more information about the mechanism via 
which this class of compounds releases CO. 
As a continuation of this project, isolation of the pure endo-isomer of oCOm-61 is 
required in order to properly compare the release profiles of these CO prodrugs. It would 
also be interesting to investigate the difference in release rates between the endo- and exo-
isomers in order to fully understand the CO release mechanism and whether the 









Chapter 6  
Experimental 
6.1 General Experimental 
Nuclear Magnetic Resonance (NMR) Spectroscopy 
1H NMR spectra were recorded at either 400 MHz on a Varian 400-MR NMR system or at 
500 MHz on a Varian 500 MHz AR Premium Shielded Spectrometer. All spectra were 
recorded in 5 mm NMR tubes at 25 °C from CDCl3 solutions unless otherwise stated. 
Chemical shifts are referenced to the residual CHCl3 singlet at 7.26 ppm according to the δ 
scale. Chemical shifts are reported to the nearest 0.01 ppm and coupling constants (J) to 
the nearest 0.1 Hz. 1H NMR data were reported using the following convention: 1H NMR 
(frequency, solvent) δ/ppm chemical shift (number of protons, multiplicity, coupling 
constant (Hz), assignment).  
13C NMR spectra were recorded at either 101 MHz on a Varian 400-MR NMR system or at 
125 MHz on a Varian 500 MHz AR Premium Shielded Spectrometer under the same 
conditions as for 1H spectra. Chemical shifts are referenced to the CDCl3 signal at 7.26 
ppm and are reported to the nearest 0.1 ppm. Where necessary to differentiate between 
similar resonances, carbon signals are reported to two decimal places. Resonances were 
assigned as follows: chemical shift (assigned carbon(s)).  
2-D correlation spectra (gCOSY, gHSQC, gHMBC, gHMQC, and ASAP-HSQC) were 






Infra-red (IR) Spectroscopy 
Infrared spectra were recorded on the BRUKER ALPHA FT-IR Spectrometer (with a 
diamond Attenuated Total Reflectance (ATR) top plate) No sample preparation was 
required. Absorbance values are reported in wavenumbers (cm-1). 
Mass Spectroscopy 
High Resolution Mass Spectroscopy (HRMS) spectra were recorded on a Bruker 
microTOFQ mass spectrometer using an electrospray ionisation (ESI) source in either the 
positive or negative mode. 
Chromatography 
Thin layer chromatography (TLC) was performed on aluminium backed sorbent silica gel 
plates (Merck). Compounds were detected using a UV lamp and/or stained with either a 
vanillin stain (2% w/v vanillin in ethanol and 0.01% H2SO4) or a PMA stain (7% w/v 
phosphomolybdic acid in ethanol) or a KMnO4 stain (1% w/v KMnO4 in ethanol with 7% 
w/v K2CO3 and 0.08% w/v NaOH) with subsequent heating using a heat gun. Normal 
phase silica gel silica column chromatography was performed using silica gel (230-400 
mesh) and the specified eluent(s). All chromatography solvents were reagent grade. 
Reverse phase silica column chromatography was performed using Isolute® C18(EC) 
10g/70 mL column cartridges purchased from Biotage, and using the specified gradient of 
0.05% TFA in H2O and CH3CN HPLC grade eluents. 
High Performance Liquid Chromatography  
 
Unless otherwise stated, High Performance Liquid Chromatography (HPLC) analyses were 
conducted on an analytical RP-HPLC (Shimadzu LC-20AD equipped with both a SPD-
20A UV [210 and 254 nm] and ELSD-LTII [350 kPa, nebulizer 60 °C] detector) using a 




equipped with an SPD-20A UV detector [210 and 254 nm]) using a Phenomenex Prodigy 
column (C–18, 5 μm, 3.00 × 250 mm) at 0.5 mL/min and heated to 40 °C. The solvent 
system for all LC purposes was a mixture of A (0.05% TFA in H2O) and B (0.05% TFA in 
CH3CN). HPLC data are reported using the following convention: Analytical-HPLC 
(Detector, Flow rate (mL min-1)) retention time (min). 
Solvents and Reagents  
Solvents specified as anhydrous were prepared by a PURE SOLV MD-6 solvent 
purification system, with the exception of anhydrous N,N-dimethylformamide (DMF), 
which was purchased in Sure/SealTM bottles. HPLC grade acetonitrile and methanol were 
purchased from Merck Chemicals. MilliQ grade H2O was obtained from a Millipore 
purification system. HPLC grade trifluoroacetic acid was purchased from Scharlau. All 
other reagents were used as received. 
Novel Compounds  
The syntheses of new compounds are indicated by the italicising of the compound name. 
Some CORMs were obtained as a mixture of endo- and exo- Diels–Alder adducts, and 
were generally inseparable. In these cases, all data are given for the mixture, with the 
exception of NMR data, in which data for the major endo- isomer is given, in addition to 









6.2 Synthetic Protocols 
 
General Procedure A: Synthesis of secondary amides from aryl halides and primary 
amine (n-butylamine) using diethyl acetylenedicarboxylate as CO source 
The two-chamber system, equipped with Teflon® coated magnetic stirrer bars, was loaded 
with all solid reagents. In Chamber A; diene dimer 4 (0.75 eq.). In Chamber B; Pd2(dba)3 
(0.025 eq.) and PPh3 (0.1 eq.). Then, all liquid reagents were added via syringe: to 
Chamber A: 1,4-dioxane (5 mL) and diethyl acetylenedicarboxylate (1.5 eq.); to Chamber 
B: 1,4-dioxane (4 mL), aryl halide (1 eq.; aryl halides that were solids at room temperature 
were added with the catalyst and ligands), n-butylamine (2.3 eq.) and Et3N (2.3 eq.). The 
system was sealed with screwcaps fitted with silicon seal inserts. The two chamber system 
was heated in an oil bath at 80 °C with stirring, for 20 h. The reaction mixtures were then 
allowed to cool to rt, and the solvents in Chamber A and B were individually concentrated 
in vacuo. The crude material obtained was purified by silica column chromatography on 
silica gel. 
General Procedure B: Synthesis of secondary and tertiary amides from aryl halides 
and primary amine (n-butylamine) using cycloadduct 28 as the CO source 
The two-chamber system, equipped with Teflon® coated magnetic stirrer bars, was loaded 
with all solid reagents. In Chamber A; cycloadduct 30 (1.5 eq.). In Chamber B; Pd2(dba)3 
(0.025 eq.) and PPh3 (0.1 eq.), the aryl halide (1 eq.), if solid, was added to Chamber B. 
Then, all liquid reagents were added to Chamber B via syringe: aryl halide (1 eq.) (if 
liquid), n-butylamine (2.3 eq.) and 1,4-dioxane (Chamber A: 5 mL, Chamber B: 4 mL). 
The system was cooled in an ice bath (with sodium chloride) and flushed with argon. Et3N 
(2.3 eq.) was added to Chamber B via syringe, and the cap (fitted with a silicon seal insert) 
screwed in place. Et3N (2.3 eq.) was also added to Chamber A via syringe, and the system 
was sealed. The two chamber system was heated in an oil bath at 80 °C with stirring, for 
20 h. The reaction mixture was then allowed to cool to rt, and the solvent in Chamber B 
was concentrated in vacuo. The crude material obtained was purified by silica column 




2,5-Dimethyl-3,4-diphenylcyclopentadien-1-one (diene dimer)67 (4) 
Benzil (10.0 g, 47.6 mmol) and pentan-3-one (7.59 mL, 71.4 mmol) 
in isopropanol (150 mL) were combined with KOH (3.47 g, 61.8 
mmol) in isopropanol (100 mL) and the reaction mixture was stirred 
for 3 h at rt Isopropanol was removed under reduced pressure, the 
residue was acidified with aqueous 5% HCl and extracted into EtOAc. The organic layer 
was washed with water and brine, and dried over anhydrous MgSO4. The filtrate was 
concentrated under reduced pressure. The residue was cooled to 0 °C, acetic anhydride (16 
mL) and conc. H2SO4 (1.0 mL) were slowly added and the mixture stirred at rt o/n. The 
solution was added to cold water (100 mL) with stirring. The precipitate was collected, 
washed with H2O, and dried under vacuum to afford the title compound (8.98 g, 34.5 
mmol, 73%) as a white powder. 1H NMR (400 MHz, CDCl3) δ 0.58 (3H, s, CH3), 1.25 (3H, 
s, CH3), 1.64 (3H, s, CH3), 2.25 (3H, s, CH3), 6.70 (2H, m, Ph), 6.89 – 7.00 (8H, m, Ph), 
7.04 – 7.12 (5H, m, Ph), 7.20 – 7.29 (5H, m, Ph); 13C NMR (400 MHz, CDCl3) δ 10.0 
(Me), 12.5 (Me), 12.6 (Me), 18.2 (Me), 58.6, 59.9, 61.2, 66.9, 127.00, 127.04, 127.2, 
127.36, 127.43, 128.0, 129.0, 129.4, 130.3, 131.0, 132.0, 133.6, 134.1, 134.2, 140.2, 143.0, 
143.3, 144.5, 166.0, 203.3 (C=O), 209.6 (C=O); HRMS-ESI m/z [M+Na]+  calc. 
for C38H32O2Na
+: 543.2295, found: 543.2278.  
3a,4,7,7a-Tetrahydro-7a-bromo-4,7-dimethyl-5,6-diphenyl-4,7-
methanoisobenzofuran-1,3,8-trione (Cycloadduct 30) 23 
 
Diene dimer (999 mg, 0.192 mmol) 
and bromomaleic anhydride (1.295 mL, 3.84 mmol) were refluxed in 
toluene (60 mL) for 4 h. The orange solution was concentrated in 
vacuo.  The product was triturated in ether and petrol to afford the title 
compound as an inseparable 6:1 mixture of the endo and exo isomers (808 mg, 1.85 mmol, 
96%) as a white solid. νmax (cm
-1) 1775 (C=O), 1218 (C-O-C), 697 (C-Br); HRMS-ESI m/z 
[M+Na]+  calc. for C23H17
79BrO4Na
+: 459.0202, Found: 459.0171. 
For the endo isomer; 1H NMR (400 MHz, CDCl3) δ inter alia 1.62 (3H, s, 7-CH3), 1.65 
(3H, s, 4-CH3), 3.74 (1H, s, H-7a), 6.93 – 6.97 (4H, m, Ph), 7.20 – 7.22 (6H, dt, J = 6.2, 
2.1 Hz, Ph); 13C NMR (400 MHz, CDCl3) δ inter alia 11.3 (CH3, C-7), 12.1 (CH3, C-4), 




128.71, 129.5, 129.8 (CH, Ph), 131.8, 131.9 (Cquat, Ph), 141.2 (Cquat, C-6), 145.6 (Cquat,C-
5), 166.8 (C=O, C-1), 167.0 (C=O, C-3), 195.6 (C=O, C-8). 
For the exo isomer; 1H NMR (400 MHz, CDCl3) δ inter alia 1.25 (3H, s, 7-CH3), 1.59 (3H, 





 Et3N (0.096 mL, 0.686 mmol) was added to cycloadduct 30 (100 mg, 
0.229 mmol) in toluene (4 mL) and heated at reflux for 3 h. The solvent 
was concentrated in vacuo and the residue extracted into EtOAc, then 
washed with 1M HCl and dried over MgSO4. The solvent was 
concentrated in vacuo to afford the title compound (73.7 mg, 0.224 mmol, 98%) as a pale 
solid. 1H NMR (400 MHz, CDCl3) δ 2.43 (6H, s, 2 x CH3), 6.89 (4H, m, Ph), 7.18 (6H, m, 
Ph). 13C NMR (400 MHz, CDCl3) δ 15.9 (2 x CH3), 127.2 (CH, Ph), 127.6 (Cquat, C-3a, C-
7a) 128.0 (CH, Ph), 129.2 (CH, Ph), 136.7 (Cquat, C-4, C-7), 137.8 (Cquat, C-5-ipso, C-6-
ipso), 150.5 (Cquat, C-5, C-6), 163.4 (2 x C=O, C-1, C-3); νmax (cm
-1) 1763 (C=O), 1685 
(C=O), 1209 (C-O-C); HRMS-ESI m/z [M+Na]+  calc. for: C22H16O3Na
+: 351.0992, found: 
351.0964. 
 
Diethyl 3,6-dimethyl-4,5-diphenylphthalate71 (44) 
 
Diethyl acetylenedicarboxylate (0.110 mL, 0.748 mmol) and diene 
dimer 4 (334 mg, 0.641 mmol) were added to a Kimax® tube, followed 
by 1,4-dioxane (6 mL). The Kimax® tube was sealed with a screwcap 
fitted with a silicon seal. The sealed system was heated to 80 °C for 20 
h. The reaction mixture was cooled to rt and the solvent concentrated in vacuo. The crude 
product was purified by silica column chromatography (EtOAc/PE 1:4-1:1) to afford the 
title compound (275 mg, 0.683 mmol, 91%) as pure white crystals. 1H NMR (400 MHz, 
CDCl3) δ 1.39 (6H, t, J = 7.1 Hz, 2 x CH3), 2.08 (6H, s, 2 x CH3, CO2CH2CH3), 4.38 (4H, 
q, J = 7.1 Hz, 2 x CH2, CO2CH2CH3), 6.88 (4H, m, Ph), 7.11 (6H, m, Ph); 
13C NMR (400 
MHz, CDCl3) δ 14.3 (2 x CH3), 18.5 (2 x CH3, CO2CH2CH3), 61.7 (2 x CH2, 




4), 144.4 (Cquat, C-2, C-3), 168.9 (C=O, CO2); νmax (cm
-1) 1723 (C=O); HRMS-ESI m/z 
[M+Na]+  calc. for C26H26O4Na
+: 425.1723, Found: 425.1736. 
6.3 Aminocarbonylation reactions 
 
N-butyl-4-methoxybenzamide48 (28) 
Diethyl acetylenedicarboxylate as CO source – One chamber 
system 
In a Kimax® tube: diethyl acetylenedicarboxylate (0.094 mL, 
0.641 mmol) and diene dimer 4 (167 mg, 0.320 mmol) were dissolved in 1,4-dioxane (6 
mL). Pd2(dba)3 (9.78 mg, 10.68 µmol), PPh3 (11.21 mg, 0.043 mmol), p-iodoanisole (100 
mg, 0.427 mmol), butylamine (0.097 mL, 0.983 mmol) and Et3N (0.137 mL, 0.983 mmol) 
were added. The Kimax® tube was sealed with a screwcap fitted with a silicon seal. The 
sealed system was heated to 80 °C for 20 h. The reaction mixture was cooled to rt and the 
solvent concentrated in vacuo. The crude 1H NMR spectrum indicated that mainly starting 
material remained. 
 
Diethyl acetylenedicarboxylate as CO source – two-chamber system  
Following General Procedure A:  
Chamber A: diethyl acetylenedicarboxylate (0.110 mL, 0.748 mmol), diene dimer 4 (334 
mg, 0.641 mmol) and 1,4-dioxane.  
Chamber B: Pd2(dba)3 (9.78 mg, 10.68 µmol), PPh3 (11.21 mg, 0.043 mmol), p-
iodoanisole (100 mg, 0.427 mmol), n-butylamine (0.097 mL, 0.983 mmol), 1,4-dioxane (4 
mL) and Et3N (0.137 mL, 0.983 mmol). The system was sealed and heated to 80 °C for 20 
h. The reaction mixture was cooled to rt, and the solvent in Chamber B was concentrated in 
vacuo. The crude product was purified by silica column chromatography (EtOAc/PE 1:4-
1:1) to afford the title compound (84.5 mg, 0.408 mmol, 95%) as white crystals. 1H NMR 
(400 MHz, CDCl3) δ 0.96 (3H, t, J = 7.3 Hz, CH3), 1.39 – 1.44 (2H, m, H-10), 1.56 – 163 
(2H, m, H-9), 3.42 – 3.47 (2H, m, H-8), 3.85 (3H, s, OMe), 5.98 (1H, br, NH), 6.92 (2H, d, 
J = 8.9 Hz, H-2, H-6), 7.72 (2H, d, J = 8.9 Hz, H-3, H-5); 13C NMR (400 MHz, CDCl3) δ 
13.8 (CH3), 20.2 (CH2, C-10), 31.8 (CH2, C-9), 39.7 (CH2, C-8), 55.4 (OMe), 113.7 (C-2, 
C-6), 127.1 (Cquat, C-1), 128.5 (C-3, C-5), 162.0 (Cquat, C-4) 167.0 (C=O, C-7); νmax (cm
-1) 




1237 (C-N stretch); HRMS-ESI m/z [M+Na]+  calc. for  C12H17NO2Na
+: 230.1151, Found: 
230.1129. 
 
CORM as CO source  
Following General Procedure B:  
Chamber A: cycloadduct 30 (280 mg, 0.641 mmol), 1,4-dioxane (5 mL) and Et3N (0.137 
mL, 0.983 mmol).  
Chamber B: n (9.78 mg, 10.68 µmol), PPh3 (11.21 mg, 0.043 mmol), p-iodoanisole (100 
mg, 0.427 mmol), n-butylamine (0.097 mL, 0.983 mmol), 1,4-dioxane (4 mL) and Et3N 
(0.089 mL, 0.641 mmol).   
The two-chamber system was sealed and heated to 80 °C for 20 h. The reaction mixture 
was cooled to rt, and the solvent in Chamber B was concentrated in vacuo. The crude 
product was purified by silica column chromatography (EtOAc/PE 1:4-1:1) to afford the 
title compound (78.2 mg, 0.377 mmol, 88%) as a white solid. 1H NMR (400 MHz, CDCl3) 
δ 0.94 (3H, t, J = 7.3 Hz, CH3), 1.35 – 1.38 (2H, m, H-10), 1.54-1.61 (2H, m, H-9) 3.40 – 
3.45 (2H, q, J = 7.1 Hz, H-8), 3.83  (3H, s, OMe), 6.15 (1H, br, NH), 6.89 (2H, d, J = 8.9 
Hz, H-2/H-6), 7.72 (2H, d, J = 8.9 Hz, H-3/H-5). 13C NMR (400 MHz, CDCl3) δ 14.0 
(CH3), 20.3 (CH2, C-10), 32.0 (CH2, C-9), 39.9 (CH2, C-8), 55.5 (OMe), 113.8 (C-2, C-6), 
127.3 (Cquat, C-1), 128.7 (C-3, C-5), 162.2 (Cquat, C-4), 167.1 (C=O, C-7); νmax (cm
-1) 3311 
(N-H stretch), 2839 (C-H), 1623 (C=O), 1502 (N-H bend), 1296 (C-N stretch); HRMS-ESI 
m/z [M+Na]+  calc. for C12H17NO2Na
+: 230.1168, Found: 230.1164. 
 
 N-butyl-4-nitrobenzamide72 (45) 
 
Diethyl acetylenedicarboxylate as CO source  
Following General Procedure A:   
Chamber A: Diethyl acetylenedicarboxylate (0.088 mL, 0.602 
mmol), diene dimer 4 (157 mg, 0.301 mmol) and 1,4-dioxane (5 mL).  
Chamber B: Pd2(dba)3 (9.19 mg, 10.04 µmol), PPh3 (10.53 mg, 0.040 mmol), 1-iodo-4-
nitrobenzene (100 mg, 0.402 mmol), n-butylamine (0.091 mL, 0.924 mmol), 1,4-dioxane 
(4 mL) and Et3N (0.129 mL, 0.924 mmol).  
The system was sealed and heated to 80 °C for 20 h. The reaction mixture was cooled to rt, 
and the solvent in Chamber B was concentrated in vacuo. The crude product was purified 




mg, 0.329 mmol, 82%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 0.98 (3H, t, J 
= 7.3 Hz, CH3), 1.38 – 1.48 (2H, dq, J = 15.6, 7.3 Hz, H-10), 1.59 – 1.67 (2H, m, H-9), 
3.47 – 3.52 (2H, td, J = 7.2, 5.3 Hz, H-8), 6.15 (1H, br, NH), 7.92 (2H, d, J = 9.0 Hz, H-2, 
H-6), 8.29 (2H, d, J = 8.3 Hz, H-3, H-5); 13C NMR (400 MHz, CDCl3) δ 13.9 (CH3), 20.3 
(CH2, C-10), 31.7 (CH2, C-9), 40.3 (CH2, C-8), 124.0 (C-2, C-6), 128.2 (C-3, C-5), 140.6 
(Cquat, C-1), 149.6 (Cquat, C-4), 165.6 (C=O, C-7). νmax (cm
-1) 3302 (N-H stretch), 1634 
(C=O), 1537 (N-H bend), 1510 (NO2), 1346 (NO2), 1295 (C-N stretch); HRMS-ESI m/z 
[M+Na]+  calc. for C12H14N2O3Na
+: 245.0897, Found: 245.0874 
 
CORM as CO source 
Following General Procedure B:  
Chamber A: cycloadduct 30 (263 mg, 0.602 mmol), 1,4-dioxane (5 mL) and Et3N (0.129 
mL, 0.924 mmol).  
Chamber B: Pd2(dba)3 (9.19 mg, 10.04 µmol), PPh3 (10.53 mg, 0.040 mmol), 1-iodo-4-
nitrobenzene (100 mg, 0.402 mmol), n-butylamine (0.091 mL, 0.924 mmol), 1,4-dioxane 
(4 mL) and Et3N (0.129 mL, 0.924 mmol.   
The two-chamber system was sealed and heated to 80 °C for 20 h. The reaction mixture 
was cooled to rt, and the solvent in Chamber B was concentrated in vacuo. The crude 
product was purified by silica column chromatography (EtOAc/PE 1:4 – 1:1) to afford the 
title compound (88.6 mg, 0.399 mmol, 99%) as a pale yellow solid. 1H NMR (400 MHz, 
CDCl3) δ 0.98 (3H, t, J = 7.3 Hz, CH3), 1.39 – 1.48 (2H, m, H-10), 1.60 – 1.67 (2H, m, H-
9), 3.47 – 3.52 (2H, m, H-8), 6.12 (1H, br, NH), 7.92 (2H, d, J = 8.7 Hz, H-2, H-6), 8.29 
(2H, d, J = 8.7 Hz, H-3, H-5); 13C NMR (400 MHz, CDCl3) δ 13.7 (CH3), 20.1 (CH2, C-
10), 31.6 (CH2, C-9), 40.1 (CH2, C-8), 123.8 (C-2, C-6), 128.0 (C-3, C-5), 140.4 (Cquat, C-
1), 149.5 (Cquat, C-4), 165.4 (C=O, C-7); νmax (cm
-1) 3302 (N-H stretch), 1634 (C=O), 1537 
(N-H bend), 1510 (NO2), 1346 (NO2), 1295 (C-N stretch); HRMS-ESI m/z [M+Na]
+  calc. 
for C12H14N2O3Na
+: 245.0897, Found: 245.0899. 
 
N-butyl-1-naphthamide75 (48) 
CORM as CO source 
Following General Procedure B:  
Chamber A: cycloadduct 30 (367.5 mg, 0.840 mmol), 1,4-




Chamber B: Pd2(dba)3 (9.01 mg, 9.84 µmol), PPh3 (10.32 mg, 0.039 mmol), 1-
iodonaphthalene (0.057 mL, 0.394 mmol), n-butylamine (0.089 mL, 0.905 mmol), 1,4-
dioxane (4 mL) and Et3N (0.126 mL, 0.905 mmol).  
The two-chamber system was sealed and heated to 80 °C for 20 h. The reaction mixture 
was cooled to rt, and the solvent in Chamber B was concentrated in vacuo. The crude 1H 
NMR indicated that 90% of the starting material was converted to the title compound. The 
crude product was purified by silica column chromatography (EtOAc/PE 1:6 – 1:3) to give 
a pale orange solid. This was then triturated in DCM and petrol to afford the title 
compound (78 mg, 0.387 mmol, 88%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 0.99 
(3H, t, J = 7.35 Hz, CH3), 1.46 (2H, m, H-11), 1.65 (2H, m, H-10), 3.56 (2H, m, H-9), 5.95 
(1H, br, NH), 7.45 (1H, dd, J = 8.3, 7.0 Hz, Ph),  7.56 (2H, m, Ph), 7.89 (3H, m, Ph), 8.30 
(1H, ddd, J = 7.8, 1.9, 0.8 Hz, Ph); 13C NMR (400 MHz, CDCl3) δ 13.8 (CH3), 20.2 (CH2, 
C-14), 31.8 (CH2, C-13), 39.8 (CH2, C-12), 124.7, 124.7, 125.4, 126.4, 127.0, 128.3, 130.1 
(CH, Ph), 130.4, 133.7, 134.9 (Cquat, Ph), 169.5 (C=O); νmax (cm
-1) 3293 (N-H stretch), 
3061 (C-H), 1653 (C=O), 1553 (N-H bend), 1298 (C-N stretch); HRMS-ESI m/z [M+Na]+ 
 calc. for C15H17NONa




Following General Procedure B:  
Chamber A: cycloadduct 30 (150 mg, 0.343 mmol), 1,4-
dioxane (5 mL) and Et3N (0.072 mL, 0.515 mmol).  
Chamber B: Pd2(dba)3 (7.85 mg, 8.58 µmol), PPh3 (9.00 mg, 0.034 mmol), 1-bromo-4-
iodobenzene (97 mg, 0.343 mmol), n-butylamine (0.078 mL, 0.789 mmol), 1,4-dioxane (4 
mL) and Et3N (0.110 mL, 0.789 mmol). The two-chamber system was sealed and heated to 
80 °C for 20 h. The reaction mixture was cooled to rt, and the solvent in Chamber B was 
concentrated in vacuo. The crude product was purified by silica column chromatography 
(EtOAc/PE 1:6 – 2:1) to afford the title compound (73.1 mg, 0.285 mmol, 81%) as crystals. 
1H NMR (400 MHz, CDCl3) δ 0.96 (3H, t, J = 7.3 Hz, CH3), 1.37 – 1.46 (2H, m, H-10), 
1.57 – 1.64 (2H, m, H-9), 3.43 – 3.48 (2H, m, H-8), 6.02 (1H, br, NH), 7.63 (2H, d, J = 8.7 
Hz, H-3, H-5), 7.86 (2H, d, J = 8.7 Hz, H-2, H-6); 13C NMR (400 MHz, CDCl3) 13.9 
(CH3), 31.0 (CH2, C-10), 31.8 (CH2, C-9), 40.0 (CH2, C-8), 125.9 (Cquat, C-1), 128.6 (CH, 





3321 (N-H stretch), 1631 (C=O), 1535 (N-H bend), 1297 (C-N stretch), 644 (C-Br); 
HRMS-ESI m/z [M+H]+  calc. for  C11H15NO




Following General Procedure B:  
Chamber A: cycloadduct 30 (322 mg, 0.735 mmol), 1,4-dioxane 
(5 mL) and Et3N (0.157 mL, 1.127 mmol).  
Chamber B: Pd2(dba)3 (11.22 mg, 0.012 mmol), PPh3 (12.86 mg, 0.049 mmol), 
iodobenzene (0.055 mL, 0.490 mmol), n-butylamine (0.111 mL, 1.127 mmol), 1,4-dioxane 
(4 mL) and Et3N (0.157 mL, 1.127 mmol). The two-chamber system was sealed and heated 
to 80 °C for 20 h. The reaction mixture was cooled to rt, and the solvent in Chamber B was 
concentrated in vacuo. The crude product was purified by silica column chromatography 
(EtOAc/PE 0:1 – 1:4) to afford the title compound (84.1 mg, 0.474 mmol, 97%) as an oil. 
1H NMR (400 MHz, CDCl3) δ 0.96 (3H, t, J = 7.3 Hz, CH3), 1.43 (2H, m, H-10), 1.61 (2H, 
m, H-9), 3.47 (2H, td, J = 7.2, 5.7 Hz, H-8), 6.09 (1H, br, NH), 7.43 (2H, m, H-2/H-6), 
7.48 (1H, m, H-4), 7.75 (2H, m, H-3/H-5). 13C NMR (400 MHz, CDCl3) δ 13.8 (CH3), 
31.0 (CH2, C-10), 31.8 (CH2, C-9), 39.9 (CH2,C-8), 127.0 (Cquat, C-1), 128.5 (C-2, C-6), 
131.3 (C-3, C-5), 134.9 (Cquat, C-4), 167.7 (C=O, C-7); νmax (cm
-1) 3317 (N-H stretch), 
1634 (C=O), 1539 (N-H bend), 1307 (C-N stretch); HRMS-ESI m/z [M+Na]+  calc. 
for C11H15NONa
+: 200.1046, Found: 200.1030. 
 
Morpholino(4-methoxyphenyl) methanone76 (49) 
 
Following General Procedure B:  
Chamber A: cycloadduct 30 (280 mg, 0.641 mmol), 1,4-dioxane 
(5 mL) and Et3N (0.137 mL, 0.983 mmol).  
Chamber B: Pd2(dba)3 (9.78 mg, 10.68 µmol), PPh3 (11.21 mg, 0.043 mmol), p-
iodoanisole (100 mg, 0.427 mmol), morpholine (0.086 mL, 0.983 mmol), 1,4-dioxane (4 
mL) and Et3N (0.137 mL, 0.983 mmol). The two-chamber system was sealed and heated to 
100 °C for 25 h. The reaction mixture was cooled to rt, and the solvent in Chamber B was 
concentrated in vacuo. The crude product was purified by silica column chromatography 
(EtOAc/PE 2:1 – 6:1) to afford the title compound (70.8 mg, 0.320 mmol, 75%) as a 




OMe), 6.90 – 6.94 (2H, m, H-2,6), 7.37 – 7.41 (2H, m, H-3,5); 13C NMR (400 MHz, 
CDCl3) δ 43.7 (C-6’), 48.7 (C-2’), 55.5 (OMe), 67.1 (C-3’, C-5’), 113.9 (C-3, C-5), 127.5 
(C-2, C-6), 129.3 (Cquat, C-1), 161.0 (Cquat, C-4), 170.5 (C=O); νmax (cm
-1) 2857 (O-Me), 
1627 (C=O), 1277 (C-N stretch), 1107 (C-O-C); HRMS-ESI m/z [M+Na]+  calc. 
for C12H15NO3Na




Following General Procedure B:  
Chamber A: cycloadduct 30 (263 mg, 0.602 mmol) 1,4-dioxane 
(5 mL) and Et3N (0.129 mL, 0.924 mmol).  
Chamber B: Pd2(dba)3 (9.19 mg, 10.04 µmol), PPh3 (10.53 mg, 0.040 mmol), 1-iodo-4-
nitrobenzene (100 mg, 0.402 mmol), morpholine (0.081 mL, 0.924 mmol) 1,4-dioxane (4 
mL) and Et3N (0.129 mL, 0.924 mmol). The two-chamber system was sealed and heated to 
100 °C for 25 h. The reaction mixture was cooled to rt, and the solvent in Chamber B was 
concentrated in vacuo. The crude product was purified by silica column chromatography 
(EtOAc/PE 1:1 – 6:1) to afford the title compound (83.1 mg, 0.352 mmol, 88%) as an 
orange solid. 1H NMR (400 MHz, CDCl3) δ 3.39 – 3.81 (8H, m, H2’,3’,5’,6’), 7.57 – 7.60 
(2H, m, H-2,6), 8.28 – 8.31 (2H, m, H-3,5); 13C NMR (400 MHz, CDCl3) δ 42.8 (C-6’), 
48.2 (C-2’), 66.9 (C-3’, C-5’), 124.1 (C-2, C-6), 128.3 (C-3, C-5), 141.6 (Cquat, C-1), 148.7 
(Cquat, C-4), 168.2 (C=O); νmax (cm
-1) 2920 (C-H bend), 1631 (C=O), 1515 (NO2), 1350 
(NO2), 1279 (C-N), 1105 (C-O-C); HRMS-ESI m/z [M+H]
+  calc. for C12H13NO3
+: 




Following General Procedure B:  
Chamber A: cycloadduct 30 (232 mg, 0.530 mmol), 1,4-dioxane (5 
mL) and Et3N (0.113 mL, 0.813 mmol). 
Chamber B: Pd2(dba)3 (8.09 mg, 8.84 µmol), PPh3 (9.27 mg, 0.035 mmol), 1-bromo-4-
iodobenzene (100 mg, 0.353 mmol), morpholine (0.071 mL, 0.813 mmol), 1,4-dioxane (4 
mL) and Et3N (0.113 mL, 0.813 mmol). The two-chamber system was sealed and heated to 
100 °C for 25 h. The reaction mixture was cooled to rt, and the solvent in Chamber B was 




(EtOAc/PE 1:1 – 4:1) to afford the title compound as an pale orange oil (67.5 mg, 0.254 
mmol, 72%); 1H NMR (400 MHz, CDCl3) δ 3.46 – 3.70 (8H, m, H-2’,3’,5’,6’), 7.28 – 7.30 
(2H, m, H-2,6), 7.55 – 7.57 (2H, m, H-3,5); 13C NMR (400 MHz, CDCl3) δ 42.8 (C-6’), 
48.2 (C-2’), 67.0 (C-3’, C-5’), 124.4 (Cquat, C-4), 129.0 (C-3, C-5), 132.0 (C-2, C-6), 134.2 
(Cquat, C-1), 169.5 (C=O); νmax (cm
-1) 1628 (C=O), 1276 (C-N stretch), 1111 (C-O-C); 
HRMS-ESI m/z [M+H]+  calc. for C11H13NO2




Following General Procedure B:  
Chamber A: cycloadduct 30 (322 mg, 0.735 mmol), 1,4-dioxane (5 
mL) and Et3N (0.157 mL, 1.127 mmol). 
Chamber B: Pd2(dba)3 (11.22 mg, 0.012 mmol), PPh3 (12.86 mg, 0.049 mmol), 
iodobenzene (0.055 mL, 0.490 mmol), morpholine (0.099 mL, 1.127 mmol), 1,4-dioxane 
(4 mL) and Et3N (0.157 mL, 1.127 mmol). The two-chamber system was sealed and heated 
to 100 °C for 25 h. The reaction mixture was cooled to rt, and the solvent in Chamber B 
was concentrated in vacuo. The crude product was purified by silica column 
chromatography (EtOAc/PE 1:1 – 4:1) to afford the title compound (93 mg, 0.486 mmol, 
99%). 1H NMR (400 MHz, CDCl3) δ 3.46 – 3.75 (8H, m, H-2’,3’,5’,6’), 7.39 – 7.43 (5H, 
m, H-2,3,4,5,6); 13C NMR (400 MHz, CDCl3) δ; 42.7 (C-6’), 48.3 (C-2’), 67.0 (C-3’, C-
5’), 127.2 (C-2, C-6), 128.7 (C-3, C-5), 130.0 (Cquat, C-4), 135.5 (Cquat, C-1), 170.6 (C=O);  
νmax (cm
-1); 1625 (C=O), 1275 (C-N stretch), 1110 (C-O-C); 544 (C-Br); HRMS-ESI m/z 
[M+Na]+  calc. for C11H13NO2Na




Following General Procedure B:  
Chamber A: cycloadduct 30 (258 mg, 0.590 mmol), 1,4-dioxane (5 
mL) and Et3N (0.126 mL, 0.905 mmol). 
Chamber B: Pd2(dba)3 (9.01 mg, 9.84 µmol), PPh3 (10.32 mg, 
0.039 mmol), 1-iodonaphthalene (0.057 mL, 0.394 mmol), morpholine (0.079 mL, 0.905 
mmol), 1,4-dioxane (4 mL) and Et3N (0.126 mL, 0.905 mmol). The two-chamber system 
was sealed and heated to 100 °C for 25 h. The reaction mixture was cooled to rt, and the 




80% of the starting material was converted into the title compound. The crude product was 
purified by silica column chromatography (EtOAc/PE 1:2 – 4:1) to afford the title 
compound (71.2 mg, 0.295 mmol, 75%). 1H NMR (400 MHz, CDCl3) δ 3.16 – 3.25 (2H, 
m, H-2’), 3.47 – 3.56 (2H, m, H-6’), 3.83 – 4.04 (4H, m, H-3’,-5’), 7.41 – 7.43 (1H, dd, J 
= 7.0, 1.3 Hz, ), 7.47 – 7.57 (4H, m, Ph), 7.84 – 7.90 (3H, m, Ph); 13C NMR (101 MHz, 
CDCl3) δ; 42.3 (C-6’), 47.8 (C-2’), 67.1 (C-5’), 67.2 (C-3’), 124.1, 124.7, 125.3, 126.7, 
127.3, 128.6, 129.5 (CH, Ph), 129.7, 133.6, 133.8 (Cquat, Ph), 169.6 (C=O); νmax (cm
-1) 
1629 (C=O), 1247 (C-N stretch), 1111 (C-O-C); HRMS-ESI m/z [M+Na]+  calc. 
for C15H15NO2Na






trione (654 mg, 1.496 mmol) was added followed by 
Toluene (6 mL). 
Chamber B: Pd2(dba)3 (19.56 mg, 0.021 mmol), tri-tert-butylphosphonium 
tetrafluoroborate (12.40 mg, 0.043 mmol), p-iodoanisole (100 mg, 0.427 mmol) were 
added followed by toluene (5 mL), butylamine (0.063 mL, 0.641 mmol) and DBU (0.128 
mL, 0.855 mmol). The system was flushed with argon then DBU (0.256 mL, 1.709 mmol) 
was added to Chamber A, the system was then sealed with screwcaps fitted with silicon 
seals. The sealed system was left to stir for 25 h. The solvent in Chamber B was 
concentrated in vacuo. The crude product was purified by silica column chromatography 
(EtOAc/PE 1:9 – 2:3) to afford the title compound (64.7 mg, 0.275 mmol, 64%) as a pale 
yellow solid. 1H NMR (400 MHz, CDCl3) δ 0.94 (3H, t, J = 7.3 Hz, CH3), 1.34 – 1.44 (2H, 
m, H-11), 1.54 – 1.61 (2H, m, H-10), 3.34 – 3.40 (2H, m, H-9), 3.87 – 3.88 (3H, m, OMe), 
6.93 (2H, dt, J = 9.0, 1.3 Hz, Ph – H), 7.15 (1H, br, NH), 8.40 (2H, dt, J = 9.2, 1.8 Hz, Ph); 
13C NMR (101 MHz, CDCl3) δ 13.8 (C-12), 20.2 (C-11), 31.5 (C-10), 39.2 (C-9), 55.7 
(OMe), 113.9 (CH, Ph, C-3, C-5), 126.6 (CH, Ph, C-2, C-6), 134.0 (Cquat, C-1), 162.4 
(Cquat, C-4), 164.8 (C=O, C-8),  186.0 (C=O, C-7); νmax (cm
-1) 3242 (NH), 2933 (OMe), 
1667, 1630 (C=O); HRMS-ESI m/z [M+Na]+  calc. for  C13H17NO3Na










tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (643 mg, 1.471 
mmol) was added, followed by 1,4-dioxane (5 mL).  
Chamber B: Pd2(dba)3 (8.98 mg, 9.80 µmol), phenylboronic acid (90 
mg, 0.735 mmol) and K2CO3 (203 mg, 1.471 mmol) were added, followed by anisole (5 
mL) and iodobenzene (0.055 mL, 0.490 mmol). The system was flushed with argon then 
Et3N (0.239 mL, 1.716 mmol) was added to Chamber A, the system was then sealed with 
screwcaps fitted with silicon seals.  
The system was allowed to sit for 30 min to release CO before being heated to 80 °C for 24 
h. The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 
vacuo. The crude product was purified by silica column chromatography to afford the title 
compound (69.3 mg, 0.380 mmol, 78%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 
7.49 (4H, m, H-3, -3’, -5, -5’),7.59 (2H, m, H-4, -4’), 7.81 (4H, m, H-2, -2’, -6, -6’). 
13C NMR (101 MHz, CDCl3) δ 128.4 (C-4, 4’), 130.2 (CH, Ph), 132.5 (CH, Ph), 137.7 (C-
1,1’), 196.9 (C=O). νmax (cm
-1) 1655 (C=O); HRMS-ESI m/z [M+Na]+  calc. 
for C13H10ONa





tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (561 mg, 
1.282 mmol) was added, followed by 1,4-dioxane (5 mL), 
Chamber B: Pd2(dba)3 (7.83 mg, 8.55 µmol), phenylboronic acid 
(78 mg, 0.641 mmol), p-iodoanisole (100 mg, 0.427 mmol) and K2CO3 (177 mg, 1.282 
mmol) were added, followed by anisole (4 mL). The system was flushed with argon then 
Et3N (0.208 mL, 1.496 mmol) was added to Chamber A, the system was then sealed with 
screwcaps fitted with silicon seals. 
The system was allowed to sit for 30 min to release CO before being heated to 80 °C for 25 
h. The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 




afford the title compound (67.5 mg, 0.318 mmol, 74%) as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 3.89 (3H, s, OMe), 6.97 (2H, d, J = 8.6 Hz, H-3, -5), 7.47 (2H, t, J = 7.6 
Hz, H-3’, -5’), 7.57 (1H, t, J = 7.5 Hz, H-4’), 7.76 (2H, d, J = 8.1 Hz, H-2’, -6’), 7.83 (2H, 
d, J = 8.5 Hz, H-2, -6); 13C NMR (101 MHz, CDCl3) δ 55.6 (OMe), 113.7 (CH, Ph, C-3, 
C-5), 128.3, 129.9, 130.3, 132.0, 132.7 (CH, Ph, C-2, C-6), 138.4 (Cquat, C-1’), 163.3 
(Cquat, C-4), 195.8 (C=O); νmax (cm
-1) 2841 (OMe), 1649 (C=O); HRMS-ESI m/z [M+Na]+ 
 calc. for C14H12O2Na




Chamber A : 3a-bromo-4,7-dimethyl-5,6-diphenyl-3a,4,7,7a-
tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (561 mg, 
1.282 mmol) was added, followed by 1,4-dioxane (5 mL). 
Chamber B: Pd2(dba)3 (7.83 mg, 8.55 µmol), (4-
chlorophenyl)boronic acid (100 mg, 0.641 mmol), p-iodoanisole (100 mg, 0.427 mmol) 
and K2CO3 (177 mg, 1.282 mmol) were added, followed by anisole (4 mL). The system 
was flushed with argon then Et3N (0.208 mL, 1.496 mmol) was added to Chamber A, the 
system was then sealed with screwcaps fitted with silicon seals. 
The system was allowed to sit for 30 min to release CO before being heated to 80 °C for 24 
h. The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 
vacuo. The crude product was purified by silica column chromatography (EtOAc/PE) to 
afford the title compound (98.8 mg, 0.401 mmol, 94%) as a yellow solid. 1H NMR (400 
MHz, CDCl3) δ 3.90 (3H, s, OMe), 6.97 (2H, d, J  = 8.9 Hz, H3, H-5), 7.45 (2H, d, J  = 8.6 
Hz, H-3’, H-5’), 7.71 (2H, d, J  = 8.5 Hz, H-2’, H-6’), 7.80 (2H, d, J  = 8.9 Hz, H-2, H-6); 
13C NMR (101 MHz, CDCl3) δ 55.7 (OMe), 113.8 (CH, Ph, C-3, C-5), 128.7 (CH, Ph, C-
3’, C-5’), 129.9 (Cquat, C-1) 131.3 (CH, Ph, C-2’, C-6’), 132.6 (Cquat, C-1’), 136.7 (Cquat, C-
4’), 138.4 (CH, Ph, C-2, C-6), 163.5 (Cquat, C-4), 194.5 (C=O, C-7); νmax (cm
-1) 2842 
(OMe), 1639 (C=O), 759 (Ar-Cl); HRMS-ESI m/z [M+Na]+  calc. for C14H11
35ClO2Na
+ : 









Ethyl 2-(4-iodophenoxy)acetate104 (63) 
 
To a solution of 4-iodophenol (1 g, 4.55 mmol) in acetone (100 
mL), K2CO3 (1.885 g, 13.64 mmol) and ethyl 2-bromoacetate 
(0.553 mL, 5.00 mmol) were added. The mixture was heated at 
reflux o/n. The reaction progress was monitored by TLC until no starting material was 
observed.  The reaction was allowed to cool to rt and the solution was concentrated in 
vacuo. The residue was dissolved in DCM and washed with water (2 x 40 mL). The 
organic layer was dried with MgSO4, filtered and concentrated in vacuo. The crude product 
was purified by silica column chromatography (DCM 100%) to afford the title compound 
(1.390 g, 4.54 mmol, 99%) as a white crystalline solid. 1H NMR (400 MHz, CDCl3) δ 1.29 
(3H, t, J = 7.1 Hz, H-10), 4.27 (2H, q, J = 7.1 Hz, H-9), 4.58 (2H, s, H-7), 6.69 (2H, d, J = 
8.9 Hz, H-3, H-5), 7.57 (2H, d, J = 8.9 Hz, H-2, H-6); 13C NMR (101 MHz, CDCl3) δ 14.3 
(C-10), 61.6 (C-9), 65.6 (C-7), 84.2 (Cquat, C-1), 117.2 (CH, Ph, C-3, C-5), 138.5 (CH, Ph, 
C-2, C-6) 157.9 (Cquat, C-4), 168.7 (C=O, C-8); νmax (cm
-1)  1754 (C=O),  1198 (C-O-C); 
HRMS-ESI m/z [M+Na]+  calc. for C10H11IO3Na+: 328.9645, found: 328.9645.  
 




1,3,8-trione (643 mg, 1.470 mmol) was added, 
followed by 1,4-dioxane (4 mL). 
Chamber B: ethyl 2-(4-iodophenoxy)acetate (150 mg, 0.490 mmol), (4-
chlorophenyl)boronic acid (115 mg, 0.735 mmol), K2CO3 (203 mg, 1.470 mmol) and 
Pd2(dba)3 (8.97 mg, 9.80 µmol) were added, followed by anisole (4 mL).  The system was 
flushed with argon then Et3N (0.239 mL, 1.715 mmol) was added to Chamber A, the 
system was then sealed with screwcaps fitted with silicon seals. 
The system was allowed to sit for 30 min to release CO before being heated to 80 °C for 30 
h. The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 
vacuo. The crude product was purified by silica column chromatography (EtOAc/PE 1:15 
– 1:5) to afford the title compound (117.6 mg, 0.369 mmol, 75%). 1H NMR (400 MHz, 
CDCl3) δ 1.31 (3H, t, J = 7.1 Hz, H-10), 4.29 (2H, q, J = 7.1 Hz, H-9), 4.71 (2H, s, H-7), 




(2H, d, J = 8.6 Hz, Ph). 13C NMR (101 MHz, CDCl3) δ 14.3 (CH3,C-10), 61.8 (CH2, C-9) 
65.3 (CH2, C-7), 114.4 (CH, Ph, C-3, C-5), 128.7 (Cquat, C-1), 130.9, 131.3, 132.6 (CH, 
Ph), 136.4 (Cquat, C-1’), 138.6 (Cquat, C-4’), 161.5 (Cquat, C-4), 168.4 (C=O, C-8), 194.4 
(C=O, C-11); νmax (cm
-1) 1755 (C=O), 1651 (C=O aryl), 1201 (C-O-C), 760 (Ar-Cl); 
HRMS-ESI m/z [M+Na]+  calc. for C17H15
35ClO4Na+: 341.0551, found: 341.0549 
 
Isopropyl 2-(4-iodophenoxy)-2-methylpropanoate (37) 
 
4-iodophenol (200 mg, 0.909 mmol) and anhydrous K2CO3 
(377 mg, 2.73 mmol) were mixed in dry acetonitrile (20 mL). 
Isopropyl 2-bromo-2-methylpropanoate (0.184 mL, 1.091 
mmol) was introduced to the suspension, and the reaction mixture was heated at reflux for 
18 h. The reaction progress was monitored by TLC.  After the mixture was cooled to rt, the 
reaction was terminated by addition of 1 M HCl (30 mL), and the product was extracted 
with ethyl acetate (50 mL). The organic layer was washed with water and brine and dried 
over MgSO4 filtered and concentrated in vacuo. The crude product was purified by silica 
column chromatography to afford the title compound (172.6 mg, 0.496 mmol, 54.5%). 
1H NMR (400 MHz, CDCl3) δ 1.21 (6H, d, J = 6.3 Hz, C-9 isopropyl), 1.57 (6H, s, C-7 
CH3), 5.07 (1H, hept, J = 6.3 Hz, H-9), 6.59 – 6.63 (2H, m, H-2, -6), 7.49 – 7.53 (2H, m, 
H-3, -5). 13C NMR (101 MHz, CDCl3) δ 21.7 (2 x CH3, C-9), 25.4 (2 x CH3, C-7), 69.3 
(CH, C-9), 79.4 (CH, C-7), 84.6 (Cquat,C-1), 121.2 (CH, Ph, C-3, C-5), 138.1 (CH, Ph, C-2, 
C-6), 155.6 (Cquat ,C-4), 173.6 (C=O, C-8); νmax (cm
-1) 1724 (C=O),  1100 (C-O-C); 
HRMS-ESI m/z [M+Na]+  calc. for C13H17IO3Na
+: 371.0115, found: 371.0111.  
 




1,3,8-trione (565 mg, 1.292 mmol) was added, 
followed by 1,4-dioxane (4 mL).  
Chamber B: isopropyl 2-(4-iodophenoxy)-2-methylpropanoate (150 mg, 0.431 mmol), (4-
chlorophenyl)boronic acid (81 mg, 0.517 mmol), K2CO3 (179 mg, 1.292 mmol) and 
Pd2(dba)3 (7.89 mg, 8.62 µmol) were added, followed by anisole (4 mL).  
The system was flushed with argon then Et3N (0.210 mL, 1.508 mmol) was added to 




system was allowed to sit for 30 min to release CO before being heated to 80 °C for 65 h. 
The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 
vacuo. The crude product was purified by silica column chromatography (DCM/PE 10% – 
100%) to afford the title compound (124.9 mg, 0.346 mmol, 80%). 1H NMR (400 MHz, 
CDCl3) δ 1.20 (6H, d, J = 6.3 Hz, 2 x CH3, C-9), 1.66 (6H, s, 2 x CH3, C-7), 5.09 (1H, sept, 
J = 6.1 Hz, H-7), 6.86 (2H, d, J = 8.3 Hz, Ph), 7.45 (2H, d, J = 8.4 Hz, Ph), 7.70 (2H, d, J = 
8.7 Hz, Ph), 7.73 (2H, d, J = 8.7 Hz, Ph). 13C NMR (101 MHz, CDCl3) δ 21.7 (2 x CH3, C-
9), 25.5 (2 x CH3, C-7), 69.5 (CH, C-9), 76.8 (CH, C-7), 117.4 (Cquat,C-3, C-5), 128.7, 
130.4, 131.3, 132.1 (CH, Ph), 136.6 (Cquat, C-1’), 138.5 (Cquat, C-4’), 159.9 (Cquat, C-4), 
173.2 (C=O, C-8), 194.4 (C=O, C-10); νmax (cm
-1) 1727 (C=O), 1653 (C=O aryl), 1144 (C-































6.5 Synthetic cannabinoids 
 
3-iodo-1H-indole (66) 
A solution of iodine (4.38 g, 17.24 mmol) in DMF (30 mL) was added 
dropwise to a solution of 1H-indole (2 g, 17.07 mmol) and KOH (2.395 g, 
42.7 mmol) in DMF (30 mL) and stirred at rt for one hour. The reaction 
mixture was poured into ice and water (400 mL) containing ammonia (0.5%) and sodium 
metabisulfite (0.1% aqueous solution). The resulting precipitate was filtered and washed 
with water to give the title compound (3.2 g, 13.17 mmol, 77%) as a crystalline solid which 
was used without further purification. 1H NMR (400 MHz, CDCl3) δ 7.18 – 7.24 (2H, m, 
H-5, H-6), 7.30 (1H, d, J = 2.5 Hz, H-2), 7.37 (1H, d, J = 7.9, H-7), 7.47 (1H, d, J = 7.7, 
H-4), 8.34 (1H, br s, N-H).  
1H-indol-3-ylphenylmethanone111 (67) 
Chamber A: 3a-bromo-4,7-dimethyl-5,6-diphenyl-3a,4,7,7a-
tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (0.656 g, 1.500 
mmol) was added, followed by 1,4-dioxane (4 mL).  
Chamber B: 3-iodo-1H-indole (0.122 g, 0.5 mmol), phenylboronic 
acid (0.073 g, 0.600 mmol), K2CO3 (0.207 g, 1.500 mmol) and 
Pd2(dba)3 (9.16 mg, 10.00 µmol) were added, followed by anisole (4 mL).  
The system was flushed with argon then Et3N (0.244 mL, 1.750 mmol) was added to 
Chamber A, the system was then sealed with screwcaps fitted with silicon seals. The 
system was allowed to sit for 30 min to release CO before being heated to 80 °C for 25 h. 
The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 
vacuo. The crude product was purified by silica column chromatography (PE: EtOAc 9:1 – 
1:1) to afford the title compound (55.4 mg, 0.25 mmol, 50%) 1H NMR (400 MHz, DMSO-
d6) δ 7.22 – 7.29 (2H, m, Ph), 7.51 – 7.57 (3H, m, Ph), 7.59 – 7.64 (1H, m, H-4), 7.79 (2H, 
d, J = 6.8 Hz, H-3’,-5’), 7.93 (1H, s, H-2), 8.26 (1H, d, J = 6.9 Hz, Ph), 12.06 (1H, s, NH); 
13C NMR (101 MHz, DMSO) δ 112.2 (CH, C-7), 115.0 (Cquat, C-3), 121.4, 121.9, 123.1, 
126.2, 128.36, 128.38, 131.0, 135.8, 136.7 (CH, C-2), 140.5 (Cquat, C-1’), 189.9 (C=O, C-
10); νmax (cm







In Chamber A: 3a-bromo-4,7-dimethyl-5,6-diphenyl-3a,4,7,7a-
tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (656 mg, 1.5 
mmol) was added, followed by 1,4-dioxane (4 mL). 
In Chamber B: 3-iodo-1H-indole (122 mg, 0.50 mmol), 2-
naphthylboronic acid (103 mg, 0.600 mmol), K2CO3 (207 mg, 
1.500 mmol) and Pd2(dba)3 (9.16 mg, 10.00 µmol) were added, 
followed by anisole (4 mL).  
The system was flushed with argon then Et3N (0.244 mL, 1.750 mmol) was added to 
Chamber A, the system was then sealed with screwcaps fitted with silicon seals. 
The system was allowed to sit for 30 min to release CO before being heated to 80 °C for 25 
h. The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 
vacuo. The crude product was purified by silica column chromatography (PE: EtOAc 9:1 – 
1:1) to afford the title compound (59.9 mg,  0.221 mmol, 44%). 1H NMR (400 MHz, 
CDCl3) δ 7.38 – 7.33 (2H, m, Ph), 7.50 – 7.46 (1H, m, Ph), 7.63 – 7.54 (2H, m, Ph), 7.77 
(1H, d, J = 3.0 Hz, Ph), 7.98 – 7.90 (4H, m, Ph), 8.34 (1H, s, H-2), 8.48 – 8.41 (1H, m, 
Ph), 8.62 (1H, s, NH); 13C NMR (101 MHz, DMSO) δ 112.3 (C-H, C-7), 115.2 (Cquat, C-
3), 121.5, 121.9, 123.2, 125.3, 126.3, 126.7, 127.64, 127.64, 128.1 (C-H, Ph-C), 129.2 (C-
H, C-1’), 132.2 (Cquat, C-8a’), 134.2 (Cquat, C-4a’), 136.0 (Cquat, C-2’), 136.7 (Cquat, C-7a), 
137.7 (C-H, C-2), 189.90 (C=O, C-10); νmax (cm
-1)  3147 (N-H stretch), 1596 (C=O); 
HRMS-ESI m/z [M+Na]+  calc. for C19H13NONa
+: 294.0889, found: 294.0868.  
 
2-morpholinoethyl methanesulfonate (69) 
 
A solution of 2-morpholinoethanol (1 mL, 8.26 mmol) and Et3N 
(3.45 mL, 24.77 mmol) in THF (50 mL) was cooled to 0 °C. 
Methanesulfonyl chloride (0.959 mL, 12.38 mmol) was added 
dropwise over 5 min to the mixture which was then stirred at 0 °C for 10 min. The ice bath 
was then removed and the reaction mixture stirred at rt for an additional 2 h. The reaction 
mixture was filtered through Celite® 545 with THF and concentrated under reduced 
pressure. The crude 2-morpholinoethyl methanesulfonate was used without further 




(2H, t, J = 5.5 Hz, H-2), 3.09 (3H, s, S-CH3), 3.74 – 3.70 (4H, m, H-4), 4.35 (2H, t, J = 5.5 
Hz, H-1). 
4-(2-(1H-indol-1-yl)ethyl)morpholine 
To 1H-indole (0.924 g, 7.88 mmol) in DMF (60 mL) at 0 °C 
was added NaH (60% dispersion in mineral oil, 1.43g, 35.8 
mmol) portion wise over 5 min. The mixture was stirred for 10 
min at 0 °C and then was allowed to warm to ambient 
temperature. The mixture was stirred for 1h at ambient temperature and then was cooled to 
0 °C. The 2-morpholinoethyl methanesulfonate (1.5 g, 7.17 mmol) in 2 mL of DMF was 
added rapidly via cannula. After the addition was complete, the ice bath was removed and 
the mixture was stirred for 4h at ambient temperature. The mixture was then cooled to 0 
°C, was quenched with 30 mL of saturated, aqueous NH4Cl and was diluted with 30 mL of 
EtOAc. The layers were separated, and the aqueous layer was extracted into EtOAc (3 x 15 
mL). The combined organic extracts were washed with water (4 x 30 mL) and brine (4 x 
30 mL) and then were dried over anhydrous MgSO4, filtered, concentrated under reduced 
pressure, and purified by silica column chromatography (DCM : MeOH 1:0 – 9:1) to 
afford the title compound (0.924 g, 4.01 mmol, 56%) as an orange oil. 1H NMR (400 MHz, 
CDCl3) δ  2.48 – 2.51 (4H, m, H-10), 2.76 (2H, t, J = 7.0 Hz, H-9),  3.70 – 3.72 (4H, m, H-
11), 4.26 (2H, t, J = 7.0 Hz, H-8), 6.50 (1H, t, J = 2.6 Hz, H-3), 7.11 (1H, t, J = 7.5 Hz, H-
5), 7.15 (1H, d, J = 3.1 Hz, H-2),7.22 (1H, t, J = 7.6 Hz, H-6), 7.36 (1H, t, J = 8.2 Hz, H-
7), 7.63 (1H, d, J = 7.8 Hz, H-4); 13C NMR (101 MHz, CDCl3) δ 44.1 (C-8), 54.0 (C-10), 
58.3 (C-9), 67.1 (C-11), 101.4 (C-3), 109.3 (C-7), 119.5 (C-5), 121.1 (C-4), 121.6 (C-6), 
128.1 (C-2), 128.7 (Cquat, C-7a), 136.1 (Cquat, C-3a); νmax (cm
-1) 2807, 1314 (C-N), 1114 
(C-O-C); HRMS-ESI m/z [M+H]+  calc. for C14H19N2O




To 3-iodo-1H-indole (0.610 g, 2.510 mmol) in DMF (30 mL) 
at 0 °C was added NaH (60% dispersion in mineral oil, 0.502 
g, 12.55 mmol) portion wise over 5 min. The mixture was 




ambient temperature. The mixture was stirred for 1 h at ambient temperature and then was 
cooled to 0 °C. The 2-morpholinoethyl methanesulfonate (1.0 g, 4.78 mmol) in 2 mL of 
THF was added rapidly via cannula. After the addition was complete, the ice bath was 
removed and the mixture was stirred for 4 h at ambient temperature. The mixture was then 
cooled to 0 °C, was quenched with 30 mL of saturated, aqueous NH4Cl and was diluted 
with 30 mL of EtOAc. The layers were separated, and the aqueous layer was extracted 
EtOAc (3 x 15 mL). The combined organic extracts were washed with water (4 x 10 mL) 
and brine (4 x 10 mL) and then were dried over anhydrous MgSO4, filtered, concentrated 
under reduced pressure, and purified by silica column chromatography (CHCl3 : EtOAc 1:0 
– 1:1) to afford the title compound (808.4 mg, 2.269 mmol, 90%) as an pale yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 2.55 – 2.45 (4H, m, H-10), 2.74 (2H, t, J = 6.8 Hz, H-9), 3.77 – 
3.67 (4H, m, H-11), 4.25 (2H, t, J = 6.8 Hz, H-8), 7.20 (1H, ddd, J = 8.0, 6.9, 1.2 Hz, H-2), 
7.24 – 7.30 (2H, m, H-5,6), 7.33 (1H, dt, J = 8.3, 0.9 Hz, H-7), 7.45 (1H, dt, J = 7.8, 1.0 
Hz, H-4); 13C NMR (101 MHz, CDCl3) δ 44.3 (C-8), 54.0 (C-10), 58.3 (C-9), 67.0 (C-11), 
109.5 (C-7), 120.5, 121.5, 122.8, 130.6 (indole-C), 132.1 (C-3), 136.2 (Cquat, C-3a); νmax 
(cm-1) 1141 (C-O-C), 726 (C-I); HRMS-ESI m/z [M+H]+  calc. for C14H18N2OI
+: 357.0458, 




In Chamber A: 3a-bromo-4,7-dimethyl-5,6-diphenyl-3a,4,7,7a-
tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (405 mg, 0.926 
mmol) was added, followed by 1,4-dioxane (4 mL). 
In Chamber B: 4-(2-(3-iodo-1H-indol-1-yl)ethyl)morpholine (110 
mg, 0.309 mmol), phenylboronic acid (45.2 mg, 0.371 mmol), 
K2CO3 (128 mg, 0.926 mmol) and Pd2(dba)3 (5.66 mg, 6.18 µmol) 
were added, followed by anisole (4 mL). 
The system was flushed with argon then Et3N (151 µl, 1.081 mmol) was added to Chamber 
A, the system was then sealed with screwcaps fitted with silicon seals. The system was 
allowed to sit for 30 min to release CO before being heated to 80 °C for 25 h. The reaction 
mixtures were cooled to rt and the solvent in Chamber B concentrated in vacuo. The crude 
product was purified by silica column chromatography (PE: EtOAc 9:1 – 1:1) o afford the 




CDCl3) δ 2.41 – 2.58 (4H, m, H-10), 2.78 (2H, t, J = 6.3 Hz, H-9), 3.68 (4H, t, J = 4.6 Hz, 
H-11), 4.26 (2H, d, J = 6.1 Hz, H-8), 7.32 – 7.42 (3H, m, Ph), 7.46 – 7.52 (2H, m, Ph),7.53 
– 7.58 (1H, m, H-4’), 7.69 (1H, s, H-2), 7.27 – 7.86 (2H, m, Ph), 8.40 – 8.47 (1H, m, Ph);  
13C NMR (101 MHz, CDCl3) δ 44.2 (C-8), 53.8 (C-10), 57.7 (C-9), 67.0 (C-11), 109.6 (C-
7), 122.8, 123.0, 123.7, 127.3, 128.4, 128.9, 131.3, 136.9, 138.0, 141.0 (Aromatic C), 
191.03 (C=O); νmax (cm
-1) 1519 (C=O), 1383 (C-N), 1114 (C-O-C); HRMS-ESI m/z 
[M+H]+  calc. for C21H23N2O2





tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (552 mg, 
1.263 mmol) was added, followed by 1,4-dioxane (4 mL). 
In Chamber B: 4-(2-(3-iodo-1H-indol-1-yl)ethyl)morpholine 
(150 mg, 0.421 mmol) in 0.2 mL anisole, (4-
methoxyphenyl)boronic acid (77 mg, 0.505 mmol), K2CO3 
(175 mg, 1.263 mmol) and Pd2(dba)3 (7.71 mg, 8.42 µmol) 
were added, followed by anisole (3.8 mL). 
The system was flushed with argon then Et3N (0.205 mL, 1.474 mmol) was added to 
Chamber A, the system was then sealed with screwcaps fitted with silicon seals. 
The system was allowed to stir for 30 min to release CO before being heated to 80 °C for 
25 h. The reaction mixtures were cooled to rt and the solvent in Chamber B concentrated in 
vacuo. The crude product was purified by silica column chromatography (CHCl3: EtOAc 
2:1 – 1:2) to afford the title compound as a (65.4 mg, 0.179 mmol, 43%) pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 2.51 (4H, t, J = 4.4 Hz, H-10), 2.79 (2H, d, J = 6.3 Hz, H-
9), 3.71 (4H, t, J = 4.8 Hz, H-11), 3.90 (3H, s, OMe), 4.27 (2H, d, J = 6.6 Hz, H-8), 6.99 
(2H, d, J = 8.7 Hz, H-3’, -5’), 7.29 – 7.37 (2H, m, indole-H), 7.40 (1H, m, H-7), 7.70 (1H, 
s, H-2), 7.85 (2H, d, J = 8.7 Hz, H-2’, -6’), 8.35 – 8.43 (1H, m, H-4); 13C NMR (101 MHz, 
CDCl3) δ 44.2 (C-8), 53.8 (C-10), 55.6 (OMe), 57.8 (C-9), 66.9 (C-11), 109.6 (C-7), 113.6 
(C-3’, -5’), 115.9 (Cquat, C-3), 122.6 (C-6), 122.9 (C-4), 123.6 (C-5), 127.5 (Cquat, C-3a), 
131.1, 133.5 (Cquat, C-1'), 136.8 (Cquat, C-7a), 137.0 (C-2), 162.4 (Cquat, C-4'), 189.9 (C=O); 
νmax (cm
-1) 2850 (C-H), 1598 (C=O), 1252 (C-N), 1114 (C-O-C); HRMS-ESI m/z [M+H]+ 
 calc. for C22H25N2O3





 (1-(2-morpholinoethyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone114 (76) 
 
In Chamber A: 3a-bromo-4,7-dimethyl-5,6-diphenyl-3a,4,7,7a-
tetrahydro-4,7-methanoisobenzofuran-1,3,8-trione (552 mg, 1.263 
mmol) was added, followed by 1,4-dioxane (4 mL). 
In Chamber B: 4-(2-(3-iodo-1H-indol-1-yl)ethyl)morpholine (150 
mg, 0.421 mmol), naphthalen-1-ylboronic acid (87 mg, 0.505 
mmol), K2CO3 (175 mg, 1.263 mmol) and Pd2(dba)3 (7.71 mg, 8.42 
µmol) were added, followed by anisole (4 mL). 
The system was flushed with argon then Et3N (0.205 mL, 1.474 
mmol) was added to Chamber A, the system was then sealed with screwcaps fitted with 
silicon seals. The system was allowed to stir for 30 min to release CO before being heated 
to 80 °C for 30 h. The reaction mixtures were cooled to rt and the anisole in Chamber B 
concentrated in vacuo. The crude product was purified by silica column chromatography 
(CHCl3: EtOAc 2:1 – 1:2) to afford the title compound as a 3:1 mixture of product to the 
non-carbonylative Suzuki side product (101.5 mg, 0.264 mmol, 63%). 1H NMR (400 
MHz, CDCl3) δ 3.04 (4H, s, H-10), 3.29 (2H, t, J = 7.1 Hz, H-9), 3.90 (4H, t, J = 4.7 Hz, 
H-11), 4.57 – 4.66 (2H, m, H-8), 7.36 – 7.57 (6H, m, Ph), 7.64 (1H, d, J = 7.5 Hz, Ph), 
7.91 (1H, d, J = 7.5 Hz, Ph), 7.98 (1H, d, J = 8.2 Hz, Ph), 8.14 (1H, d, J = 8.5 Hz, Ph), 8.45 
– 8.52 (1H, m, Ph), 13C NMR (101 MHz, CDCl3) δ 41.5 (CH2, C-8), 52.7 (CH2, C-10), 
56.1 (CH2, C-9), 64.1 (CH2, C-11), 109.5 (C-7), 119.2, 123.5, 123.8, 124.7, 124.8, 125.8, 
126.1, 126.5, 127.07, 127.11, 128.5, 130.6, 130.7, 133.9, 135.6, 137.3 (C-2), 138.5 (Cquat), 
192.3 (C=O, C-12); νmax (cm
-1) 1672 (C=O), 1196 (C-N stretch), 1133 (C-O-C); HRMS-
ESI m/z [M+H]+  calc. for C21H25N2O2












6.6 oCOm-21 analogues 
 
N-(Ethoxycarbonyl)maleimide117, 123 (78) 
 
Ethyl chloroformate (5.42 mL, 56.7 mmol) in ethyl acetate (10 mL) 
was added to a cooled solution of maleimide (5.0 g, 51.5 mmol) and 4-
methylmorpholine (6.23 mL, 56.7 mmol) in ethyl acetate (100 mL). 
The mixture was stirred at 0° for 15 min then 1h at rt. The reaction mixture was filtered 
then concentrated in vacuo to give a pale yellow solid that was purified by flash 
chromatography (PE : EtOAc 1:0 – 3:2) to yield the title compound as an orange oil that 
formed a white crystalline solid when dried under high vacuum (6.258 g, 37.0 mmol, 
71.8%). 1H NMR (400 MHz, CDCl3) δ 1.40 (3H, t, J = 7.1 Hz, CH3), 4.43 (2H, q, J = 7.2 
Hz, CH2), 6.83 (2H, s, H-4, -5);
 13C NMR (101 MHz, CDCl3) δ 14.2 (CH3), 64.2 (CH2), 
135.3 (C-4, -5), 147.7 (C=O), 165.9 (2 x C=O, C–1 and C–3); νmax (cm
-1) 3104 (C–H), 
1754 (C=O), 1714 (C=O), 1245 (C-O-C). HRMS-ESI m/z [M+Na+MeOH]+ calc. 
for C8H11NO5Na
+: 224.0529, found: 224.0531. 
 
tert-Butyl 3-(1,3-dioxo-1,3-dihydro-1H-pyrrol-1-yl)ethylcarbamate117 (80) 
 
To a solution of tert-butyl (2-aminoethyl)carbamate (3.09 mL, 
19.51 mmol) in saturated NaHCO3 (80 mL) at 0 ºC was added N-
(ethoxycarbonyl)maleimide (3.3 g, 19.51 mmol). The reaction 
mixture was warmed to rt and stirred for 15 min. THF (60 mL) 
was then added and the reaction mixture stirred for a further 45 min. H2O (50 mL) was 
added and the aqueous phase extracted with EtOAc (3 x 100 mL). The combined organic 
extracts were washed with brine (150 mL) and dried over MgSO4. Removal of the solvent 
in vacuo gave an off-white solid that was purified by flash chromatography (0%, then 5%, 
then 10% EtOAc in DCM) to yield the title compound as a white crystalline solid (2.35 g, 
9.78 mmol, 50%). 1H NMR (400 MHz, CDCl3) δ 1.40 (9H, s, C(CH3)3), 3.33 (2H, m, H-
2’), 3.66 (2H, t, J = 6.0 Hz,  H-3’), 4.71 (1H, br s, H-1’), 6.71 (2H, s, H’4, H’5); 13C NMR 
(101 MHz, CDCl3) δ 28.4 (CH3, C(CH3)3), 38.1 (C-2’), 39.4 (C-3’), 79.6 (C(CH3)3), 134.3 
(2 x CH, C–4 and C–5), 156.1 (C=O, NHBoc), 170.9 (2 x C=O, C-2, -3); νmax (cm
-1) 3348 
(N–H), 3086 (C–H), 1700 (C=O), 1682 (C=O). HRMS-ESI m/z [M+Na+MeOH]+ calc. for 
C12H20N2O5Na




tert-Butyl 3-(4-bromo-1,3-dioxo-1,3-dihydro-1H-pyrrol-1-yl)ethylcarbamate19 (81) 
A solution of tert-butyl 3-(1,3-dioxo-1,3-dihydro-1H-pyrrol-1-
yl)ethylcarbamate (2.0 g, 8.32 mmol) in DCM (18 mL) was 
treated with Br2 (0.472 mL, 9.16 mmol) and heated to reflux 
for 1 h. The reaction was cooled to rt and concentrated in 
vacuo to give the dibromo intermediate as a thick orange oil which was then diluted in 
anhydrous THF (40 mL) and cooled to 0 °C. Anhydrous Et3N (1.160 mL, 8.32 mmol) was 
added dropwise and the reaction mixture stirred for 2 h at 0 °C. The resulting thick off-
white suspension was diluted in H2O (20 mL) and the aqueous phase extracted with EtOAc 
(3 x 20 mL). The combined organic extracts were dried over MgSO4 and concentrated in 
vacuo to give a dark brown oil that was purified by flash chromatography (0%, then 5%, 
then 10% EtOAc in DCM) to afford the title compound as a pale yellow solid (1.792g, 5.61 
mmol, 67.5%). 1H NMR (400 MHz, CDCl3) δ 1.40 (9H, s, C(CH3)3), 3.34 (2H, q, J = 5.8 
Hz, H-2'), 3.70 (2H, m, H-3’), 4.70 (1H, br s, NH), 6.88 (1H, s, H-5); 13C NMR (101 
MHz, CDCl3) δ 28.3 (CH3, C(CH3)3), 39.1 (CH2, C–2'), 39.2 (CH2, C–3'), 79.7 (Cquat, 
C(CH3)3), 131.4 (Cquat, C–4), 131.9 (CH, C–5), 156.0 (C=O, NHBoc), 165.4 (C=O, C–3), 
168.6 (C=O, C–1); νmax (cm
-1) 3396 (N–H), 1715 (C=O), 1681 (C=O). HRMS-ESI m/z 
[M+Na+MeOH]+ calc. for C12H19N2O5





2,5-dihydro-1H-pyrrol-1-yl)ethyl)carbamate (690 mg, 
2.162 mmol) and diene dimer 4 (563 mg, 1.081 mmol) 
were dissolved in anhydrous toluene (10 mL). The 
mixture was then heated to 70 °C o/n. After cooling to rt, the solvent was removed in 
vacuo to afford a brown oil. Purification by flash chromatography (0%, then 2%, then 10% 
EtOAc in DCM) to afford the title compound as a white foamy solid in two fractions: the 
pure endo-cycloadduct (348.1 mg, 28%) and a mixture of endo- and exo-cycloadducts 




Endo characterisation data: 1H NMR (400 MHz, CDCl3) δ 1.42 (9H, s, C(CH3)3), 1.61 (3H, 
s, 7-CH3), 1.62 (3H, s, 4-CH3), 3.34 – 3.42 (2H, m, H-2’), 3.52 (1H, s, H-7a), 3.73 (2H, t, J 
= 5.8 Hz, H-3’), 4.72 (1H, br. s, NH), 6.83 – 6.88 (4H, m, Ph), 7.15 – 7.19 (6H, m, Ph); 13C 
NMR (101 MHz, CDCl3) δ 11.7 (CH3, 7–CH3), 12.6 (CH3, 4–CH3), 28.5 (CH3, C(CH3)3), 
38.8 (CH2, C–2'), 40.1 (CH2, C–3'), 56.5 (Cquat, C–7), 58.8 (Cquat, C–4), 60.5 (CH, C–7a), 
60.9 (Cquat, C–3a), 79.9 (Cquat, C(CH3)3),, 128.3 128.4 128.5 129.4 129.7 (CH, Ph), 132.5 
132.6 (Cquat, Ph), 140.5 (Cquat, C–5), 144.7 (Cquat, C–6), 155.8 (C=O, NHBoc), 172.6 (C=O, 
C–1), 172.8 (C=O, C–3), 196.9 (C=O, C–8); νmax (cm
-1) 2984, 2937, 1790 (C=O), 1713 
(C=O), 1390, 1366, 1248, 1201, 737, 699; HRMS-ESI m/z [M+Na]+ calc. for C30H31
79Br 
N2O5Na
+: 601.1309, found: 601.1271; RP-HPLC (10% to 100% B over 12.5 min, then 
100% B for 2.5 min), tR = 14.56 min. 
 
Exo characterisation data (inter alia): RP-HPLC (10% to 100% B over 12.5 min, then 





A solution of pure endo tert-butyl (2-(3a-bromo-4,7-
dimethyl-1,3,8-trioxo-5,6-diphenyl-3a,4,7,7a-tetrahydro-1H-
4,7-methanoisoindol-2(3H)-yl)ethyl)carbamate (340 mg, 
0.587 mmol) in 1,4-dioxane (3 mL) was prepared under an 
ambient atmosphere. In a separate vessel, concentrated aqueous HCl (3.1 mL, 36% = 11.65 
M) was diluted with 1,4-dioxane (2.9 mL) to afford a solution of 6 M HCl in 1,4-dioxane. 
The solution of Boc-protected cycloadduct was placed in an ice bath prior to the addition 
of the 6 M HCl solution. The reaction mixture was allowed to warm to rt. Upon 
consumption of the starting material (4-5 h), the solvent was removed in vacuo. The 
residue was dissolved in a mixture of approximately 75% H2O in 1,4-dioxane (40 mL) and 
lyophilised. The crude off-white solid obtained was dissolved in approximately 16% 
CH3CN in H2O (12 mL) and loaded onto a pre-washed C-18 solid phase extraction 
cartridge (100% CH3CN [2 x 10 mL]), then 90%, then 50% CH3CN in H2O [1 x 10 mL 
each], 10% CH3CN in H2O [2 x 10 mL]). The product was eluted from the C-18 cartridge 
(20% to 40% CH3CN in H2O [10% increments, 2 x 10 mL each], then 50% to 100% 




RP-HPLC (10% to 100% B over 12.5 min, then 100% B for 2.5 min, tR = 9.76 min) and 
lyophilised to afford the title compound oCOm-21 as a white powder (272.7 mg, 0.529 
mmol, 90%). 1H NMR (400 MHz, DMSO-d6) δ 1.45 (3H, s, 7–CH3), 1.52 (3H, s, 4–CH3), 
2.88 – 3.09 (2H, m 2'–H), 3.77 – 3.80 (2H, m 3'–H), 3.93 (1H, s, H-7a), 6.81 – 6.88 (4H, 
m, Ph), 7.18 – 7.26 (6H, m, Ph), 7.88 – 8.20 (3H, br. s, NH3); 
13C NMR (126 MHz, 
DMSO-d6) δ 11.2 (CH3, 4–CH3), 11.7 (CH3, 7–CH3), 32.7 (CH2, C–3'), 36.0 (CH2, C–2'), 
36.4 (CH2, C–2''), 38.7 (CH2, C–3''), 55.7 (Cquat, C–7), 58.3 (CH, C–7a), 58.9 (Cquat, C–3a), 
60.0 (Cquat, C–4), 128.0, 128.1, 128.3, 129.1, 129.4 (CH, Ph), 132.3, 132.4 (Cquat, Ph), 
139.5 (Cquat, C–5), 144.6 (Cquat, C–6), 171.9 (C=O, C–3), 172.3 (C=O, C–1), 196.7 (C=O, 
C–8); νmax (cm
-1) 3378 (br), 2979, 1937, 2873, 1781 (C=O), 1711 (C=O), 1676, 1520 (br), 
1444; HRMS-ESI m/z [M-Cl]+ calc. for C28H29
79BrN3O4
+ 550.1336; Found 550.1355. 
 
tert-butyl 3-(4-iodo-1,3-dioxo-1,3-dihydro-1H-pyrrol-1-yl)ethylcarbamate (85) 
A solution of tert-butyl 3-(4-bromo-1,3-dioxo-1,3-dihydro-1H-
pyrrol-1-yl)ethylcarbamate  (0.6 g, 1.880 mmol) and sodium 
iodide (3.2 g, 21.35 mmol) in acetone (7 mL) was heated to 
reflux o/n. The solvent was removed. The residue was taken up 
into EtOAc and water. The aqueous layer was back extracted with EtOAc and the 
combined organic layers were washed with water and brine, before being dried over 
MgSO4 and concentrated in vacuo to give a dark brown solid that was purified by flash 
chromatography (0%, then 5%, then 10% EtOAc in DCM) to afford the title compound as 
a pale yellow solid (0.630 g, 1.720 mmol, 91%). 1H NMR (400 MHz, CDCl3) δ 1.40 (9H, 
s, C(CH3)3), 3.34 (2H, q, J = 6.0 Hz, H-2’), 3.67 – 3.75 (2H, m, H-3’), 4.70 (1H, br. s, 
NH), 7.18 (1H, s, H-5); 13C NMR (101 MHz, CDCl3) δ 28.5 (CH3, C(CH3)3), 39.4 (CH2, 
C–2'), 79.7 (CH2, C-3’), 107.4 (C-4), 132.1 (C(CH3)3), 140.7 (C-5), 156.1 (C=O, NHBoc), 
166.9 (C-3), 170.0 (C-1); νmax (cm
-1) 3392 (N-H). 2976 (C-H), 1701 (C=O). HRMS-ESI 
m/z [M+Na]+ calc. for C11H15IN2O4Na











dihydro-1H-pyrrol-1-yl)ethyl)carbamate (520 mg, 1.420 
mmol)) and diene dimer 4 (370 mg, 0.710 mmol) were 
dissolved in anhydrous toluene (15 mL). The mixture 
was then heated to 70 °C for 4 h. After cooling to rt, the solvent was removed in vacuo to 
afford an orange oil. Purification by flash chromatography (0%, then 2%, then 5% EtOAc 
in DCM) to afford the title compound as a white foamy solid in two fractions: the pure 
endo-cycloadduct (306.2 mg, 34%) and a 3.5: 1 mixture of endo- and exo-cycloadducts 
(452.7 mg, 50%). 
 
Endo characterisation data: 1H NMR (400 MHz, CDCl3) δ 1.43 (9H, s, C(CH3)3), 1.60 (3H, 
s, 7-CH3), 1.65 (3H, s, 4-CH3), 3.37 (2H, s, H-2’), 3.64 (1H, s, H-7a), 3.72 (2H, t, J = 5.6 
Hz, H-3’), 4.73 (1H, br. s, NH), 6.82 – 6.90 (4H, m, Ph), 7.17 (6H, m, Ph);  13C NMR (126 
MHz, CDCl3) δ 12.6 (CH3, 7–CH3), 15.8 (CH3, 4–CH3), 28.6 (CH3, C(CH3)3), 38.3 (CH2, 
C–2'), 38.8 (Cquat, C-3a), 39.9 (CH2, C–3'), 56.8 (Cquat, C-7), 60.8 (Cquat, C-4),, 63.1 (CH, 
C–7a), 79.9 (Cquat, C(CH3)3), 128.26, 128.28, 128.4, 128.5, 129.4, 129.8 (CH, Ph), 132.69, 
132.73 (Cquat, Ph), 139.3 (Cquat, C–5), 144.5 (Cquat, C–6), 155.9 (C=O, NHBoc), 173.3 
(C=O, C–1), 174.4 (C=O, C–3), 197.1 (C=O, C-8). νmax (cm
-1) 2976, 2933, 1782 (C=O), 
1706 (C=O), 1381, 1250, 1168, 731, 702; HRMS-ESI m/z [M+Na]+ calc. for 
C30H31IN2O5Na
+: 649.1170; found: 649.1140.  
 
Exo characterisation data (inter alia): 1H NMR (400 MHz, CDCl3) δ 1.35 (3H, s, 7-CH3),  
1.45 (9H, s, C(CH3)3), 1.50 (3H, s, 4-CH3), 3.10 – 3.30 (2H, m, ), 3.52 (1H, s, H-7a), 3.59 
– 3.65 (1H, m,), 3.80 – 3.86 (1H, m), 4.66 – 4.77 (1H, br. m, NH), 7.02 – 7.08 (2H, m, Ph), 








methanoisoindol-2(3H)-yl)ethanaminium chloride (oCOm-60) 
A solution of pure endo tert-butyl (2-3a-iodo-4,7-dimethyl-
1,3,8-trioxo-5,6-diphenyl-3a,4,7,7a-tetrahydro-1H-4,7-
methanoisoindol-2(3H)-yl)ethyl)carbamate (325 mg, 0.519 
mmol) in 1,4-dioxane (2 mL) was prepared under an 
ambient atmosphere. In a separate vessel, concentrated aqueous HCl (3.1 mL, 36% = 11.65 
M) was diluted with 1,4-dioxane (2.9 mL) to afford a solution of 6 M HCl in 1,4-dioxane. 
The solution of Boc-protected endo cycloadduct was placed in an ice bath prior to the 
addition of the 6 M HCl solution. The reaction mixture was allowed to warm to rt and 
monitored by RP-HPLC (10% to 100% B over 12.5 min, then 100% B for 2.5 min, 0.5 
mL/min). Upon consumption of the starting material (4-5 h), the solvent was removed in 
vacuo. The residue was dissolved in a mixture of approximately 75% H2O in 1,4-dioxane 
(40 mL) and lyophilised. The crude off-white solid obtained was dissolved in 
approximately 16% CH3CN in H2O (12 mL) and loaded onto a pre-washed C-18 solid 
phase extraction cartridge (100% CH3CN [2 x 10 mL]), then 90%, then 50% CH3CN in 
H2O [1 x 10 mL each], 10% CH3CN in H2O [2 x 10 mL]). The product was eluted from the 
C-18 cartridge (20% to 40% CH3CN in H2O [10% increments, 2 x 10 mL each], then 50% 
to 100% CH3CN in H2O [10% increments, 10 mL each]). The fractions collected were 
analysed by RP-HPLC (10% to 100% B over 12.5 min, then 100% B for 2.5 min, tR =  
9.67 min) and lyophilised to afford the title compound oCOm-60 as a white solid (250.7 
mg, 0.445 mmol, 86%). 1H NMR (400 MHz, DMSO-d6) δ 1.47 (3H, s, 7-CH3), 1.49 
(3H, s, 4-CH3), 2.86 – 3.04 (2H, m, CH2), 3.72 – 3.79 (2H, m, CH2), 3.89 (1H, s, H-7a), 
6.81 – 6.88 (4H, m, Ph), 7.17 – 7.25 (6H, m, Ph), 8.02 (3H, br. s, NH3); 
13C NMR (126 
MHz, DMSO-d6) δ 11.9 (CH3, 7–CH3), 15.3 (CH3, 4–CH3), 36.1 (Cquat, C-3a), 36.2 (CH2, 
C-2’), 36.7 (CH2, C-3’), 55.6 (Cquat, C-7), 60.1 (Cquat, C-4), 60.9 (CH, C–7a), 127.97, 
128.01, 128.2, 129.1, 129.3 (CH, Ph), 132.5 132.6 (Cquat, Ph), 138.7 (Cquat, C–5), 143.9 
(Cquat, C–6), 173.4 (C=O, C-3) 174.4 (C=O, C-1), 196.8  (C=O, C-8). νmax (cm
-1) 2977, 
1782 (C=O), 1708 (C=O), 1603, 1388, 731. HRMS-ESI m/z [M+H]+ calc. for 
C25H24IN2O3







A solution of tert-butyl (2-(3-bromo-2,5-dioxo-2,5-dihydro-
1H-pyrrol-1-yl)ethyl)carbamate (1.00 g, 3.13 mmol) and 
tetrabutylammonium chloride (4.35 g, 15.67 mmol) in acetone 
(10 mL) was heated at reflux o/n. The reaction was cooled to 
rt. The solvent was removed under reduced pressure and the residue was extracted into 
EtOAc. The organic extract was washed with water and brine, and dried over anhydrous 
MgSO4. The organic layer was concentrated in vacuo and the residue was purified by flash 
chromatography (0%, then 5%, then 10% EtOAc in DCM) to afford the title compound as 
a white solid (768.2 mg, 2.80 mmol,  89%). 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 
3.34 (2H, q, J = 6.0 Hz,), 3.65 – 3.73 (2H, m,), 4.70 (1H, br. s, NH), 6.64 (1H, s, H-5); 13C 
NMR (101 MHz, CDCl3) δ 28.4 (CH3, C(CH3)3), 39.1 (CH2, C–2'), 39.3 (CH2, C-3’), 79.8 
(Cquat, C(CH3)3), 127.0 (C-4), 141.1 (C-5), 156.1 (C=O, NHBoc), 165.2 (C-3), 168.0 (C-1); 
νmax (cm
-1) 3398 (NH), 2978 (C-H), 1709 (C=O), 1164, 730; HRMS-ESI m/z [M+Na]+ 
calc. for C11H15
35ClN2O4Na






2,5-dihydro-1H-pyrrol-1-yl)ethyl)carbamate (500 mg, 
1.820 mmol)) and diene dimer 4 (474 mg, 0.910 mmol) 
were dissolved in anhydrous toluene (20 mL). The 
mixture was then heated to 70 °C o/n. After cooling to rt, the solvent was removed in 
vacuo to afford a brown oil. Purification by flash chromatography (0%, then 2%, then 5% 
EtOAc in DCM) gave the product as an inseparable 3:1 mixture of the endo and exo 
isomers (968.4 mg, 1.810 mmol, 99%) as a white foamy solid. 
 
Endo characterisation data (inter alia): 1H NMR (400 MHz, CDCl3) δ 1.41 (9H, s, 
C(CH3)3), 1.58 (3H, s, 7-CH3), 1.61 (3H, s, 4-CH3), 3.36 – 3.40 (2H, m, H-2’) 3.37 (1H, s, 
H-7a), 3.72 (2H, t, J = 5.8 Hz, H-3’), 4.73 (1H, br. s, NH), 6.82 – 6.89 (4H, m, Ph), 7.16 – 




28.5 (CH3, C(CH3)3), 38.8 (CH2, C–2'), 40.2 (CH2, C–3'), 56.3 (Cquat, C–7), 59.5 (Cquat, C–
4), 62.4 (CH, C–7a), 67.5 (Cquat, C–3a), 79.94 (Cquat, C(CH3)3); 128.27, 128.30, 128.4, 
128.45, 128.47, 129.4, 129.5, 129.7, 129.8 (CH, Ph), 132.4, 132.6 (Cquat, Ph), 140.9 (Cquat, 
C–5), 144.6 (Cquat, C–6), 156.0 (C=O, NHBoc), 172.2 (C=O, C–1), 172.5 (C=O, C–3), 
197.1 (C=O, C–8); νmax (cm
-1) 1785 (C=O), 1714 (C=O), 905, 724; HRMS-ESI m/z 
[M+Na]+ calc. for C30H31
35C lN2O5Na
+: 557.1814; found: 557.1807. 
 
Exo characterisation data (inter alia): 1H NMR (400 MHz, CDCl3) δ 1.40 (9H, s, C(CH3)3), 
1.45 (3H, s, 7-CH3), 1.46 (3H, s, 4-CH3), 3.19 – 3.23 (2H, m, H-2’) 3.21 (1H, s, H-7a), 
3.78 – 3.84 (2H, m, H-3’), 4.69 – 4.72 (1H, br. m, NH), 7.05 – 7.07 (4H, m, Ph), 7.22 – 
7.23 (6H, m, Ph) 
2-(-3a-chloro-4,7-dimethyl-1,3,8-trioxo-5,6-diphenyl-3a,4,7,7a-tetrahydro-1H-4,7-
methanoisoindol-2(3H)-yl)ethanaminium chloride (oCOm-61) 
A solution of tert-butyl (2-(3a-chloro-4,7-dimethyl-1,3,8-
trioxo-5,6-diphenyl-3a,4,7,7a-tetrahydro-1H-4,7-
methanoisoindol-2(3H)-yl)ethyl)carbamate (595 mg, 1.112 
mmol) in 1,4-dioxane (3 mL) was prepared under an ambient 
atmosphere. In a separate vessel, concentrated aqueous HCl (3.1 mL, 36% = 11.65 M) was 
diluted with 1,4-dioxane (2.9 mL) to afford a solution of 6 M HCl in 1,4-dioxane. The 
solution of Boc-protected cycloadduct was placed in an ice bath prior to the addition of the 
6 M HCl solution. The reaction mixture was allowed to warm to rt. Upon consumption of 
the starting material (4-5 h), the solvent was removed in vacuo. The residue was dissolved 
in a mixture of approximately 75% H2O in 1,4-dioxane (40 mL) and lyophilised. The crude 
off-white solid obtained was dissolved in approximately 16% CH3CN in H2O (12 mL) and 
loaded onto a pre-washed C-18 solid phase extraction cartridge (100% CH3CN [2 x 10 
mL]), then 90%, then 50% CH3CN in H2O [1 x 10 mL each], 10% CH3CN in H2O [2 x 10 
mL]). The product was eluted from the C-18 cartridge (20% to 50% CH3CN in H2O [10% 
increments, 2 x 10 mL each], then 60% to 100% CH3CN in H2O [10% increments, 10 mL 
each]). The fractions collected were analysed by RP-HPLC (10% to 100% B over 12.5 




inseparable ~3:1 mixture (endo:exo) of the title compound oCOm-61 as a white powder 
(482.6 mg, 1.024 mmol, 92%).  
Endo characterisation data (inter alia): 1H NMR (400 MHz, CDCl3) δ 1.53 (3H, s, 7-CH3), 
1.57 (2H, s, 4-CH3), 3.18 – 3.39 (2H, m, 2’-CH2), 3.73 – 3.81 (2H, m, 3’-CH2), 3.76 (1H, 
s, H-7a), 6.71 – 6.84 (4H, m, Ph), 7.08 – 7.24 (6H, m, Ph) 8.26 (3H, br. s, NH3); 
13C NMR 
(126 MHz, DMSO-d6) δ 9.02 (CH3, 7–CH3), 11.8 (CH3, 4–CH3), 36.4 (CH2, C-2’), 37.0 
(CH2, C-3’), 55.4 (Cquat, C-7), 57.7 (Cquat, C-4), 61.1 (Cquat, C-3a), 67.7 (CH, C–7a), 128.1, 
128.2, 128.4, 129.1, 129.2 (CH, Ph), 132.2, 132.4 (Cquat, Ph), 139.8 (Cquat, C–5), 144.5 
(Cquat, C–6), 171.6 (C=O, C-3), 172.3 (C=O, C-1), 196.5 (C=O, C-8); νmax (cm
-1) 2978, 
1784 (C=O), 1715 (C=O), 1390, 733, 700; HRMS-ESI m/z [M+H]+ calc. for C25H24
35C 
lN2O3: 435.1470; found: 435.1439. 
 
Exo characterisation data (inter alia): 1H NMR (400 MHz, CDCl3) δ 1.33 (3H, s, CH3), 
1.38 (2H, s, CH3), 3.18 – 3.39 (2H, m, 2’-CH2), 3.51 (1H, s, H-7a), 4.05 – 4.09 (2H, m, 3’-
CH2), 7.01 – 7.08 (4H, m, Ph), 7.08 – 7.24 (6H, m, Ph) 8.26 (3H, br. s, NH3). 
13C NMR 
(126 MHz, DMSO-d6) δ 7.3 (CH3, 7–CH3), 9.0 (CH3, 4–CH3), 36.0 (CH2, C-2’), 36.6 
(CH2, C-3’), 56.4 (Cquat, C-7), 56.9 (Cquat, C-4), 61.1 (Cquat, C-3a), 71.6 (CH, C–7a), 127.9, 
128.2, 128.3, 129.2, 130.0 (CH, Ph), 132.6, 132.8 (Cquat, Ph), 142.7 (Cquat, C–5), 144.6 




chloride (79 mg, 0.140 mmol) and DBU (0.126 mL, 0.842 
mmol) in THF (5 mL) were stirred at rt until the reaction 
was complete. The product was extracted with DCM, washed with water and 1M HCl, 
dried over MgSO4, filtered and concentrated in vacuo. The crude yellow solid was 
dissolved in approximately 16% CH3CN in H2O (12 mL) and loaded onto a pre-washed C-
18 solid phase extraction cartridge (100% CH3CN [2 x 10 mL]), then 90%, then 50% 
CH3CN in H2O [1 x 10 mL each], 10% CH3CN in H2O [2 x 10 mL]). The product was 




each], then 50% to 100% CH3CN in H2O [10% increments, 10 mL each]). The fractions 
collected were analysed by RP-HPLC (10% to 100% B over 12.5 min, then 100% B for 2.5 
min, tR =  9.86 min) and lyophilised to afford the title compound as a white solid (53.6 mg, 
 0.132 mmol, 94%). 1H NMR (400 MHz, DMSO-d6) δ 2.32 (6H, s, 2 x CH3), 3.10 
(2H, t, J = 6.1 Hz, CH2), 3.86 (2H, t, J = 5.8 Hz, CH2), 6.91 – 7.01 (4H, m, Ph), 7.08 – 7.29 
(6H, m, Ph), 7.86 (3H, br. s, NH3). 
13C NMR (101 MHz, DMSO-d6) δ 15.2 (2 x CH3, 4–
CH3 and 7–CH3), 35.1 (CH2, C–3'), 37.6 (CH2, C–2'), 126.9, 127.8 (CH, Ph), 128.0 (2 x 
Cquat, C-4 and C-7), 129.3 (CH, Ph), 133.2 (2 x Cquat, C–3a and C–7a), 138.2 (2 x Cquat, 
Ph), 147.8 (2 x Cquat, C–5 and C–6), 168.4 (2 x C=O, C–1 and C–3); νmax (cm-1) 1700 
(C=O), 1398, 700; HRMS-ESI m/z [M+H]+ calc. for C24H23N2O2: 371.1754; found: 
371.1758. 
tert-Butyl (2-(4,7-dimethyl-1,3-dioxo-5,6-diphenylisoindolin-2-yl)ethyl)carbamate 
To a solution of Boc-protected oCOm-21 (90 mg, 0.174 
mmol, endo:exo 3:1) THF (12.0 mL) at 0 ºC was added 
DBU (26.1 µl, 0.174 mmol) via an auto pipette. The 
yellow reaction mixture was allowed to warm to rt. Upon 
consumption of starting material by TLC (approximately 10 min), saturated NH4Cl (7 mL) 
was added and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined 
organic extracts were dried over MgSO4 and concentrated in vacuo to afford a pale yellow 
solid. Purification by flash chromatography (0%, then 5%, then 10% EtOAc in DCM) gave 
the title compound as white crystals (65 mg, 92%%). 1H NMR (400 MHz, CDCl3) δ 1.40 
(9H, s, C(CH3)3), 2.41 (6H, s, 4–CH3 and 7–CH3), 3.42–3.47 (2H, m, 2'–H), 3.85 (2H, t, 
3J3',2' 5.6, 3'–H), 4.89 (1H, br s, 1'–H), 6.87–6.89 (4H, m, Ph), 7.10–7.18 (6H, m, Ph); 
HRMS-ESI m/z [M + Na]+ calc. for C29H30N2NaO4
+ 493.2098; Found 493.2097. Data 







4.3 Solubility Studies  
Solubility studies were conducted on oCOm-60 and -61, to determine their water solubility 
at room temperature. HPLC chromatograms and further details are available on request 
(stored on group drive). If any impurity was present in the sample, this was accounted for 




4.3.1 Standard Solutions  
A series of standard solutions (typically 0.5, 1, 2, 3, 4, 5 mg mL-1) of the sample in 
CH3CN were prepared. The absorbance of the standards at 254 nm was measured using 
triplicate HPLC analyses (UV detector, flow rate 0.5 mL min-1). The average peak areas 
and concentrations of each solution were used to construct a standard curve. 
 
4.3.2 Water Solubility of CORMs  
To a known mass of sample (generally ~30 mg) was added 1 mL of tissue culture water at 
room temperature. This solution was sonicated briefly and warmed gently to allow 
maximum dissolution. The sample was then centrifuged (3500 rpm, 15 min) and filtered 
(nylon, 0.45 μm). The concentrated aqueous solution was then analysed in triplicate by 
HPLC with the same detector and flow rate as for the standards. The average peak area 
was used with the equation for the standard curve to calculate the concentration of the 
original saturated aqueous sample and therefore the solubility of the CORM in water at 
room temperature. 
4.4 CO Release Studies  
CO release studies were conducted to determine the rate of CO release by the CORMs in 
aqueous buffer at 37 °C at the specified pH. The PBS buffer that was used for all CO 
release studies was stored at 4 °C. Before each study an aliquot of buffer was removed and 




CORM samples (approx. 2.5 mg) and buffer (5 mL) were allowed to equilibrate to 37 °C 
for 1 hour. The buffer was then added to the CORM sample, filtered (nylon, 0.45 μm), and 
the timer started. Immediately after addition of buffer, the sample was sonicated briefly to 
facilitate dissolution, before being lightly sealed. Aliquots (100 μL) were removed from 
the vial at the specified times, added to 2 M HCl (500 μL) and shaken to quench. These 
samples were analysed by HPLC (UV detector, 0.5 mL min-1) as soon as possible and the 
relative peak areas of the CORM and BP-CORM were compared. The half-life was 
determined as the time at which the peak areas of both the CORM and BP-CORM were 
approximately 50%. HPLC chromatograms and detailed figures of CO release are available 
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